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ABSTRACT 
Cardiovascular diseases are the leading cause of death worldwide. Blood vessel 
replacement is a common treatment for vascular diseases such as atherosclerosis, 
restenosis and aneurysm, with over 300,000 bypass procedures performed each year. 
However, vein grafts are limited due to their availability. Although synthetic vascular 
replacements have been successful for large diameter arteries, hey have shown minimal 
success in arteries with diameters <6mm. This is because most synthetic materials induce 
thrombus formation which, within a few months of implantation, causes failure of the 
vascular graft due to occlusion. Tissue engineering is a promising approach to the 
fabrication of non-thrombogenic vascular grafts, but a reliable and expandable cell source 
for tissue-engineered vascular graft (TEVG) has not been established.  
The work presented here is motivated by the current unavailability of an ideal 
tissue engineered blood vessel replacement. Our overall goal is to create a living tissue 
engineered vascular graft that is biodegradable, non-thromobogenic, presents low 
antigenicity and has mechanical properties that match the native arterial tissue. For this 
purpose, we have created and characterized pure elastin (EL) tubes from porcine carotid 
arteries as the scaffolds. We have shown that these elastin scaffolds obtained by our 
technique are pure, have increased porosity (over decellularized arteries), are highly 
biocompatible and possess an architecture that is similar to the nativ artery which may 
help integration with the host tissue.  
In order to repopulate the scaffold with vascular cells to make it a living, 
responsive blood vessel replacement, we developed a novel in vivo cell recruitment 
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technique. The local release of growth factors through an agarose gel d liv ry system 
within the lumen of the scaffold attracted vascular cells into the scaffold when placed in 
adipose tissue in a rabbit model. To reduce thrombogenicity, heparin ws immobilized 
onto the EL scaffolds. A significant improvement in in vitro blood compatibility was seen 
with heparin immobilization. Platelet adhesion was reduced, thrombin inactivation was 
elevated, and plasma clotting time was significantly prolonged. Endothelial cells seeded 
on these heparin immobilized EL scaffolds maintained a quiescent profile with high 
thrombomodulin and PECAM-1 expression and low ICAM-1 expression. A majority of 
the cells were even able to resist detachment on exposure to physilogical levels of shear 
stress.  
These studies provide a new strategy to engineer a small diameter blood vessel 
with excellent antithrombogenicity, tissue compatibility and mechanics to integrate with 
host tissue. The true test of function though, lies in future animal vascular implant 
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Tissue engineering of small diameter vascular grafts involves th  creation of a 
replacement artery that matches the characteristics of the native tissue as closely as 
possible [1]. This includes the matching of mechanical properties – with collagen 
providing the strength and elastin providing the compliance and recoil during pulsation, 
cellular components – fibroblasts in the adventitia synthesizing collagen, vasoactive 
SMCs within the medial layer, and endothelial cells providing the natural non-
thrombogenic interface in addition to various signals to prevent SMC proliferation, check 
inflammation and maintain hemostasis. 
In order to achieve all the above properties, the main components required are – 
correct scaffold material, vascular cell source, scaffold cellularization technique, and the 
maintenance of cell function within the living graft.  
The obvious choice of cells is autologous cells since it would eliminate the 
immune response problem. The difficulty to obtain large numbers of vessel derived 
autologous cells for immediate transplantation (single stage seeding) or the need to grow 
them in culture (two-stage seeding) while maintaining the functional properties and 
preventing contamination inhibits their use. New sources of vascular ells such as bone 
marrow or adipose derived stem cells represent a more accessible and regenerative source 
[2, 3]. 
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Scaffold material choice and engineering is a very important aspect of tissue 
engineering. Manipulation of cell function can be achieved by creating a scaffold that 
provides the mechanical and biochemical environment that cells are familiar with. 
Synthetic grafts of Dacron and ePTFE that have been successful in large diameter arterial 
replacements have not shown the same success in small diameter applications. Beside the 
thrombogenic blood contacting surface of these materials and the absence of recognizable 
sequences on their surfaces for cells to attach, their other drawback was also the 
mismatch of mechanical properties – especially the compliance with the adjacent native 
tissue which led to hyperplasia of SMCs and eventual restenosis [4].  
Biodegradable synthetic polymers such as PLGA have been used to create tissue 
engineered arteries such that the seeded cells secrete extracellular matrix proteins 
collagen and elastin, while the synthetic scaffolds degrades, eventually leaving behind a 
completely biological graft [5]. This approach however, is limited by the amount of time 
in culture it takes to grow the artery and also the possibility of small amounts of synthetic 
material remaining behind which may initiate a strong inflammatory reaction that could 
affect the graft’s long term function. 
Biological scaffold materials not only express peptide sequences that allow cells 
to recognize the surface and adhere to, but can also be remodeled by the cells to help 
integration with the native tissue thus providing the ideal substrate for cell attachment 
and signalling. Most biological scaffolds, especially those made from reconstituted 
proteins like collagen/fibrin, do not possess the perfect mechanical properties to be able 
to withstand hemodynamic forces [6]. This has been attributed to the lack of orientation 
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of protein fibers which in native tissue provides structural integrity and even signaling. 
The use of mechanical and biochemical cues in vitro to improve scaffold properties has 
met with some success [7, 8]. 
Acellular tissue based scaffolds have been widely investigated as they resemble 
native tissue in terms of architecture, viscoelastic properties, c ll recognizable basement 
and most of all the potential for cellular remodeling and integration with native tissue [9, 
10]. However, recruitment of cells into an acellular tissue scaffold is quite difficult.  
In order to create a tissue engineered blood vessel that meets all the above 
requirements, we propose to investigate the use of modified acellul r tissue based 
scaffolds with increased porosity to improve cellularization, autologous cell recruitment 
by a novel in vivo technique, endothelial cell seeding for nonthrombogenic blood 
interface and prevention of intimal hyperplasia, and heparin immobilization as a 
additional anti-thrombotic layer as well as interaction with growth factors for improved 











LITERATURE REVIEW  
 
2.1 Circulatory system 
The circulatory system is composed of blood vessels that regulate blood flow by 
varying their resistance. The main function of arteries is to carry blood into capillaries, 
which provide the maximum resistance to blood flow, thereby allowing exchange of 
nutrients to and waste from all body tissues. The metabolites from tissues are carried 
back to the heart through the venous system. 
2.1.1 Anatomy of a normal artery 
A normal artery consists of three layers - the intima (tunica interna), the media 
(tunica media) and the adventitia (tunica externa). The intima is the innermost, blood-
contacting layer of arteries and is composed of endothelial cells (EC ) that rest on a 
basement membrane composed of laminin, collagen, heparin sulfate proteoglycan and 
fibronectin [11].  
Besides providing a barrier between blood and the surrounding tissue, ECs secrete 
a number of factors responsible for regulating vascular tone, SMC hyper-proliferation 
and thrombosis. ECs possess both thromboresistant as well as pro-thrombotic properties. 
Unactivated ECs exhibit thromboresistance in various ways – by interfering with the 
coagulation cascade, inhibiting platelet adhesion/aggregation as well as activating 
fibrinolytic pathways. Heparin like molecules synthesized by ECs bind thrombin and 
antithrombin III causing their inactivation [12]. Thrombin also interacts with 
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thrombomodulin (expressed on ECs) and gets inactivated [13]. ECs synthesize 
prostacyclin (PGI2) and nitric oxide (NO) - potent inhibitors of platelet aggregation [14, 
15]. NO also mediates vasodilation, limits smooth muscle cell (SMC) proliferation and 
inhibits leukocyte-EC interactions. ECs also synthesize fibrinolytic enzymes such as 
tissue plasminogen activator (tPA) and urokinase plasminogen activator (uPA) [16].  
 
 
Figure 2.1 Structure of an artery [17] 
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However, when perturbed (mechanically/chemically), ECs promote coagulation 
by synthesis of pro-coagulant factors such as tissue factor (thrmboplastin) [18], von 
Willebrand factor (vWf) , plasminogen activator inhibitor, platelet activ ting factor and 
extracellular matrix (ECM) components . vWf is synthesized by ECs and secreted into 
the ECM where its bound by the collagens. Platelet adhesion to ECM is mediated by vWf 
and gpIIb/IIIa (a receptor on the surface of platelets) [19].  
The middle layer of arteries is composed of SMCs arranged circumferentially 
within a matrix consisting mainly elastin and collagen secretd by them. The elastin 
within the media is responsible for maintaining the structure of the artery as it undergoes 
continuous pulsations brought about by the contractions of the smooth muscle. This is the 
layer that imparts mechanical characteristics to the artery. The adventitia is composed of 
a collagenous matrix containing fibroblasts, blood vessels (vasa vasorum) to supply 
nutrients to arterial tissue, and nervous innervation. The complex ECM of an artery, with 
elastin, collagen and proteoglycans, is responsible for its’ unique, viscoelastic properties. 
  
2.2 Vascular disease and pathology 
Hypertension is a major risk factor for most symptomatic vasculr diseases. It 
causes muscular hypertrophy as well as intimal thickening (arteriosclerosis) in both large 
and small arteries. This leads to progressive hardening of the arterial wall and loss of 
elasticity which can result in ballooning of the artery (aneurysm) which could lead to 
rupture, disturbed blood flow patterns and hence turbulence leading to endothelial cell 
damage which causes thrombus formation and eventually occlusion of the artery [20]. 
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Pathologies affecting small and medium sized blood vessels are the major cause of death 
worldwide [21].  
Aneurysms are caused due to injury to the medial layer of the artery [22]. 
Degradation of elastic tissue within this layer causes the localized dilatation of the artery 
causing turbulence of blood flow. This increases the chances of thrombus formation 
and/or rupture of the artery. Aneurysms can also be caused due to trauma, congenital 
defects as well as microbial attack. 
Atherosclerotic arterial disease is the most common condition leading to a 
failing artery. It is a systemic disease which begins with injury to the endothelial lining 
causing endothelial dysfunction which causes changes in EC properties such as 
permeability, interaction with inflammatory cells, and response to various stimulatory 
agents. ECs become permeable to lipoproteins which accumulate in the sub-endothelial 






       
    
 
Figure 2.2 Cut section of an artery showing features of an atherosclerotic plaque [24] 
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This accumulation of oxidized LDL (low density lipoproteins) damages the 
arterial wall by producing oxygen radicals and causes changes in platelet adherence to 
ECs and activation of ECs to secrete various chemokines that cause prolif ration of 
SMCs and macrophages. Accumulation of lipid-filled macrophages (known as foam 
cells) in the intima, particles of lipid and calcium, and eventually the buildup of fibrous 
plaque that causes narrowing of the lumen and hence disturbed blood flow, is 
characteristic of the progression of atherosclerotic disease [20]. 
Although atherosclerotic lesions may occur in arteries of all sizes, there are a few 
areas such as the abdominal aorta, iliac, carotid and coronary arteries as well as vascular 
bifurcations that are more prone [25]. 
2.2.1 Treatments currently used 
The majority of research involving treatments has focused on nipping the problem 
in the bud by treating risk factors. Dietary control, changes in lifestyle (exercise) and 
reducing smoking are some such examples. 
Thrombotic disease can be treated with anticoagulation or fibrinolytic therapy 
however, progression of disease condition warrants surgical interveion. Balloon 
angioplasty is a method that involves the insertion of a balloon into the stenosed artery 
using a catheter. The balloon is inflated to dilate the artery and crack the plaque thus 
restoring blood flow. Sometimes a metallic stent is used to hold t e artery open and 
prevent re-stenosis. New drug-eluting stents to reduce thrombosis are being evaluated.  
The other surgical option is bypass or replacement of the diseased artery to estore 
blood flow. The preferred replacement is the patient’s own blood vessel such as the 
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internal mammary artery or the saphenous vein however in many patients th se vessels 
are unavailable either from being diseased themselves or from previous use. Also, the 
need for multiple surgery to remove these vessels and causing donor site morbidity, make 
these options less desirable. All these reasons prompted the search for an artificial blood 
vessel replacement. 
 
2.3 History of vascular conduits 
As early as 1906, Carrel and Gutherie demonstrated the use of homologus and 
heterologous arteries and veins for human arterial replacement however lack of immune 
rejection knowledge prevented the success of these transplantations [26]. These attempts 
were followed by the use of inert, impervious non-biologic materials such as paraffin 
lined glass and aluminum and even ivory [27] as structural replacements. In the 1940’s, 
Hufnagel developed polymethylmethacrylate tubes. This was followed by polyethylene 
and siliconized rubber tubes [28] where it was hoped that their smooth and impermeable 
surfaces might help to minimize the formation of thrombus. In the early 1950s, Vorhees 
made an observation that a piece of silk thread lying in a dog’s ventricl  was covered by 
a smooth endothelium-like surface. Inspired by this observation, he hypothesized that a 
woven rather than a smooth material, by stimulating the formation of this smooth layer, 
would provide a non-thrombogenic surface suitable for an arterial prosthesis. In a 
preliminary study, a hand-woven fabric made from Vinyon N (co-polymer of vinyl 
chloride and acrylonitrile) was used successfully to bridge arteri l defects in dogs [29]. In 
a subsequent and more complete report, Blakemore and Vorhees described the first 
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clinical use of this fabric as an arterial prosthesis and showed that leakage of blood 
through the graft had ceased within 1 min after the prosthesis was filled with blood at 
arterial pressure [30].  
Once the idea of porous woven fabrics was introduced, a variety of materials 
including Nylon (polyamide), Teflon (polytetrafluoroethylene), Orlon (acrylonitrile), 
Dacron (polyethylene terephthalate), and polyurethane (PU) were test d. The first 
commercial fabric graft was made from braided nylon (by Dr. Edwards in 1955) and 
sealed with fibrin. It was quickly realized that a porous graft was necessary to allow 
neotissue ingrowth thus allowing better healing. However, incomplete healing of the 
inner surface of the nylon graft led to thrombosis and also, these ubes frayed causing 
graft ruptures. Elastic nylon yarn (Helanca) was used in a canine model in which all the 
implants remained patent in the 12 month implant period however, there was a loss in 
tensile properties of about 80% which caused concern about success in longer implant 
periods [31]. In order to avoid kinking when bent, crimped nylon grafts were used. 
Crimping also reduced the loss in tensile strength to about 20-30% [32]. 
Ivalon sponge (PVA) was considered a suitable vascular prostheses mat rial in 
the 1950s due to its similarity in mechanical properties to normal arteries. It is obtained 
as a rubbery foam which on boiling in water for several minutes and then drying 
completely becomes a woody block that can be cut into slices of any thickness. On 
wetting, these slices regain their softness and elasticity [33]. An animal study by Harrison 
[34] showed that though the grafts were easy to insert, and had very good properties 
before implantation, they became brittle soon after implantation and failure was seen due 
 11
to loss in elasticity and rupture of grafts. The small diameter grafts in the same study, 
occluded due to thrombosis. Shumway et al. [35] used PVA for aortic replacement and 
showed some success, however, their method of preparing the scaffold was quite 
cumbersome.  
 In 1957 Teflon was evaluated as a vascular graft material due to its known 
inertness. Teflon has proved superior to all synthetic materials used as vascular 
prostheses. It elicits minimal tissue reaction, healing is rapid nd it has shown no loss in 
tensile properties over two years of implant. Infact, Teflon seemed to gain strength after 
implanting. Due to its unwettability, up to a certain pore size, it prevents blood leakage. 
However, this same property has been cited as the reason for a non-adherent neointima 
formation which is susceptible to detachment. A crimped tube of knitted Teflon was used 
by Edwards et al. which was easy to suture and had all the other excellent properties of 
Teflon [36, 37]. 
Wesolowski et al. [38] made grafts of Orlon mesh and showed patency in high 
flow sites in a canine model at 6 months but also saw loss of strength on implantation.. 
DeBakey et al., introduced the Dacron graft in 1958 [27]. Dacron has good stability and 
is seen to maintain structure for over 10 years without deterioration with 5 year patency 
rates of 93% for aortic replacements but only 43% for smaller diameters (such as below 
knee). Also, Dacron grafts tend to lose strength though not as rapidly as n lon and are 
thus thought to be suitable only for old patients whose requirement is for ~10years.  
In the late 1960s, a process was developed to create microporous, non-fabric 
grafts from PTFE by heating, stretching and thus expanding it (ePTFE) to improve tissue 
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adhesion [39]. It is a fluorocarbon polymer, formed into sheets by a paste extrusion 
process, producing a porous material that has solid nodes inter connected by fine fibrils. 
The intranodal distance can be varied to change the graft porosity. These prostheses were 
first used clinically in 1972 and have thence been in use for medium s zed vessel 
reconstruction.  
Dacron and ePTFE are the most common synthetic polymers used for large 
diameter vessel replacement. All synthetic polymers show thrombosis and thus occlude 
small diameter (< 6mm) vessels. It has been shown that the rate of occlusion due to 
thrombosis is higher in tightly woven grafts in vessels smaller than the aorta, due to low 
porosity. Velour grafts are superior to knitted or woven grafts in this respect. With a 
number of studies it has been shown that synthetic grafts work well as high flow, large 
diameter replacements. 
 
2.4. Small diameter arterial replacements 
Blood vessels with an internal diameter less than 6mm are known as sm ll 
diameter arteries. The majority of patients requiring arteri l surgery or replacement 
involve these small arteries (coronary and peripheral artery disease). Damage to arteries 
of the legs and hands, especially in diabetic patients, may also lead to amputation if not 
replaced in time [40]. 
Due to the success of ePTFE and Dacron in large diameter vascular replacements, 
they were the obvious first choices of materials for replacement of small diameter arteries 
with synthetic prostheses however their success was not replicatd when used as smaller 
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arteries [41, 42]. The biggest reason for the lack of success of biomaterials in small 
diameter situations is the low blood velocity allowing more interaction between blood 
and the biomaterial surface. Since no ideal replacement has yet been found, ePTFE is still 
the most frequently used conduit for femoropopliteal reconstruction (when autologous 
saphenous veins cannot be used), because it is smooth, can be handled easily, and does 
not need preclotting [42, 43].  
2.4.1 Causes of small diameter graft failure 
Graft related complications such as dilatation, occlusion due to thrombosis, 
intimal hyperplasia, pseudo-aneurysm formation at the suture line, and graft deterioration 
are experienced clinically. Injury induced responses are exacerbated by vascular graft 
materials because the contacting tissues are reacting to surgical injury as well as the 
implanted foreign body (synthetic material).  
Three distinct modes of failure (according to the times after implantation they 
occur) have been identified. Within 30 days of surgery, failure mainly results from 
technical or judgmental errors. The development of stenosis within the graft is the most 
common cause of failure during the first year whereas after a year or more, the 
progression of atherosclerosis is the most prominent failure method [44].  
2.4.1.1. Short term modes of failure 
Mechanisms causing failure of vascular prostheses within the first few days post-
operatively are termed as short term modes. Surgical errors introduced during clamping 
can cause graft failure within 1 month in as many as 20% cases [45]. Infection of grafts 
is one of the most catastrophic forms of failure. Implantation site and graft material are 
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the two major determinants of infection. Rigorous aseptic techniques ne d to be 
maintained to prevent any infections.  
Hematoma can result from leakage through the graft ends if suturing has been 
incorrectly performed. It can also occur due to a puncture in the graft causing blood to 
spread between the tissue and the graft wall, resulting in swelling and discoloration. 
False aneurysms can result from the repeated puncture of the graft at a single site. This 
results in a large hole in the wall of the graft and leads to loss of an area for puncture and 
perhaps a hematoma. The chance of infection and clotting of the graft is also greater. 
From the time of implantation, the graft is subjected to continuous pulsatile flow that 
creates tension in the wall as well as exerts shear stress on it. The graft also faces strong 
biochemical agents that lead to graft degradation. Dilatation  can occur almost 
immediately after surgery and continue to increase with time. 
2.4.1.2 Occlusive (long term) failure 
The two most common causes of occlusive failure of grafts are thrombosis and 
intimal hyperplasia. 
2.4.1.2.1 Thrombosis 
Thrombosis involves the activation of three interconnected regulatory systems, 
the coagulation cascade, the complement cascade and the cellular components of the 
blood such as leukocytes and platelets which when activated, lead to the f rmation of a 
clot within the blood vessel thereby obstructing blood flow. On normal, un-activated, 
confluent endothelium, tissue factor (TF) expression is low or absent, a d 
thrombomodulin (TM) expression is high, prostacyclin (PGI2) secretion is low or absent, 
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nitric oxide (NO) secretion is present but low, von Willebrand factor (vWF) is present 
within the EC but not secreted, and the number of cell adhesion molecules expressed on 
the EC surface is also low. Activation of ECs causes a reversal of this profile i.e. 
increased secretion of NO, PGI2, vWF and increased expression of cell surface adhesion 
molecules [46].  
All materials that are clinically used today as vascular replacements are inherently 
thrombogenic. When artificial biomaterials come into contact with blood, a number of 
thrombotic and inflammatory reactions occur - similar to what occurs when blood is 
exposed to the ECM of a disrupted vessel. On exposure to blood, adsorption of plasma 
proteins occurs. The type and amount of protein adsorbed depends on the characteristics 
of the biomaterial surface. Albumin adsorption is usually considered beneficial because it 
induces an inhibition of the activation of the complement system and reduces platelet 
aggregation [47] whereas adsorption of fibrinogen is detrimental [48] becaus  platelet 
membrane receptors recognize RGD sequences in fibrinogen [49]. Alphagranules on 
platelets contain glycoproteins that cause increased platelet deposition on the surfac . The 
conformational change that occurs after platelet adhesion can cause the exposure of a 
larger number of receptors to various aggregation factors thus increasing thrombosis [50]. 
It has been suggested that a minimum flow velocity of 6-8 ml/sec/cm2 (known as 
the thrombotic threshold velocity - TTV) is required to maintain a thin, stable, fibrin layer 
on the graft surface [48]. Since the blood velocity in small vessels i  less than the TTV, 
the effects of thrombosis are more pronounced. 
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2.4.1.2.2 Intimal hyperplasia 
Neointimal hyperplasia is a response to injury in vascular tissues which promotes 
abnormal thickening of vascular walls with luminal narrowing. It involves the 
proliferation and migration of vascular smooth muscle cells from the media to the intima, 
with subsequent synthesis of matrix proteins and other extracellular material causing the 
narrowing of the lumen. Cell proliferation in the media begins immediat ly after injury 
and peaks at 2 days, then declines by 7 days. The intimal cells continue to divide and 
intimal proliferation peaks at 1 week, then declines by 2 weeks [51].The number of 
SMCs in the intima remains fairly constant after 2 weeks, but intimal size continues to 
increase up to 8 weeks presumably due to the accumulation of extracellular matrix. 
Studies have shown a progressive increase in intimal thickening from 2 t  8 weeks after 
balloon injury, without an increase in SMC number but with matrix accumulation [52]. 
In normal arteries it has been shown that a reduction in shear str ss is associated 
with intimal hyperplasia [53]. If the shear stress departs from the optimum value, a 
complex series of events occur which include the release of vasoactive substances such as 
nitric oxide (NO) and prostacyclin (PGI2), mitogens such as platelet derived growth 
factor (PDGF) and basic fibroblast growth factor (bFGF), activation of vascular cell 
transcription factors, protein synthesis and re-arrangement of the cy oskeleton, causing 
changes in vessel stiffness. When the shear stress falls belowthe optimum value intimal 
hyperplasia occurs, leading to a reduction in the diameter of the vessel lumen, causing the 
mean flow velocity and consequently the shear stress to increase [53]. It is generally 
accepted that mechanical factors are important in its genesis. The e include disturbed 
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flow at the anastomosis leading to fluctuations in shear stress at the endothelium, injury 
due to suturing and stress concentration at the anastomosis. Intimal hyperplasia 
commonly causes graft failure in the first 2 years after surgery.  
Among the various factors influencing graft failure, compliance and size 
mismatch between graft and native vessel are believed to be the most important physical 
factors whereas wall shear stress is thought to be the most iportant hemodynamic 
factor. Wall shear stress affects platelet aggregation [54]. Low shear rates promote 
platelet aggregation. High shear rates do not prevent platelet adhesion to the wall but do 
decrease the size of aggregates however, shear stress greater than 70 dynes/cm2 causes an 
exponential increase in platelet activation [55, 56]. Studies have shown that shear stress is 
the parameter determining arterial diameter. It has been shown that arterial diameter 
increases or decreases in response to changes in blood flow in a ma ner that maintains a 
constant shear force [57]. 
The effect of thrombosis contributes more to the failure in the short term as 
compared to compliance mismatch induced hyperplasia which becomes pre-dominant 
once a fairly thromboresistant flow surface has been established. 
2.4.2 Characteristics of ideal small diameter replacements 
After tremendous experience by a number of researchers, certain ch racteristics 
have been deemed necessary for the success of a small diameter rterial replacement. The 




flexibility and ease of suturing 
 
ability to be stretched, and provide circumferential strength to sustain pulsatile flow, 




mechanical properties that match those of the native vessel 
 
lack of chemical reactivity 
 
very low thrombogenicity 
 
porosity that should allow the leakage of a small amount of blood to allow the creation 
of a tightly adherent thrombus, and the ingrowth of fibrous tissue 
 
resistance to infection 
 
ability to be sterilized and stored for long periods before use 
  
availability in a wide range of sizes 
 
Table 2.1 Requirements for a sucessful small diameter vascular graft  
 
2.5 Tissue engineering of small diameter grafts - from bioinert to biointeractive 
vascular prostheses 
Vascular replacements are no longer passive conduits that provide structural 
replacement but are looked at as functional devices. Initially materials that did not react 
at all with the body were selected (bio-inert), followed by materi ls that allowed 
preferential reaction such as albumin adsorption instead of fibrinogen adsorption 
(bioactive) and now materials that react with a specific mechanism to allow healing (bio-
interactive) eg. heparin binding to reduce thrombogenicity are being investigat d.  
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Tissue engineering approaches which involve the colonization of a biomaterial 
with the required cell types to achieve a living prostheses as a functional replacement 
[58] have shown potential to create biocompatible, strong and compliant grafts that have 
the capability of remaining patent.  
2.5.1 Modification of traditional materials 
Since the required mechanical properties such as suture strength, ase of suture, 
vessel wall thickness, were available in existing commercial materials, the first attempts 
to manipulate body responses were aimed at surface modification of these materials with 
the aim of achieving the ideal healing response. 
2.5.1.1. Anti-thrombogenic coatings 
Thrombosis prevention has been attempted by creating surfaces that prevent 
protein adsorption (non-fouling surfaces), those that inhibit the activity of hrombin and 
those that prevent platelet adhesion and aggregation. Various synthetic and natural 
materials have been investigated. 
Early studies of the electrochemistry occurring at the blood-graft interface and in 
normal blood vessels established that the inner surface of blood vessels are 
electronegative when compared with their outer surfaces [59]. Also, it is known that 
platelets are negatively charged. These results prompted the theory that a neg ive surface 
charge prevents thrombosis by causing electrostatic repulsion of the negatively charged 
cells involved in thrombosis while a positive surface charge promotes it.  
Carbon is one such electronegative material that was used to coat the surface  of 
grafts to act as a thrombosis deterrent. Early animal studies of carbon-coated vascular 
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prostheses demonstrated improved patency rates compared with uncoated controls. Arabi 
et al. [60] showed that a homogeneous and stable coating of graphite on polyester 
vascular grafts (GPVG) reduced the number of adherent platelets and prevented platelet 
activation and spreading on the surface in comparison with non-coated and control 
(collagen sealed polyester) grafts however suturing of GPVG was more difficult in 
comparison with the other types. Aebischer et al. [61] also showed lesser thrombosis and 
thinner fibrin capsule on turbostratic, high-density carbon coated Dacron grafts compared 
to control non-coated grafts. However, surface irregularities on carbon-lined ePTFE 
grafts have contributed to poor performance in other investigations [62]. 
Salicylic acid and its derivatives have been used as pharmaceutical agents for a 
very long time. Aspirin was developed years later as a more palatable form of salicylate. 
It is now known that the mechanism of action of aspirin is through the in ibition of 
prostaglandin biosynthesis which further blocks thromboxane formation in blood 
platelets [63]. This anti-aggregatory property of salicylic acid derived drugs has been 
used by a number of researchers to create non-thrombogenic luminal surface  of vascular 
grafts.  
San Roman et al. [64], created hydrophilic acrylic polymer coatings bearing 
salicylic acid residues for Dacron vascular grafts and showed improved 
antithrombogenicity with respect to the uncoated prosthesis. Rodriguez et al. [65], created 
resorbable coatings of a polyacrylic derivative of Triflusal (2-acetyloxy-4-
trifluoromethyl)benzoic acid (a derivative of salicylic acid with a well-established platelet 
aggregation inhibitory profile [66]) on vascular grafts. The system allowed the slow 
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release of Triflusan improving anti-aggregating properties without the use of any other 
anti-thrombogenic drugs. A biodegradable coating of polylactic acid (PLA) containing a 
microparticulate suspension of aspirin was applied to the luminal surface of small 
diameter vascular prostheses to reduce platelet deposition on canine implanted arterial 
grafts. Less platelet deposition was observed on the coated grafts when compared to 
controls 2 and 24 hr post implant however there was no significant differenc  in platelet 
deposition on coated and control grafts at 2 weeks or 1 month post implant [67]. 
Tissue factor (TF), a protein present in platelets and leukocytes, is involved in 
coagulation by converting prothrombin to thrombin. St Pierre et al. [68] showed that the 
intravenous administration of recombinant tissue factor pathway inhibitor (rTFPI) for 
24 hours showed reduced platelet accumulation, fibrin deposition, and factor X  activity 
in an arterial injury animal model. The same group also showed that pre-clotted Dacron 
grafts incubated in rTFPI and implanted in pig femoral arteries showed reduced 
thrombogenicity (although the results were not statistically significant) [69].
Hirudin  is another substance that is used for its anti-thrombotic properties. It s 
secreted by the buccal glands of leeches and is capable of preventing coagulation by 
inactivating thrombin. It has been used in medicine as an anticoagulant coating. Dacron 
surfaces with covalently bound indium-labeled recombinant hirudin (25I-rHir) had no 
gross thrombus and a thin pseudointima of platelets and plasma proteins whereas the 
control patches had a thick pseudointima composed of fibrin-rich thrombus. rHir, 
covalently bound to Dacron patches, maintained its biologic activity as well as prevented 
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thrombus formation on the graft surface [70]. Although these results are encouraging, this 
study was performed ex vivo for only 2hr thus limiting the results to short-term success.   
Heparin is a sulfate-containing polysaccharide most commonly used as annti-
coagulant. It has the highest negative charge of all known biologic molecules. This 
negative charge is thought to be the first reason for reduced platelet in raction due to 
electrostatic repulsion. Also, the action of antithrombin (AT) inhibiting hrombin through 
the formation of a covalent complex is catalyzed by heparin or heparin analogs present in 
the endothelial tissue [47]. The first attempt to immobilize heparin onto biomaterials was 
carried out in 1963 [71]. These researchers used electrostatic binding of heparin to the 
biomaterial through its anionic groups. Due to the weak binding, the heparin w s lost 
very quickly on establishment of flow.  This initiated covalent binding of heparin to 
biomaterials. Although covalent binding improved short term thrombogenicity, loss of 
bound heparin over time still occurred.  
One innovative idea explored the coupling of heparin to prostaglandins coated on 
polymers. These heparin-prostaglandin materials exhibited low fibrin formation and 
platelet aggregation, both in vitro and in vivo [47]. Heparin analogs were also 
synthesized, since the AT-binding sequence was identified as a pentasacch ride segment, 
to mimic the natural catalytic sites known to confer anticoagulant and antithrombotic 
properties to heparin [72, 73]. These synthetic heparin-like polymers were shown to 
exhibit anticoagulant properties similar to heparin. The in vivo antithrombotic activity is 
more complex than that explained above, as not only activation of AT is important but 
also other mechanisms, such as release of Tissue Factor Pathway Inhibitor (TFPI) 
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contribute to the antithrombotic effect. Long-term clinical studies with heparinized grafts 
need to be performed before this methods’ efficacy is known.  
As part of the vascular wall, elastin is thought to have minimal platelet adhesion 
and aggregation however due to difficulty in isolating elastin due to its insolubility, the 
focus has been on creating elastin-mimetic materials. The repeating peptide sequence 
VPGVG in elastin is the primary feature of most animal elastins (including humans) and 
exhibits a unique property known as coacervation. Poly(VPGVG) have been shown to be 
easy to produce and unreactive to macrophages and other cell types makingthem less 
thrombogenic [74]. 
2.5.1.2 Endothelialization 
Early failure due to thrombosis is greater in prosthetic grafts than in vein grafts. 
This has been attributed to the lining of endothelial cells in vein grafts which is absent in 
artificial materials. In contrast to animals, the flow surface of synthetic vascular grafts in 
humans remains unhealed. Growth of endothelium from the adjacent vessel is limited to 1 
cm from the anastomosis [75] whereas in young pigs complete endothelialization occurs 
in 1 month and in dogs in 4 months. Also, the graft surface is covered with compact, 
crosslinked fibrin matrix which is though to be the reason for reduced cellular ingrowth 
[76]. Canine models have been identified as the closest to humans in terms of their 
healing pattern [47]. 
Malcolm Herring, in 1978 introduced the concept of autogenous endothelial cell 
transplantation to improve patency of small diameter vascular grafts [77]. His hypothesis 
was that providing the natural, biological lining of blood vessels would provide 
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antithrombotic properties and have an antiproliferative effect on SMCs hence preventing 
failure of small diameter vascular grafts by both thrombosis a  well as hyperplasia.  A 
monolayer of ECs line the vasculature and through the expression and secretion of a 
spectrum of molecules regulate vascular tone and permeability, inflammation, 
thrombosis, and fibrinolysis. When artificial biomaterials come into contact with blood, a 
number of thrombotic and inflammatory reactions occur similar to what occurs when 
blood is exposed to the ECM of a disrupted vessel. To prevent these reactions, EC are 
being combined with biomaterials as a strategy to create an interface that covers the 
underlying biomaterial, enabling blood contact without significant inflammation and 
thrombosis, and maintenance of graft patency [46]. A number of investigators have 
attempted to coat the entire surface of their biomaterials with ECs. However, to date, this 
technique has not proven clinically successful due to a number of reasons – technical 
complications that need to be overcome in order to isolate (in large enough numbers) and 
seed (such that they do not detach) in a short time frame (less than 2 hrs is acceptable) all 
under sterile conditions. Also, the success of this method seen in animal models has not 
been translated in humans because the endothelium in humans does not regenerate as it 
does in animals. The source of the neo-endothelium is not clear, however, studies indicate
proliferation from adjacent arteries (pannus ingrowth), through vascular ingrowth in 
prostheses pores, and even circulating progenitor cells. Also, molecular st dies suggest 
that confluent ECs display a non-thrombogenic profile of molecules on the majority of 
biomaterials tested however at sub-confluent densities, EC appeared to be more 
thrombogenic [46]. 
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2.5.1.2.1 EC sources and harvesting 
Jaffe et al., in 1973 [78], were the first to describe the isolation nd culture of ECs 
from human umbilical veins. The two primary sources of ECs are (i) non-essential 
vessels and (ii) adipose tissue (omental or subcutaneous fat). Mechanical scraping [79] 
and enzymatic digestion [80] are the two methods used to isolate ECs from blood vessels. 
Mechanical scraping tends to damage the cells. Also, the maximum efficiency obtained 
with this method has been 75%. Enzymatic digestion of basal lamina proteins also causes 
some damage to ECs. The main disadvantage of isolating ECs from blood vessels is the 
limited quantity obtained. In in vitro cell culture techniques have been used to overcome 
this, however that prevents the use of these cells in emergency cases. Also, the possibility 
of morphological and genotypic changes occurring in culture and the possibility of 
contamination still remain.  
Jarrell et al. [81], in 1986, isolated microvascular endothelial cells (MVECs) from 
adipose tissue capillaries. This alternative source was pursued due to the large number of 
cells obtained. Large enough numbers of pure MVECs are obtained by this procedure 
within 2hrs with a maximum efficiency of 84%. There has been debate about whether 
these MVECs are actually ECs or mesothelial cells and whether they will function as ECs 
[82] however, several studies have shown that these cells express characteristic 
ECmarkers such as vWF, CD31, CD34 [83, 84] and remain adherent on biomater al 




2.5.1.2.2 EC seeding techniques 
Three methods have commonly been used for the seeding of ECs on the luminal
surface of grafts. The gravitational technique [85, 86] involves filling the graft lumen 
with the cell suspension and rotating the graft periodically to allow attachment of cells to 
the entire surface. It has been shown that the majority of cells transplanted by this method 
are lost on exposure to flow [87]. In the hydrostatic technique, a pressure difference is 
used to force the EC suspension through the interstices of the prostheses. Just as in the 
gravitational method, a minimum of 2 hr culture time is required to prevent cell loss on 
exposure to flow.  The third technique, electrostatic seeding, utilizes the knowledge that 
ECs are negatively charged [88-90]. A temporary positive charge is induced on the 
material surface thus attracting ECs to it. In vitro evaluations of this method have shown 
complete coverage of ePTFE grafts in 16 minutes indicating that this method is superior 
to the other methods employed earlier.  
2.5.1.2.3 Improving cell adherence to surface/ Surface modification for EC attachment 
EC adherence to untreated traditional graft materials (ePTFE, Dacron) is very 
poor [91] and even if they attach during culture, are usually lost on exposure to flow. This 
has prompted the search for an appropriate coating that will increase the number of ECs 
attached as well as improve their morphology (flattened). Various basement membrane 
proteins such as fibronectin [92], arginine-glycine-aspartate (RGD)–containing peptide 
(the active component of fibronectin) [93], gelatin [94, 95], collagen [96], or laminin [95, 
97] when coated on traditional graft materials have shown to improved EC adhesion over 
untreated graft materials. The disadvantage of coating basement membrane proteins is 
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that exposure of any of these biocomponents to blood either due to inadequate 
endothelialization or the loss of ECs due to shear, initiates a thrombotic reaction [87]. 
Krijgsman et al. [98], showed that bonding of RGD,  heparin, and both RGD and heparin 
accelerates and enhanced EC retention onto PU grafts whereas simple coating of 
basement membrane proteins conferred no advantage over native PU grafts. Sipehia et al. 
[99], applied ammonia plasma treatment to traditional materials and showed increased 
EC densities on treated surfaces.  
2.5.2 Scaffold engineering 
The most important aspect of tissue engineering is the construction of a scaffold 
that takes into consideration all the lessons learnt from failures with traditional materials. 
The scaffold needs to match the natural tissue in structure as well as function while being 
easy to manufacture on a large scale, sterilize and store for extended periods of time.  
Three main aspects of tissue engineering that have been investigat d most 
extensively are the creation of porous scaffolds, scaffolds to match ar ery mechanics 
(compliant materials) and design of biodegradable materials (to timulate native tissue 
regeneration). 
2.5.2.1 Porous scaffolds 
On contact with blood, all arterial prostheses develop a luminal coating of fibrin. 
In non-porous grafts, this layer remains disorganized and prevents adherent endothelial 
growth whereas in porous grafts, (in certain animal models), the thin fibrin layer is 
replaced by endothelial cells spreading from the anastomotic region. However, this type 
of healing is not seen in humans. The pattern of healing in dogs is seen to best mimic that 
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of humans. Inspite of these differences in animal models, it has been seen that porosity 
increases the patency rates of grafts across all species. Unfortunately, there is a maximum 
porosity level beyond which the graft fails due to excessive hemorrhage. 
2.5.2.1.1 Leak-proofing porous prostheses 
Porosity is an important aspect of vascular prostheses healing and long term 
patency. Porosity is required for the transfer of nutrients and for the ingrowth of tissue to 
allow better integration. The major disadvantage of porous grafts, however, is their 
permeability to blood during implantation. This contradictory need indicates that the graft 
needs to have low initial, implantation porosity but high healing porosity to allow 
fibroblastic growth. Pre-clotting the graft with the patient’s blood prior to implantation 
was used as a means to make it leak-proof however a number of difficulties arose with 
this technique. Studies have thus focused on producing a coating such as a biodegradable 
component that will provide the initial seal but will degrade over time to produce a 
porous graft.  
A few research groups reported the complete sealing of grafts using fibri  glue . 
However, surface thrombogenicity and calcification (on subdermal implantation) was 
higher than non-treated grafts [100, 101]. 
The deposition of albumin on implant surfaces has been known to be 
advantageous. It is shown to passivate the surface thus preventing thrombosis. Numerous 
in vitro and animal studies proved this by providing leak-proof grafts that he led better. 
The albumin coated prostheses is now commercially available in Canada d Europe and 
are undergoing clinical trials in U.S. [47]. 
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Gelatin exhibits very poor antigenicity in humans and was thus used for graft 
impregnation under the trade name Gelseal Triaxial graft. It promoted healing and 
cellular growth and tissue integration without increase in thrombogenicity or patency 
[102, 103]. 
Collagen was used to coat as well as impregnate porous grafts. Various studies 
showed faster healing as well as endothelial layer formation in collagen treated grafts. 
The three major grafts to have undergone animal and clinical studies are Dacron-collagen 
coated – Hemashield in which the collagen (bovine type I) is impregnated and lightly 
crosslinked with formaldehyde, and Hemaguard and Tascon grafts in which the sealant is 
more heavily crosslinked with glutaraldehyde. Questions about the immunogenicity of 
the collagen as well as thrombogenicity have been raised but a number of studies have 
shown that crosslinking reduced thrombosis [104]. The collagen impregnated grafts are 
the most widely used impervious grafts to date. 
Other biodegradable materials such as alginate, chitosan, agar, PGA, PLA and 
their co-polymers are also being studied. 
2.5.2.2 Compliance matching 
The most commonly used graft materials (Dacron and ePTFE) are rigid at the 
time of implantation and this difference in compliance increases ov r time due to the 
formation of a neointima which in porous grafts is further alleviated by the infiltration of 
fibrous tissue within the interstices. This plays a very important role in graft 
complications – especially at the anastomosis [76, 105].  
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Compliance is defined as the ability of a vessel to dilate under pressure and is 









Compliance mismatch between the host artery and the prostheses has been cited 
as a reason for intimal hyperplasia. The abrupt changes in elasticity at the anastomosis 
puts a stress on the natural vessel, which causes hyperplasia of smo th muscle [48]. 
Tissue hyperplasia is thought to be a means of compensating for lack of tissue 
compliance and contractility [106]. Also, in rigid grafts, the flow velocity profile is 
different from a compliant tube [107]. Since rigid synthetic grafts cannot adapt their 
diameter to maintain constant wall shear stress (WSS), optimal WSS levels will not be 
maintained. Increased shear stress damages endothelial cells and reduced shear stress 
creates areas of relative stasis which are prone to platelet ctivation and deposition as 
well as turbulent flow profiles. The aim of matching compliance is to minimise these 
disruptive flow characteristics [108]. To reduce ill effects of c mpliance mismatch, 
investigators have shown that stresses can be minimized when the ratio of diameter of 
rigid graft to compliant artery is about 1.4 [109, 110]. 
Patency results of the human femoral artery were compared with grafts currently 
in use [105] - human saphenous vein (HSV), knitted Dacron (DAC), glutaraldehyde-
treated umbilical cord vein (DBM), bovine heterograft, and ePTFE and correlated to the 
compliance. After two years, patency rates of the more compliant m terials (HSV, DBM) 
exceeded 80%, while less than 45% of the incompliant grafts (DAC, PTFE) remained 
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patent. These studies show that the clinical performance of synthetic grafts might be 
improved by use of prostheses in which the viscoelastic characteristi s match those of 
arteries more closely. The mechanical properties of grafts need to match the 
physiological characteristics, replicating elasticity, to withstand continuous pulsation, and 
have high tensile strength for large pressures.  
Van der lei et al. [111] demonstrated the necessity of both compliance d 
biodegradability in regenerating a neo-artery that microscopically and functionally 
matches the native tissue. In an elegant study evaluating three groups: I) compliant, 
biodegradable, II) complant, biostable and III) non-compliant, biodegradable grafts 
implanted in rat abdominal aortas for 6 weeks, they observed pulsations only in group I. 
Histologically, SMCs were present in all samples however, elastic l minae were present 
almost throughout the neomedia only in group I, restricted to the luminal layers of the 
neomedia in group II, and totally absent in the neomedia of group III. Theyconcluded 
that the compliance of the grafts allowed smooth muscle cells to be mechanically 
stimulated by the arterial pulsations to produce elastin and due to th  biodegradation of 
these grafts, compliance was maintained (which in other porous stable materials is lost 
due to fibrous ingrowth). 
2.5.2.3 Biodegradable scaffolds 
Biodegradable materials can provide a temporary scaffold on whose support a 
completely biological vessel can develop. These materials allow the gradual shift of 
mechanical properties from the biomaterial to the healing tissue. This temporal response 
can be modulated either by varying the crosslinking density or making co-polymers to 
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achieve ideal mechanical properties over time. A successful reslt with biodegradable 
materials requires guided tissue regeneration which can withstand arterial pressures. This 
would depend upon the mechanical properties, degradation characteristics of the scaffold. 
The concept of biodegradable prostheses started with Vorhees et al., when they 
implanted porous Vinyon-N fabric tubes that allowed tissue ingrowth. Although these 
materials leaked, the concept of biodegradable materials emergd – so that the graft 
would have low porosity at implantation and then become more porous due to component 
degradation. Biodegradable materials have been used in a variety of wa s – as standalone 
materials, in combination with non degradable materials, or as a coating.  
2.5.2.3.1 Synthetic biodegradable materials 
Polylactic, polyglycolic acid and co-polymers 
The most widely investigated bioresorbable polymers are polylactic id (PLA) 
and polyglycolic acid (PGA). PGA is a highly crystalline, hydrophilic polymer which 
undergoes rapid hydrolysis. L-PLA is semi-crystalline, less hydrophilic (hence degrades 
slower) than PGA, and produces a physiologic degradation product (L-lactic acid). These 
reasons make it a more common biomaterial than PGA. Also, co-polymers of glycolic 
and lactic acid are commonly used. 
The concept of a resorbable vascular graft was introduced in the 1960s, and the 
first fully-resorbable graft was reported in 1979 [112]. These grafts uptured and dilated. 
In 1982, Greisler et al. implanted 3.5mm woven PGA grafts in rabbit abdominal aortas 
[113]. The grafts were resorbed and replaced by tissue that resembled native aorta 
histologically with a luminal coating of factor VIII positive cells, sub-endothelial region 
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of smooth muscle-like myofibroblasts and an outer layer of vascularized connective 
tissue. These replacements also remained patent at 7.5 months. The success of this study 
raised a number of questions - Was this response due to porosity of the ma erial? Was it 
due to the material degradation or the interaction of the material with inflammatory cells 
such that the release of growth factors by macrophages caused EC and myofibroblast 
recruitment?  
Comparison of this PGA graft with a Dacron graft with similar po osity (but non 
degradable) concluded that porosity alone was not responsible for improved healing. 
Several studies that followed strengthened the belief that factors related to macrophage 
mediated degradation of the material enhanced arterial regeneratio . The main factor, 
released by macrophages, responsible for the mitosis of SMCs, was identified to be 
bFGF.  
Aneurysmal dilatation has been the biggest obstacle with resorbable grafts. In 
order to prevent dilatation, the important aspect in resorbable grafts is that they must 
encourage regeneration of tissue of sufficient strength before the loss of prosthetic 
material strength occurs. Attempts to reduce dilatation have been made by slower 
degradation rate compositions eg. copolymers of pg910 Vicryl-polydioxanone (PDS) 
[114], Vicryl-polypropylene [115], enhancing tissue regeneration with growth factors 





Polyurethane and co-polymers 
Polyurethanes (PUs) are composed of a soft segment that provides flexibility and 
a hard segment that provides strength. PUs with a variety of mechanical properties can be 
made by using different monomers for these segments [39]. PUs have been tested as 
arterial substitutes since the 60s due to their superior elastic and compliant mechanical 
properties and their acceptable biocompatibility [116].  Polyester PUs were the first ones 
used for vascular applications; however, they underwent deterioration since they are 
susceptible to hydrolysis, and majority occluded in the first year of grafting [117]. 
Polyether based PUs were then created which underwent drastic biodegradation and were 
thus abandoned [118]. The Vectra graft (polyetherurethaneurea vascular a cess graft) 
received FDA approval in 2000 [39].A small diameter coronary bypass graft made of the 
same material is undergoing clinical trials. A variety of reinforcements (internal as well 
as external) have been researched to improve the mechanical properties of PU grafts 
however, due to differences in the mechanical properties(such as extensibility) of these 
materials, there is fear of delamination. Combining PU with PLLA improved suturability 
and allowed complete coverage with endothelial cells [119]. Animal trials with PUs have 
been very successful [120] though clinical trials showed disappointing results [121] since 
PUs are quite unstable in vivo. Also, there is concern over their degradation products 
being carcinogenic [19]. 
Polycarbonate based PUs resistant to hydrolytic as well as oxidative degradation 
have been synthesized [122, 123]. This graft is also undergoing clinical trials. 
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2.5.2.3.2 Biological scaffolds 
After years of studying synthetic polymers, it was thought that t e body’s 
response to natural/physiological materials might be better since they can be remodeled 
by cells and thus research on natural materials as vascular substitutes began. Natural 
materials have receptors for cell attachment and proliferation [124]. The first attempt to 
create entirely biologic vascular structures in vitro, using collagen and cultured vascular 
cells, was reported in 1982 [125]. 
Acellular ECM tubes 
Allograft rejection is a well known phenomenon. Studies conducted in 1970s 
showed that the main components causing an immune reaction in allografts were cells, 
and to some extent proteoglycans. Removal of these components proved the success of 
acellular dermal substitutes and inspired the use of this technique to prepare arterial 
substitutes. Small diameter arteries (porcine, canine, ovine) have been treated with a 
variety of chemicals to remove the cells and crosslinked by aldehydes, thereby reducing 
its antigenecity, while conserving all the material properties of the original tissue. 
Detergents such as sodium dodecyl sulfate (SDS), Triton X-100, enzyms such as trypsin 
and a combination of hyper and hypotonic buffers are the common methods of 
decellularization. Advantages of using decellularized arteries as vascular grafts are, ready 
availability, ease of procurement from donors (mostly xenogeneic), the avoidance of 
significant immunogenic issues usually associated with xenograft tissues and 
preservation of extracellular matrix important for strength and cell attachment [126]. 
Glutaraldehyde (which is the most common tissue fixative) however, is shown to be 
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cytotoxic and increases the material’s susceptibility to calcification [127]. Also, 
repopulation by host cells is seen to be incomplete. 
Modified human umbilical vein graft 
The unmodified human umbilical vein (HUV allograft) proved unsuccessful as an 
arterial replacement and hence was modified by glutaraldehyde treatment. Although early 
reports were positive, long term results indicated a high incidence of aneurysms (upto 
57% after 2yrs) [128]. 
Bovine carotid artery graft (xenograft) 
Studies involving heterologous tissue began as early as 1954 with the idea that the 
enzymatic removal of antigenic material such as cells could provide a xenogeneic (easy 
to obtain) non-immunogenic tissue substitute. However, clinical experienc with these 
grafts was similar to HUV grafts in that short term results were promising but incidence 
of aneurysms were very high within 4 yrs [129]. Also, some studies found that these 
grafts got stiffer after a few years and also had high late occlusion rates [130, 131]. 
Bovine ureter 
A product based on bovine ureter (FloNova) consisting of the ureters covered in 
polyester mesh are being marketed. Though they have not been tested in huma s, animal 
studies have shown good patency and resistance to dilatation after 17 months of 
implantation [132].  
Small intestinal submucosa (SIS) 
Various forms of intestinal tubes were employed as vascular substitute  but they 
were subject to thrombosis and aneurysms. The most investigated form was the small 
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intestinal submucosa (SIS). Although they exhibited good patency, aneurysms were still 
noted and in small diameter replacements, thrombosis was also observed. 
The failure of non-vascular tubes is attributed to the intrinsic difference in 
structure of arteries and these tubes. The intestinal collagen y r (ICL) derived from the 
submucosa of the small intestine which is primarily composed of type I collagen, was 
proposed as a vascular substitute over 30 years ago. It showed good patency as a large-
diameter (10 mm) graft [133]. As a small-diameter (4–5 mm) graft, the construct 
maintained sufficient mechanical strength, a non-thrombogenic surface, and long-term 
resistance to hyperplasia and aneurysm formation while acting as a scaffold for 
infiltration by host cells [134]. 
2.5.3 Creation of living grafts 
After the initial attempts to implant scaffolds and allow tissue ingrowth to occur, 
cell seeding in vitro was investigated to initiate functional tissue regeneration. For the 
complete functionality of a tissue engineered small diameter blood vessel to be realized, 
it was seen that cells would play an important role. 
2.5.3.1 In vitro cell seeding on scaffolds 
2.5.3.1.1 Synthetic materials 
PGA/PLA and co-polymers 
Niklason et al. [5] cultured bovine aortic SMCs onto tubular biodegradable 
polyglycolic acid (PGA) scaffolds and placed them in pulsatile flow bioreactors. The 
surface of the PGA scaffolds was chemically modified with sodium hydroxide, which 
caused ester hydrolysis on the surface of the fibers, leading to i creased hydrophilicity, 
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increased adsorption of serum proteins, and hence improved SMC attachment. Aft r 8 
weeks of pulsatile stretch in the bioreactor, ECs were seeded in the luminal surface of the 
grafts. These grafts were implanted in cows and remained patent in vivo up to 1 month. 
However, attempts to translate this approach to adult human cells initially failed.  
Hoerstrup et al. prepared tissue engineered grafts from nonwoven polyglyc ic-
acid (PGA) mesh coated with a thin layer of poly-4-hydroxybutyrate (P4HB) that were 
seeded with vascular cells. The seeded constructs were grown in vitro for 21days using 
biomimetic conditions and were then implanted as pulmonary artery replacements in 
lambs and were follwed up for 100 weeks. There was no evidence of thrombus formation, 
calcification, or aneurysm. Histology revealed cellularity and proteoglycans and 
increased collagen contents in all of the groups. The mechanical profiles f the grafts 
showed stronger but less elastic tissue properties than native pulmonary arteries [135].  
Poly(diol citrate) 
Novel biphasic scaffolds of concentric nonporous and porous layers of poly(diol 
citrate) were fabricated by Yang et al. [136]. The nonporous phase w  expected to 
provide a continuous surface for EC adhesion, proliferation, and differentiatio  and 
mechanical strength to the scaffold. The porous phase was to facilitate the infiltration and 
differentiation SMCs. Human aortic smooth muscle cells (HASMCs) and endothelial 
cells (HAECs) were seeded on these scaffolds where these cell  demonstrated survival 
and differentiation. When implanted subcutaneously, these scaffolds produced a thin 
fibrous capsule and allowed tissue ingrowth. 
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Poly(ethylene glycol) (PEG) 
Hahn et al. [137] designed poly(ethylene glycol) based hydrogels containing an 
adhesive ligand (RGDS) and a collagenase degradable sequence. They encapsulated 
mouse smooth muscle progenitor cells within these scaffolds and subjected them to 
biomechanical conditioning for 7 weeks. The conditioned scaffolds had significantly 
higher collagen levels and improved moduli relative to those grown under static 
conditions. 
Poly(caprolactone) (PCL) and copolymers 
A number of researchers [138, 139]are investigating elastic, poly(L-lactide-co-
epsilon-caprolactone) (PLCL) for vascular applications. Jeong et al. [140] seeded 
vascular SMCs on PLCL scaffolds. Cell adhesion and proliferation was seen to increase 
with increasing pore size.   
Shin’oka et al. prepared tubular scaffolds of PLCL with a PGA fabric 
reinforcement. These scaffolds were seeded them with autologous bone marrow cells and 
implanted in young patients for ~1-1.5 years. There were no complications such as 
thrombosis, stenosis, aneurysm formation or calcification [141]. 
PU and copolymers 
Van der li et al., prepared microporous, compliant, biodegradable, graftsfrom a 
mixture of polyurethane (95 weight %) and poly-L-lactic acid (5 weight %). When 
implanted in rat abdominal aortas for 12 weeks, the implants remained pat nt with no 
signs of dilatation or stenosis. ECs and SMCs grew in from the adjacent rterial tissue 
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[142, 143]. Also, elastic laminae were regenerated and this was attributed to the 
compliance and biodegradation of the material [111]. 
Williamson et al. [144] prepared composite scaffolds of PCL fibres to form the 
luminal surface, then electrospinning porous PU onto the back of the PCL fibres to form 
the vessel wall substitute. Human endothelial cells demonstrated strong attachment to 
these composite PCL-PU scaffolds and proliferated to form a monolayer with strong 
differentiation markers such as vWf and PECAM.  
2.5.3.1.2 Natural materials 
Reconstituted collagen 
Collagen from various sources is easily available in powder or solubilized form. 
Collagen gels have also been used because collagen is a major component of the 
extracellular matrix of blood vessels and a natural cell substrate. On gelation, soluble 
collagen assembles into linear filaments which aggregate to form fibers. This form is 
conducive to cell mediated remodeling and can be resorbed over time as th cells lay 
down their own matrix. However, these gels are found to have inadequate mechanical 
properties to withstand hemodynamic pressures and shear stresses. Conditioning of the 
gels with pulsatile flow has been explored as a means of stimulang matrix production 
and fiber alignment in order to strengthen them. While this conditioning has shown about 
200 % increase in tensile strengths, these values are still not sufficient for implantation 
[145, 146]. 
Crosslinking has also been utilized to increase strength and stability of collagen-
based vascular constructs however most crosslinking agents like glutaraldehyde, 
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carbodiimides are cytotoxic. Several groups have also used various non-degradable 
support structures to reinforce their collagen-based constructs, the most common being 
Dacron [147, 148]. This method however, moves away from the completely biological 
scaffold idea that drove the use of collagen in the first place. Berglund et al. [149] used a 
dehydrated, crosslinked collagen sleeve as a temporary support. Theyused 
dehydrothermal treatment and UV irradiation for crosslinking in order to eliminate the ill 
effects of glutaraldehyde crosslinking. This reduced the cytotoxici y due to crosslinking 
and provided ease of remodeling since lightly crosslinked matrices emodel better than 
highly crosslinked ones. However, delamination of the actual graft and support sleeve is 
an important concern in this method of reinforcement. Also, the rate of sleeve 
degradation and the level of integration between the layers are important.  
Tranquillo et al. [150] used magnetic force to orient collagen fibrils 
circumferentially during their formation in order to mimic the natur l vessel architecture 
thus improving mechanics as well as causing SMCs to orient circumferentially as well. 
Hyaluronic acid 
Esterified hyaluronic acid, Hyaff-11, is a hyaluronan-based biodegra able 
polymer developed for tissue-engineering applications [151, 152]. Turner et al. [153] 
examined the attachment and proliferation of human ECs on Hyaff-11. They observed 
that a specific type of Hyaff (pressed) supported cell growth the best. It allowed the 
formation of a complete monolayer by 20 days and the deposition of basement membrane 
components such as laminin, fibronectin, type IV and type VIII collagen. L pidi et al. 
[154] implanted HYAFF-11 tubes (2 mm diameter, 1 cm length) in the abdominal aortas 
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of rats as temporary absorbable guides to promote regeneration of vascular structures and 
observed that at 15 days, the luminal surface was completely endothelialized and by 21 
days matrix components such as elastin and collagen were synthesized [155]. 
Elastin 
Model polymers such as poly (GVGVP), the highly conserved, core sequence of 
elastin, were prepared and exhibited an elastic modulus similar to the femoral artery 
[156]. However, these polymers do not support cell adhesion very well. Nicol et al. [157] 
showed that the incorporation of RGD into these sequences can improve cell adhesion 
while maintaining the mechanical properties.  
A number of researchers are investigating electrospinning of biopolymers to 
create tubular scaffolds with nanoscale fibres. Daamen et al. [158] prepared a variety of 
biological scaffolds with defined biochemical, biomechanical, and morphologica  
characteristics using different ratios of elastin, collagen and chondroitin sulfate. Li et al. 
[126] compared the properties of electrospun fibers made of gelatin, collagen, solubilized 
alpha-elastin, and as a first, recombinant human tropoelastin. In contrast to collagen and 
gelatin, which could be spun into fibers in the nanometer scale, the diameter of 
alphaelastin and tropoelastin fibers was always in the range of microns. At an optimum 
delivery rate of 1.5 ml/h, fibers made of alpha-elastin and tropoelastin were elastic and 
had a wavy pattern, which mimic the wavy topology of elastin in atural tissues such as 





Fibrin is the natural regenerative biomaterial of the body. It can be formed by the 
crosslinking of autologous fibrinogen by thrombin, and the degradation rate of fibrin gels 
can be controlled by addition of fibrinolytic inhibitors such as aprotinin or α-
aminocaproic acid [159]. Fibrin stimulates synthesis of collagen and elastin and yields 
tissue engineered constructs with improved mechanical properties [160]. Fibrin also 
promotes angiogenesis through attachment and proliferation of endothelial cells but does 
not support platelet adhesion, suggesting that fibrin may be less thrombogenic than other 
biomaterial substrates [159]. Long et al. [161] also noticed organized elastic fibers within 
fibrin gels when neonatal SMC were cultured in fibrin gels. Also, the quantity of 
crosslinked elastic fibers was enhanced by treatment with TGF-beta1 and insulin. 
The advantage of gel systems are that scaffolds can be creatd in any shape and 
dimension and cells can be encapsulated within the liquid before gelation thus 
eliminating the problem of inadequate cell infiltration. Although a few r searchers [159] 
have shown that fibrin-based small-diameter tissue-engineered blood vessels exhibited 
enough mechanical strength to withstand implantation in the jugular veinsof lambs, 
where they remained patent for 15 weeks, all gel-based systems have been unable to 
function well under arterial pressures.  
2.5.3.2 In vitro cell ECM synthesis - Cell sheets 
In order to eliminate the effects of the biomaterial, some groups developed a 
strategy to produce a completely biological blood vessel engineered by the self-assembly 
method whereby sheets of fibroblasts, smooth muscle cells and endothelial cells are 
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wrapped around mandrels and then cultured under pulsatile flow to bring aout matrix 
production [162]. The monolayer of endothelial cells rests on a decellularized biologic 
extracellular matrix, named the inner membrane, which is composed of a scaffold of 
extracellular matrix components produced by human dermal fibroblasts in culture [163]. 
The major disadvantage with this method is the amount of time required to grow these 
vessels to obtain a mechanically strong vessel. Also the possibility of aneurysm 
formation is questioned.  
2.5.3.3 In vivo cell assembly - Fibro-collagenous tubes 
Taking advantage of fibrous tissue formation during wound healing, Eiken [164], 
Schilling et al. [165, 166], and most well known, Sparks [167, 168] first suggested the 
subcutaneous implantation of a mandril to allow a fibrocollagenous capsule to grow 
around it in 3–4 weeks. The mandril was removed and the tube that formed aroun  it was 
used for vascular replacements. Though this method provided a completely autologous 
vessel, a follow up study by Hallin et al. [169] showed that the tubes occluded very 
quickly due to thrombus formation mainly due to the exposure of collagen fib rs to 
blood. More recently, this idea of growing a blood vessel in the body was revived by 
Campbell et al. [170, 171] when they implanted polymer tubing into the periton al and 
pleural cavities of animals to grow vessels similar to natural arteries. The collagenous 
capsule mainly contained myofibroblasts and was covered by a confluent layer of 
mesothelial cells. Before implantation as carotid interposition grafts in rabbits, the tubes 
were everted so that the mesothelium lined the lumen. This allowed the grafts to remain 
patent for at least 4 months. Although all these methods eliminated immunogenic 
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problems (and later, thrombogenicity), two main questions arise. First, since the 
formation of a capsule is the body’s way of sealing off a foreign body, these 
fibrocollagenous tubes that form in vivo are relatively avascular and thus may reduce 
exchange between cells and blood when implanted intravascularly. Second, these 
‘‘biotubes’’ are rich only in collagen. Collagen provides tensile strength to arteries 
however, in order to sustain continual pulsatile flow and prevent dilatation (aneurysm 
formation), elastin is a necessary component [25]. Unfortunately, elastogenesis in tissue 
engineered constructs has been very limited [161, 172]. 
2.5.4 Environmental cues to improve graft properties 
In order to control and manipulate cell function, mechanical and biochemi al cues 
are required.  
2.5.4.1 Mechanical conditioning 
Different mechanical stimuli such as strain, pulsation and even flow have been 
used as a means to organize and hence strengthen, condition, and even cultur  tissue 
engineered constructs (TECs).  
Seliktar et al applied a 10% radial cyclic strain to human aortic smooth muscle 
cell-embedded collagen constructs for 4 or 8 days [173]. They showed that the 4-day 
strained constructs exhibited an enhancement of mechanical properties whereas after 8 
days of straining the mechanical properties deteriorated. On further investigation [174] 
they observed that MMP (specifically MMP-2) expression was significantly upregulated 
in the strained samples and the inhibition of this enzyme prevented the enhancement of 
mechanical properties. Since MMP-2 is known to degrade type I collagen s a normal 
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part of the process of matrix remodeling, they explained the observed changes in 
mechanical properties by hypothesizing that cyclic strain results in an upregulation and 
activation of MMP-2, leading to the local degradation of collagen fibrils as the cells 
reorganize the network. As more active MMP-2 accumulates in the constructs, matrix 
degradation far exceeds the reconstruction and organization by cells thus decreasing the 
ultimate stress and modulus of the constructs (at 8 days vs. 4 days). Kim et al. [175] 
performed short and long term (10 and 20 week) studies and observed that at both time 
scales SMC proliferation and expression of collagen and elastin increased in strained 
samples. 
Baguneid et al. [176] preconditioned their TECs in an in vitro pulsatile flow 
circuit to determine the effect of pre-conditioning on EC adherence a d retention on the 
establishment of physiologic flow and observed that retention was significantly enhanced 
by a period of preconditioning. 
Niklason et al. [5] cultured constructs made of SMCs and ECs on biodegradable 
scaffolds in specially designed pulsatile bioreactors. After 8 weeks of culture they were 
able to create vessels with rupture strengths greater than 2000 mmHg, collagen contents 
of up to 50 percent and differentiated SMCs.  
2.5.4.2 Chemical conditioning 
Chemical agents, especially aldehydes, have been used extensively to improve 
properties of TECs. Glutaraldehyde has been used by a number of researchers to 
crosslink and reduce the antigenicity of collagenous structures [149, 177] however it is 
seen to be cytotoxic and induces calcification thus leading to implant failure [178]. Other 
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crosslinkers such as epoxy compounds [179] and carbodiiamide based compounds [180] 
have also been investigated.  
Girton et al. [181] used a novel nonenzymatic crosslinking (glycation) of proteins 
to stiffen and strengthen tissue equivalents and to increase their resistance to 
collagenolytic degradation, without loss of cell viability. They added glucose and ribose 
to cell culture medium to increase glycation of tissue constructs and also showed that 
glycated tissue equivalents did not elicit inflammation or induce calcifi tion upon 
subcutaneous implantation. 
Other researchers have added various chemicals such as PDGF to increase SMC 
proliferation and TGFβ to increase smooth muscle alpha-actin expression [182], 20% 
FBS, ascorbic acid, copper sulfate, praline, alanine and glycine to provide buil ing blocks 
for protein synthesis as well as increase crosslinking of these prot ins [5] and sodium 
ascorbate to improve mechanical properties [183]. 
2.5.4.3 Genetic engineering 
In an artificial blood vessel the most important functions of ECs are preventing 
thrombus formation, elimination of fibrin layer if formed (clot removal) and preventing 
hyper-proliferation of SMCs (and hence hyperplasia). Genetic manipul tion of ECs is an 
avenue being pursued to achieve these functions however due to the number of 
complications concerning the transfection agent, behavior (adherence, proliferati n) of 
transfected cells, and testing for tranfection, limited in vivo studies with relevant genes 
have been performed.  
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Canine jugular ECs were transfected with human tissue plasminogen activator 
(tPA) using a retroviral vector [184]. Human tPA was detected by immunohistochemical 
staining in ~ 61% of the transduced cells and no significant difference in the rates of 
adherence or proliferation was seen in vitro between the transduced and non-transduced 
ECs. However, adherence of the transduced ECs in vivo was significantly lower than that 
of nontransduced ECs which the authors hypothesize to be due to reduced adherence after 
exposure to hemodynamic forces. Dunn et al. [185] also observed the same trend 
(reduced adherence of transduced cells on exposure to flow) however they also noticed 
that transduction with another gene (such as β-gal) did not affect adherence. They thus 
hypothesized that the cell loss may be due to proteolytic activity of tPA. On the addition 
of a protease inhibitor cell adherence improved, confirming this hypothesis. Kimura et al. 
[186] however observed no significant difference in retention between tPA transduced 
and control (lacZ transduced) cells. Their use of an adenovirus for transfection may be a 
possible cause for better retention.  
Rat smooth muscle cells (SMCs) stably transfected with the gene for the 
phenotype regulating protein cyclic guanosine monophosphate-dependent protein kinase 
(PKG) were used as a cell source in the preparation of three-dimensional (3D) collagen 
type I vascular constructs. PKG-transfected cells expressed sev ralfold higher levels of 
the contractile protein smooth muscle alpha-actin (SMA), relative to untransfected SMCs 
[187]. 
In conclusion, a number of strategies are being investigated to create a fully 
functional small diameter arterial replacement. New techniques and a number of 
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investigations are required to fully “engineer” an ideal blood vessel that matches every 


























An ideal tissue engineered blood vessel has not yet been created. Although cryopreserved 
allografts have been used quite successfully as vascular grafts in animal models [188, 
189], their limited shelf life, complications associated with the process of 
cryopreservations and most of all their availability still hamper th  widespread use [190]. 
Xenogeneic arteries do not have the problem of unavailability but cannot be used as is 
due to immune problems. Decellularization has been widely used to eliminate this 
problem since it maintains the extracellular tissue architectur  q ite well. However, 
decellularized arteries cannot be repopulated by host cells completely [10, 191]. We 
hypothesize that this is due to the dense collagen-elastin network. Also, the collagen 
within these scaffolds is highly thrombogenic and antigenic. We thus came up with the 
idea that removal of collagen in addition to cells leaving behind a pure elastin matrix will 
increase porosity of the scaffold hence improving host cell infiltration while reducing 
thrombogenicity as elastin is known to be non-thrombogenic [192, 193]. The long term 
objective of our research is to create ideal tissue engineered grafts. Consistent with the 
trends of tissue engineering, we aim to use a natural material – purified elastin - as our 
scaffold. Since our scaffold possesses natural tissue architecture, we hypothesize that it 
will integrate better with the native tissue. Also, since it is derived from a native artery, 
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the EL scaffold will have mechanical properties similar to the host tissue which will lead 
to lesser compliance mismatch at the anastomosis and hence better healing. 
 
3.2 Specific Aims 
Aim I : To create and characterize tubular pure elastin scaffolds for small diameter 
blood vessel tissue engineering  
Earlier studies have shown the complete removal of cells and collagen from porcine 
aortic tissue by treatment with cyanogen bromide. However this method of elastin 
scaffold formation caused a high degree of calcification in vivo. We will thus prepare 
tubular elastin scaffolds from porcine carotid arteries using the same method but will 
attempt to alleviate the calcification of these scaffolds by ethanol treatment which has 
been shown to reduce the calcification of tissue scaffolds [194].The scaffolds will be 
characterized for purity by histology and DNA analysis, mechanics by tensile test and 
burst pressure measurement and biodegradability by incubation in enzyme solution.  
Aim II : To repopulate the scaffold with vascular cells  
Since a tissue engineered graft must function immediately upon implantation, it must 
contain all the vascular cells that will provide all the signals necessary for proper 
functioning. Earlier studies have shown that cells do not infiltrate the scaffold in static in 
vitro culture. Thus dynamic culture using a pulsatile flow bioreactor and in vivo cell 
recruitment techniques will be used to repopulate the scaffold with all t e vascular cells 
(fibroblasts, smooth muscle cells (SMCs) and endothelial cells (ECs)). 
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Aim III : To reduce the thrombogenicity of the tubular elastin scaffolds 
Although elastin is inherently non-thrombogenic, we have seen platelet dh sion on our 
elastin scaffolds. In order to reduce this adhesion and hence improve the overall blood 
compatibility of our scaffolds, we intend to use a two pronged approach: 1) eparin 
immobilization and 2) endothelial cell culture on luminal surface. Heparin is a known 
anticoagulant that reduces platelet adhesion and activation and brings about the 
inactivation of thrombin by binding to antithrombin III. We aim to covalently bind 
heparin to elastin using EDC-NHS chemistry and testing the thrombogenicity of these 
crosslinked scaffolds (EL-Hep) in vitro with platelet adhesion assays, clotting time 
assays, and the ability of heparin to bind antithrombin and hence inactivate thrombin. 
Endothelium forms the natural anti-thrombogenic blood interface in arteries. We intend 
to mimic that by culturing endothelial cells on EL-Hep scaffolds. Endothelial cell culture 
on biomaterials has been investigated as a means to reduce thrombogenicity; however, 
two main problems remain.  The cells get activated just by culture on biomaterials or if 
they remain quiescent, they detach on establishment of flow. We will thus test both the 
profile of cells seeded on EL-Hep scaffolds as well as measure their retention on 
exposure to shear. 
 
3.3 Clinical Significance 
Cardiovascular diseases are the leading cause of death worldwide. Blood vessel 
replacement is a common treatment for vascular diseases such as atherosclerosis, 
restenosis and aneurysm, with over 300,000 bypass procedures performed each year. 
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Vein autografts are limited due to their availability. Although synthetic vascular 
replacements have been successful for large diameter arteries, hey have shown minimal 
success in arteries with diameters < 6mm. This is because most synthetic mat rials induce 
thrombus formation which, within a few months of implantation, causes failure of the 
vascular graft due to occlusion. Tissue engineering enables the development of fully 
biological vascular substitutes that restore, maintain and improve tissue function in a 
manner identical to natural host tissue; however, a reliable and xpandable cell source for 
tissue-engineered vascular graft (TEVG) has not been established. Our long term goal is 
to create a living tissue engineered vascular graft that is biodegradable, non-
thromobogenic, non-immunogenic and has mechanical properties that match the native 
arterial tissue. We propose to create pure elastin scaffolds fr m porcine carotid arteries, 
repopulate these scaffolds with vascular cells to make a living, responsive blood vessel 
replacement and also make these scaffolds nonthrombogenic by covalently binding 
heparin on the luminal surface of EL scaffolds and also culturing endothelial cells on the 
surface to provide a natural non-thrombogenic surface. The systematic approach 
proposed above could bring about a new development in the tissue engineerin of 
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Tissue engineered blood vessels represent the new era of small diameter vascular 
replacements that are ready to use, resemble native arterial tissue in mechanics, structure 
and function and above all, can provide a completely regenerated artery. Most tissue 
engineering approaches rely on a scaffold material to provide a temporary support for 
cells to attach to, grow on and synthesize their natural extracellular matrix. Synthetic 
polymers such as polyglycolic [195] or polylactic acid [196],  polyurethanes [197],   
naturally derived materials such as collagen [88], fibrin [159], and even combinations of 
natural and synthetic materials [139] have been investigated for tissue engineered 
arteries. Some researchers have even created completely autologo s tissues either in vitro 
by culturing sheets of vascular cells that they rolled to create tubes from [198] or in vivo 
by implanting polymeric tubes subcutaneously [199] or in body cavities [171] to create a 
tubular collagenous capsule as a graft.  
Decellularized tissues have also been investigated since they provide a natural 
structure for tissue engineering purposes. They match the host tissue properties very 
closely, provide a familiar matrix organization for cells to attach and grow on, and allow 
for true replacement and regeneration [200-202]. However, decellularized tissues have 
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shown limited repopulation [126]. We hypothesized that this may be due to the dense 
collagen – elastin network preventing cell infiltration [203]. In order to circumvent this 
problem, we have created tubular pure elastin scaffolds by selectiv y removing cells and 
collagen from porcine carotid arteries. This maintains the native arterial structure while 
increasing the porosity of the scaffold to allow repopulation in vitro or with host cells in 
vivo.  
Earlier studies in the lab showed that these scaffolds support vascular cell 
adhesion and proliferation; however, repopulation was still limited in static cultures even 
with the supply of exogenous growth factors, enzymes to help degrade the matrix, and 
even co-culture of fibroblasts with macrophages [204]. 
In this study, we wanted to evaluate the effect of mechanical stimulus on the 
repopulation of the elastin scaffolds. We designed a pulsatile flow bi reactor to mimic 
the in vivo arterial flow conditions and hence enhance scaffold cellularization. Pulsatile 
bioreactors have been used in the repopulation of decellularized heart valves [205], 
creation of functional blood vessels from biodegradable synthetic polymers [5, 206], and 
the pre-conditioning of engineered grafts before vascular implantation [176].  
 
4.2 Methods 
4.2.1 Preparation of tubular elastin scaffolds 
Porcine carotid arteries (5-7mm diameter) were harvested at a local 
slaughterhouse, rinsed in cold phosphate buffered saline (PBS) and transported to the 
laboratory on ice. They were then cleaned of adherent tissue and fat and rinsed in cold 
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PBS. Vessels were treated with cyanogen bromide (CNBr) [207] to remove cells, 
collagen and other ECM components, leaving behind pure elastin tubes. Briefly, f esh 
tubular carotid artery samples were treated with 50 mg/ml CNBr (Acros Organics; Morris 
Plains, NJ) in 70% formic acid (Acros Organics; Morris Plains, NJ ) (8 ml/cm2) for 19 h 
at 20° C with gentle stirring, followed by 1 h at 60° C and boiling for 5 min to inactivate 
CNBr. The scaffolds were then stored in 70% ethanol as a disinfectant. 
4.2.2 Characterization of scaffolds 
4.2.2.1 Histology 
Elastin tubes were rinsed with phosphate buffered saline (PBS), embedded in 
Tissue Tek OCT compound (Sakura Finetek, U.S.A. Inc., Torrance, CA),and frozen at -
80°C after which 6 µm thick sections were cut using a cryostat (Microm HM 505 N, 
Mikron Instruments, Inc.) and collected on glass slides. The samples were evaluated 
using hematoxylin and eosin (H&E) staining for general morphology, Masson’  
trichrome stain to verify removal of collagen from the matrix and Verhoff-Van Gieson 
stain (VVG) to evaluate the integrity of elastic fibers.  
4.2.2.2 DNA assay 
Quantitative DNA analysis for the scaffolds was done using the DN asy® tissue 
kit (Qiagen Inc. Valencia, CA). The protocol for DNA purification from rodent tails was 
used as described in the kit since the expected yield was 1 – 4µg DNA/mg wet tissue. 




4.2.2.3 In vitro biodegradability 
Elastin scaffolds, 5–10 mg lyophilized samples (n = 3) were incubated in 1 mL of 
0.1 U/mL ultra-pure elastase (dissolved in 100 mM Tris, 1 mM CaCl2, 0.02% NaN3, pH 
7.8) for a total of 12 days on a shaker at 37°C. At day 1, 2, 3, 7, 8, 10 and 11, samples 
were retrieved, rinsed three times with distilled water and lyophilized. The percentage of 
mass remaining after digestion was calculated from the dry weight before and after 
enzyme digestion.  
4.2.2.4 Mechanical testing - Uniaxial tensile testing of rings 
2-3 mm wide rings of fresh porcine carotid arteries and tubular elastin scaffolds  
(n = 6 each) were subjected to radial tensile testing at a strain rate of 5 mm/s until failure 
on an MTS (Synergie 100) machine. Stress strain characteristics were plotted and the 
ultimate stress and engineering strain values were calculated. Young’s modulus was 
calculated between 10 and 20% strain on the stress strain curve since this is the maximum 
strain usually experienced by arteries. 
4.2.2.5 Mechanical testing - Burst pressure 
Burst testing of the scaffolds was performed by the delivery of distilled water 
through a peristaltic pump. The maximum (burst) pressure of the scaffold was determin d 
using a pressure transducer connected to a data acquisition program on a laptop. Thirty-
millimeter long scaffolds were attached via tapered adapters directly onto the transducer 
on one side and the pressurized water on the other. The system was progressively 
pressurized until vessel failure. 
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4.2.3 Repopulation of scaffolds 
4.2.3.1 Design of pulsatile flow bioreactor 
The flow chart of the bioreactor system developed for mechanical conditioning of 
the constructs and stimulation of in vitro scaffold repopulation is shown in Figure 4.1. A 
Masterflex L/S variable speed digital peristaltic pump fitted with an L/S multichannel 
pump head (Cole-Parmer, Vernon Hills, IL) was used with platinum-cured silicone 
tubing (Cole Parmer) to create the flow loop of the cell culture media. The flow from the 
peristaltic pump was passed through a pressure unit controlled by a timer circuit (an IC 
555 pulse generator circuit with variable resistors and capacitor shown in Figure 4.2) to 
provide the required beats/min pulse rate by adjusting the opening and closing of a 
solenoid valve to allow air flow onto the polyurethane balloon through which te media 
flowed. Check valves at the inlet and exit of the pump and pressure unit prevented 
backflow of the media. Pulse rate could be adjusted by changing the resistor/capacitor 
components of the timer circuit. Gas exchange in the construct chamber and media 
reservoir occurred through 0.2 µm filters that were fitted to ports created in the vessels. 
The gas permeable platinum-cured silicone tubing interconnecting system components 
also provided an additional means of gas exchange. System components were terilized 
(autoclave or ethylene oxide) prior to assembly in a laminar-flow hood, and all 
components except the peristaltic pump digital controller and bioreact circuitry were 
housed in a 5%CO2/37°C tissue culture incubator for studies.  
Vessel-wall shear stress was computed using the Hagen–Poiseuille formula:  
shear stress=4 µQ/πR3, 
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with µ being fluid viscosity (N-s/m2) , Q being the volumetric flow (m3/s), and R being 
the radius of the graft (m). 




Figure 4.1 Flow chart of pulsatile flow bioreactor connection. The pressure unit contains 
a polyurethane balloon that is inflated and deflated with the help of air let in and out by 








Figure 4.2 IC 555 pulse generator circuit. 
 
4.2.3.2 Cell culture 
 
Figure 4.3 Solidworks designs of (A) construct chamber and (B) pulley system for 
rotation during seeding 
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Rat aortic vascular cells (fibroblasts/SMCs) were seeded onto the EL scaffolds 
either on the adventitial side or on the luminal side and allowed to culture under static 
conditions for 1-7 days before being subjected to pulsatile flow in the bior actor system. 
Table 4.1 gives the descriptions of experiments. With all the different cell culture 
methods used, flow rate was changed in different experiments (to change wall shear 
stress) as another variable for cell infiltration. Even for the static culture period, the 
scaffolds were connected in the construct chamber (Figure 4.3 A) before seeding. When 
cells were seeded on the adventitial side, the cell suspension was pipetted onto one side 
of the scaffold and allowed to sit for 30 mins before being turned around to expose the 
other half onto which cells were then suspended. However when cells were se ded onto 
the luminal side, a cell suspension was pipetted directly into the lumen of the scaffold and 
the pulley arrangement (shown in Figure 4.3 B) was used to slowly rtate the scaffolds to 
allow the cells to attach throughout the inner surface. Figure 4.4 shows the experimental 
set-up of the pulsatile bioreactor system. Cell seeded scaffolds were cultured for 1-8 
weeks under pulastile flow in a humidified environment at 37°C in a CO2 incubator. 
















Cell suspension pipetted onto adventitial surface, static culture 4h - 7 




Cell suspension pipetted onto adventitial surface, rotation for 1.5 days 




Cell suspension filled within scaffold lumen, static culture 1 - 4 h, 




Cell suspension filled within scaffold lumen, slow rotation for 48h, 




Cell suspension filled within scaffold lumen, slow rotation for 48h + 













Cell sheet formation by addition of ascorbic acid 2-phosphate, 





Encapsulation in collagen and collagen-agarose gel as delivery 
mechanism: 
loaded within lumen, static culture 2 - 7 days, pulsatile flow 4 weeks 






Exogenous bFGF added to circulating media, static culture 1 - 7 days, 
pulsatile flow 4 weeks 
Table 4.1 Details of cell culture experiments for improving cell infiltration in 




Figure 4.4 Experimental set-up of bioreactor system. (A) Electrical components, (B) 
system within incubator, (C) pump drive, (D) pressure unit with polyurethane balloon 
and (E) construct chamber 
 
4.2.3.3 Analysis 
Many different cell seeding and flow regimen were followed after which the 
grafts were removed from the chamber, each split into three groups and analyzed by 
DNA assay (as described earlier), LIVE/DEAD assay (live cells appear green and dead 
cells red) as described by the manufacturer (Molecular Probes, Eugene, OR) or H&E 





4.3 Results and Discussion 
4.3.1 Scaffold Characterization 
Histological analyses showed complete removal of collagen and cells by CNBr 
treatment leaving behind a highly porous, pure elastin scaffold. DNA assay (Figure 4.5) 
confirmed the complete removal of cells from porcine carotid arteries (95 % lesser DNA 
in elastin scaffolds compared to fresh carotid arteries). H&E staining (Figure 4.6 A, B) 
showed complete removal of cells, Masson’s trichrome (Figure 4.6 C, D) showed 
complete removal of collagen and VVG staining (Figure 4.6 E, F) showed that the elastin 
fibers maintained their integrity and were not degraded. 
 
 
Figure 4.5 DNA assay of fresh carotid artery and elastin scaffolds showing more than 95 




Figure 4.6 Histological analyses of porcine carotid artery before and after CNBr 
treatment. (A) H&E, fresh (B) H&E, CNBr treated (C) Masson’s trichrome, fresh (D) 
Masson’s trichrome, CNBr treated (E) VVG, fresh (F) VVG, CNBr treated. In Masson’s 
trichrome stain blue represents collagen and pink represents elas in. In VVG stain black 
represents elastin and pink represents collagen (Magnification x200). 
 
In vitro biodegradability studies showed that elastin scaffolds degraded 
gradually with time, reaching 50% degradation in less than 2 daysand complete 













Figure 4.7 In vitro enzyme degradation of elastin scaffolds. Values are expressed as 
percentage (%) mass remaining after exposure to enzyme. 
 
Uniaxial tensile test data (representative curves in Figure 4.8) showed that fresh 
carotid arteries exhibited typical biphasic characteristics with low modulus (150–200 
kPa) up to ~50% strains and high modulus (3.5–4MPa) from 100% to 150% strain. The 
ultimate stress ranged from 1.76 to 2.64MPa whereas the maximum strain ranged from 
110% to 200%. Elastin scaffolds showed perfectly linear stress - strain characteristics 
with a modulus ~400 kPa. The ultimate stress ranged between 0.42 and 0.85MPa for 
strains between 80% and 140%. These characteristics are very much within the range of 











Figure 4.8 Tensile testing of 3mm wide rings of fresh and CNBr treated carotid arteries. 
 
On increasing the pressure of water through the elastin scaffolds during burst 
pressure measurement, the scaffold underwent pulsations of increasing amplitudes until 
~100mmHg beyond which the pressure in the scaffolds did not increase due to leakage 
due to the high porosity of the scaffolds. Thus the burst pressure could not be determined. 






Figure 4.9 Burst pressure measurement system. (A) Set-up of entire system (inset shows 
curve of  pulsatile flow through scaffold), (B) EL scaffold before flow is started, (C) 
porous scaffold starts leaking at ~80mmHg 
 
4.3.2 Scaffold repopulation 
We have created a bioreactor which can simulate physiological smal diameter 
arterial flow conditions in terms of wall shear rate, pulsatile flow and pressure, all of 
which are under the user’s control. This system can support the growth and maturation of 
tissue engineered grafts. A number of strategies (detailed in Table 4.1) were employed to 
improve cell infiltration into the EL scaffolds. Initial experiments were conducted with 
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SMCs cultured statically either on the adventitial or luminal side for 1 day after which 
pulsatile flow of different flow rates was established for 1 – 4 weeks. At the end of the 
dynamic (flow) culture, no cells were seen on the surface or within the interstices of the 
scaffold. We hypothesized that the cells may have detached due to th shear stress on 
exposure to flow. Thus, static culture time was increased and experiments were 
conducted with 4h – 1 week static culture before flow. When cells were statically 
cultured for > 48h, they were able to resist detachment and live cells w re seen on the 
surface however they did not infiltrate the scaffold at all. Figure 4.10 shows 
representative Live Dead assay (A) and H&E staining (B) images after 1 week of culture 
under flow and after 4 weeks of flow (C) after 1 week of static culture.  
 
 
Figure 4.10 (A) Image of live dead analysis after 1 week of bioreactor culture (B) Image 
of H&E stain after 1 week of bioreactor culture, (C) Image of live dead analysis after 4 
weeks of bioreactor culture. 
 
Due to this lack of cell infiltration, a vacuum suction mechanism (nspired by that 
described by Soletti et al. [209] was created where the cell suspension was passed 
intraluminally in a small loop while vacuum was applied to the entir chamber. This 
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method is meant to allow the medium (liquid phase) to come out of the porous scaffold 
while the cells get lodged within the interstices however this method too did not provide 
any infiltration although it allowed the establishment of flow within 1 day of vacuum 
application without the loss of cells.  
In order to improve cell adhesion to scaffolds to improve the chances of 
infiltration, we created cell sheets with fibroblasts or SMCs by the addition of ascorbic 
acid 2-phosphate to the culture medium. After 1 week of culture, cell sh ets were scraped 
from the culture plates and these sheets were placed on the adventitial side of the scaffold 
and allowed to culture statically for 48h before the start of pulsatile flow.  bFGF was also 
added to the circulating medium to improve infiltration by chemotaxis. However, despite 
all the stimulation, mechanical and chemical, the elastin scaffolds used in this study were 
not repopulated by cells even after 8 weeks of culture. 
 
4.4 Conclusions 
We successfully designed and used a pulsatile flow bioreactor with controllable 
flow properties however, when used for providing mechanical stimulus to encourage cell 
infiltration into elastin scaffolds, the system did not help. Cells r mained on the surface 
of the scaffold irrespective of the culture time, culture conditions eg. addition of 
exogenous growth factors, and even mechanical stimulation (physiological y similar 
pulsation and shear stress). In previous biocompatibility studies in rats [203], the 
scaffolds were completely repopulated by cells. This led us to believe that a mul if ctorial 
environment (with growth factors and enzymes) will enable the repopulation of these 
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elastin scaffolds. We thus decided to investigate a novel in vivo repopulation technique 























IN VIVO CELLULAR REPOPULATION OF TUBULAR ELASTIN SCAFFOLDS 
MEDIATED BY BASIC FIBROBLAST GROWTH FACTOR 
 
5.1 Introduction 
Cardiovascular diseases are the leading cause of death in the US. More than 
500,000 bypass surgeries are performed annually [210]. Typically, autologous saphenous 
veins or internal mammary arteries are used for these procedures; however, limited 
availability has urged the need for synthetic replacements. In small diameter arterial 
replacements (<6mm), synthetic grafts often fail due to thrombosis-related occlusion. 
Tissue engineering of small diameter arteries has been the holy grail of research in the 
last decade. Since the overall goal is to mimic natural arteries, extracellular matrix 
(ECM) materials have been widely researched. Due to its abund nce in the ECM, 
collagen is the most common matrix component utilized for vascular tissue engineering. 
On gelation, soluble collagen assembles into linear filaments which aggregate to form 
fibers. This fibrillar form is conducive to cell mediated remodeling and is remodeled over 
time as the cells lay down their own matrix [149]. However, these g ls have inadequate 
mechanical properties to withstand hemodynamic pressures and shear stresses [145]. 
These collagen-based grafts also lack the elastin required to withstand continual pulsatile 
flow. 
Other materials being researched for vascular graft tissue engineering are 
decellularized arteries (porcine, canine, ovine) containing the native collagen and elastin 
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networks [126, 127, 211]. Advantages of using decellularized xenogeneic arteries as 
vascular grafts include ready availability, ease of procurement from donors, and the 
preservation of the ECM which is important for strength and cell attachment [126]. 
However, cellular repopulation in decellularized arteries has been shown to be 
incomplete [212, 213]. We hypothesized that this lack of cellular infiltration is related to 
the lower porosity of tissue due to dense collagen-elastin networks, and that the removal 
of collagen from the artery, in addition to cells, would increase the porosity of the 
scaffold. In our previous study, small square elastin scaffolds made from porcine aortic 
wall showed better in vivo repopulation compared to patches of decellularized aorta when 
implanted subdermally in rats [203]. 
In the present study, we wanted to test if small diameter tubular elastin scaffolds 
could be repopulated in vivo, in a rat subdermal implant model, for vascular graft 
applications. We also wanted to test if controlled release of bioactive molecules such as 
bFGF would enhance cellular infiltration in these scaffolds. The results demonstrated that 
the sustained release of bFGF brings about enhanced repopulation of elastin sc ffolds 
while inhibiting calcification. Such an in vivo repopulation technique could be used as a 
minimally invasive method for autologous cell repopulation of elastin scaffolds for 
vascular grafts in bypass surgeries. If this approach is succe sful, it can be easily 
translated to clinical needs. We can envision placing tubular scaffolds subdermally in the 
same patient who needs vascular replacement surgery. After appropriate time for tissue 
remodeling, the cellularized graft can be explanted and used immediately for vascular 
replacement.  
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5.2 Materials and methods 
5.2.1 Tubular scaffold preparation 
Porcine carotid arteries (5-7mm diameter) were harvested at a local 
slaughterhouse, rinsed in cold phosphate buffered saline (PBS) and transported to the 
laboratory on ice. They were then cleaned of adherent tissue and fat and rinsed in cold 
PBS. Tissues were subsequently processed for the preparation of tubular elastin scaffolds, 
by cyanogen bromide (CNBr) treatment, to remove cells, collagen and other ECM 
components except elastic fibers [207]. Briefly, fresh tubular carotid artery samples were 
treated with 50 mg/ml CNBr (Acros Organics; Morris Plains, NJ) in 70% formic acid 
(Acros Organics; Morris Plains, NJ )(8 ml/cm2) for 19 h at 20° C with gentle stirring, 
followed by 1 h at 60° C and boiling for 5 min to inactivate CNBr. Thescaffolds were 
then stored in 70% ethanol as a disinfectant. This method produced pure elastin sc ffolds 
(shown in chapter 4). For the subdermal implant study, samples wer  further washed in 
sterile saline.  
5.2.2 Preparation of bFGF loaded elastin tubes 
Human recombinant basic fibroblast growth factor (bFGF, PeproTech Inc, Rocky 
Hill, NJ) was reconstituted in 5mM Tris buffered saline (TBS) (pH = 7.6) and diluted in 
the same buffer to a working concentration of 6.6 µg/ml. Agarose (MP Biomedicals; 
Solon, OH) solution (2 %) was made in TBS, microwaved for 2 minutes to dissolve the 
agarose and maintained at 40°C on a heating plate. This solution was mixed with the 
working solution of bFGF in a 1:1 ratio to give a final agarose solution of 1 % containing 
3.3 µg/ml bFGF. For the experimental (EL-Gel-FGF group), 300 µl of this solution was 
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pipetted into tubular elastin scaffolds. The agarose gel solidified immediately and then 
both sides of the scaffold were tied with a suture to keep the gel within the scaffold for 
the entire duration of implants. For the control (EL-Gel group), elastin tubes were filled 
with 1% agarose gel only. This entire procedure was done under sterile conditions. The 
scaffolds (n = 6 per group per time point) were prepared 1-2 hours before use and were 
stored in sterile conditions until implanted. 
5.2.3 In vitro bFGF release 
To evaluate the sustained release of bFGF from agarose gel within the elastin 
scaffold, we prepared bFGF loaded tubes in the same way as described above. These 
samples were then immersed separately in 1ml TBS (pH 7.6 containing sodium azide) in 
centrifuge tubes and gently shaken at 37°C for 28 days. Solutions were replaced at 
regular time points with fresh TBS. The quantity of bFGF released in solution was 
evaluated using a bFGF ELISA kit (Calbiochem; San Diego, California).  
5.2.4 Subdermal implantation of tubular elastin scaffolds 
EL-Gel-FGF and EL-Gel samples were implanted subdermally (n = 6 per group 
per time point) in adult male Sprague Dawley CD rats weighing 250–300g, placed under 
general anesthesia, as described earlier [214]. Briefly, a 1 cm wide skin incision was 
made on the back of the rats, and two subcutaneous pouches were created in each rat by 
blunt dissection. One scaffold (~20 mm long, containing 300µl gel) was placed into each 
pouch and the incision closed with surgical staples. Animals were recovered and 
provided with food and water ad libitum. Upon recovery, analgesic (buprenorphine, 0.05 
mg/kg, s.c.) was provided. After 7 and 28 days, animals were euthanized by CO2 
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asphyxiation and the implants along with surrounding capsules were retri ved for 
analysis. The agarose gel was removed from all samples and stored separately.  
5.2.5 Histology 
Explanted elastin tubes were rinsed with phosphate buffered saline (PBS), 
embedded in Tissue Tek OCT compound (Sakura Finetek, U.S.A. Inc., Torrance, CA),
and frozen at -80°C. 6 µm thick sections were cut using a cryostat (Microm HM 505 N, 
Mikron Instruments, Inc.) and collected on glass slides. The samples were evaluated 
using hematoxylin and eosin (H&E) staining for general morphology and Gomori’s one 
step trichrome (Gomori’s) stain for matrix formation. Dahl’s Alizarin stain was used for 
identifying calcium deposits. Verhoff-Van Gieson stain (VVG) was used to evaluate the 
integrity of elastic fibers. For explant analysis, digital pictures were taken from each 
section at 200X magnification and cell infiltration depth was measur d using the Spot 
Advanced software (Diagnostic Instruments Inc., Sterling Heights, MI). Cells populated 
elastin scaffolds from outside in and thus infiltration depths were measured as the 
distance (in micrometers) between the innermost cellularized layer and the outer 
(abluminal) edge of the scaffold. Six measurements were taken from each slide for each 
implant. (n = 3 slides per group; 18 measurements per group) 
5.2.6 Immunohistochemistry 
Cryosections (n = 3 per group) were immunostained using anti-rat prolyl-4-
hydroxylase primary antibody (1:500 dilution) for fibroblasts (Sigma, St. Louis, MO), 
anti-rat macrophage (1:200 dilution) (Chemicon, Temecula, CA), anti-α-smooth muscle 
actin (1:200 dilution) for myofibroblasts (Sigma, St. Louis, MO) and ti-rat smooth 
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muscle heavy chain myosin (1:3000 dilution) for smooth muscle cells. Vectastain Elite 
ABC Kit for mouse IgG and DAB substrate were used to visualize the specific staining 
(Vector Laboratories, Burlingame, CA). To minimize cross reactivity, rat-adsorbed 
biotinylated anti-mouse IgG at 5 mg/ml (Vector Laboratories) was used in place of the 
biotinylated secondary antibody provided with the staining kit. Negative controls were 
included with the omission of the primary antibodies. Sections were counterstained with 
hematoxylin. 
5.2.7 Protein extraction and analysis 
Elastin scaffolds and gels (5 samples each) were separately weighed and 
homogenized on ice for two minutes in 300µl of extraction buffer (5mM TBS pH 7.6, 
0.05% Triton X-100, 1mM proteinase inhibitor cocktail (Sigma Aldrich)). The 
homogenate was left on ice for 2 hrs after which it was ultracentrifuged (10,000 rpm, 20 
minutes at 4°C). The supernatant was collected and analyzed for total pr tein content 
using BCA assay, bFGF content using an ELISA kit (Calbiochem) and matrix degrading 
enzymes such as MMPs using gelatin zymography. 
5.2.8 Mechanical testing 
2-3 mm wide rings of fresh porcine carotid arteries, tubular elastin scaffolds 
(before implant, after 7 and 28 days of subdermal implantation) (n = 6 each) were 
subjected to radial tensile testing at a strain rate of 5 mm/s until failure on an MTS 
(Synergie 100) machine. Stress strain characteristics were plott d and the ultimate stress 
and engineering strain values were calculated. Young’s modulus was calculated between 
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10 and 20% strain on the stress strain curve since this is the maximum strain usually 
experienced by arteries. 
5.2.9 Calcium assay 
Quantitative analysis of calcium content in explanted scaffolds was performed 
according to a previously described procedure [215]. Briefly, a section of the capsule-free 
scaffold (n = 6 per group) was lyophilized, weighed and digested in 1ml of 6N HCl at 95 
°C for 10 h. Digested samples were evaporated under a continuous stream of nitrogen gas 
until dry, and the residual material was dissolved in 1ml of 0.01N HCl. Ca cium 
concentration was determined using an atomic absorption spectrophotometer 
(PerkinElmer, Norwalk, CT) and expressed as µg Ca/mg dry tissue. 
5.2.10 DNA assay 
Quantitative DNA analysis for the scaffolds was done using the DN asy® tissue 
kit (Qiagen Inc. Valencia, CA). The protocol for DNA purification from rodent tails was 
used as described in the kit since the expected yield was 1 – 4µg DNA/mg wet tissue. 
Absorption was measured and the quantity of DNA calculated. Values are expressed as 
µg DNA/mg wet sample weight (n=6). 
5.2.11 Statistical analysis 
Results are expressed as means ± standard error of the mean (SEM). Statistical 
analyses of the data were performed using single-factor analysis of variance (ANOVA). 
Subsequently, differences between means were determined using the least significant 




The purity of elastin scaffolds prepared by the CNBr treatmen , valuated by 
histology, SEM and other assays has been described in detail previously [203]. In the 
current study we attempted to repopulate tubular elastin scaffolds with cells by 
implanting them in a rat subdermal model. We developed an agarose gel system for the 
sustained delivery of bFGF within the scaffolds to improve cell infiltration (Figure 5.1).   
 
 
Figure 5.1 Schematic of in vivo cell recruitment strategy into tubular elastin scaffolds 
 
5.3.1 Release of bFGF from agarose gels 
In vitro release studies of bFGF from 1% agarose gels showed a steadyrelease of 
bFGF up to ~92% in 10 days (Figure 5.2 A). Quantification of bFGF extracted from 
explanted scaffolds and gels showed that the growth factor was gradually released over 
28 days from the agarose gel in the lumen and it moved into the elastin scaffold (Figure 
5.2 B). There was a 70% release from the gel in 7 days and a total 80% release in 28 
days. Thus, in vivo release of bFGF correlated well with n vitro release. 
5.3.2 Cellular infiltration and neo-matrix deposition in subdermal implants 
Macroscopically, the explants maintained their tubular structure and were covered by a 
very thin capsule that could be removed easily (Figure 5.3 A and 5.3 B). Agarose gels 
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placed in the lumen were intact and could be removed easily.  H&E staining showed that 
at 7 days there was almost no cellular infiltration in the EL-Gel group whereas there was 
a little infiltration in the EL-Gel-FGF group (Figure 5.3 C and 5.3 D).  
 
 
Figure 5.2 Sustained release of bFGF from agarose gels in vitro and in vivo (A) shows 
70% release in 7 days. In vivo release of bFGF (shown as triangles), matches well with in 
vitro results. The total release in vitro was ~92% in 10 days. (B) shows the gradual 
decrease of bFGF in the gel and a corresponding increase in the surrounding scaffold 
showing the sustained release through the gel and into the scaffold. 
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At 28 days, EL-Gel showed similar infiltration as EL-Gel-FGF at 7 days whereas EL-
Gel-FGF showed dense, organized infiltration halfway into the tissue (Figure 5.3).  
Infiltration depth measurements (Table 5.1) showed significantly higher infiltration at 28 
days in the EL-Gel-FGF group (45.59% ± 1.98) as compared to all othergroups. 
Gomori’s trichrome staining (Figure 5.3 F) for collagen showed organized collagen 
deposition within spaces between the sheets of the elastin only in the 28d EL-Gel-FGF 
scaffolds.  There was hardly any collagen deposition in the remaining groups (data not 







Figure 5.3 Macroscopic and histological features of explanted EL scaffolds (A) hows 
the thin capsule over the explants (B) shows the structural integrity of the explants. 7d 
EL-Gel (C), 7d EL-Gel-FGF (D) and 28d EL-Gel-FGF (E) representative images. Host 
cells could only infiltrate scaffolds by abluminal side. There is visibly reduc  cell 
infiltration in EL-Gel group. Gomori’s trichrome staining (F) shows new collagen fibers 
between layers of elastin only in the 28d EL-Gel-FGF group. The red lines indicate the 
scaffold-capsule interface. H&E stain (cell nuclei are dark blue and matrix is p nk), 
Gomori’s trichrome stain (cell nuclei are dark blue, collagen is blue – green and elastin is 
pink. Original magnifications (C–E), 200 X and (F) 400 X. 
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Table 5.1 Depth of cellular infiltration into elastin scaffolds implanted subdermally. 
There was significantly more repopulation in the 28dEL-Gel-FGF scaffolds as compared 
to EL-Gel scaffolds (p<0.01). 
 
The majority of infiltrating cells in both groups at both time points were 
fibroblasts of which some stained positive for smooth muscle α-actin indicating their 
myofibroblastic phenotype (Figure 5.4 A and 5.4 B). Significant macrophage infiltration 
was observed at 7 days which reduced considerably at 28 days (Figure 5.4 C and 5.4 D). 
However, there were no smooth muscle cells as observed by the absence of smooth 
muscle heavy chain myosin staining (data not shown). 
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Figure 5.4 Immunohistochemical characterization of infiltrating cells in EL-GelFGF 
scaffold. A)  immunostained for fibroblasts at 28 day, B) immunostained for smooth 
muscle α-actin at 28 day, C) immunostaining for macrophages at 7 day, D) 
immunostaining for macrophages at 28 day. The red lines indicate the scaffold-capsule 
interface. Insets show negative stains. Original magnifications 400 X. 
 
Quantification of DNA (Figure 5.5) indicated twice as much DNA in the 28d EL-
Gel-FGF group (300 ± 40 ng/mg wet tissue) as compared to 28d EL-Gel as well as 7d 
EL-Gel-FGF (160 ± 50 ng/mg wet tissue). The value for 28d FGF group was statistically 




Figure 5.5 Quantification of DNA within explanted scaffolds. At 28 days EL-Gel-FGF 
scaffolds had significantly more DNA (p<0.05) 
 
5.3.3 Changes in mechanical properties  
Uniaxial radial tensile testing of rings of fresh porcine carotid arteries, elastin 
scaffolds (before implantation) and samples explanted at 7 and 28 days was done up to 
failure (Figure 5.6). Fresh carotid arteries showed typical biphasic characteristics with 
low modulus (150-200 kPa) up to ~ 50% strains and high modulus (3.5 – 4MPa) from 
100 – 150% strain. The ultimate stress ranged from 1.76 – 2.64 MPa whereas the 
maximum strain ranged from 110% to 200%. Elastin scaffolds showed perfectly linear 
stress strain characteristics with a modulus ~400 kPa. The ultimate stress ranged between 
0.42 and 0.85 MPa for strains between 80 – 140%. These characteristics are very much 
within the range of mechanical properties of pure elastin. [208]  
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Figure 5.6 Uniaxial tensile testing of fresh artery and scaffold rings. By 28 days, EL 
scaffolds were stiffer and less elastic. 
 
 
Table 5.2 Mechanical properties of pre-implant and subdermally implanted elastin 
scaffolds. Values are averages of 6 samples ± SEM. 
 
Both the EL-Gel and EL-Gel-FGF groups after 7 day subdermal implantation had 
exactly the same characteristics as the unimplanted elastin scaffold. However, after 28 
days of implantation, both groups were stiffer with moduli ranging 1.3 – 1.65 MPa and 
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had reduced elasticity. EL-Gel-FGF scaffolds could be strained upto ~80% whereas EL-
Gel scaffolds were even less elastic and could only be strained upto ~50% (Table 5.2). 
MMP-2 was detected in both groups at both 7 and 28 days whereas MMP-9 was detected 
in both groups only at day 7 (Figure 5.7 A). Elastic fiber degradation was also seen on th  
outer (abluminal) side of the scaffolds (Figure 5.7 B).  
 
5.3.4 Absence of calcification in subdermal implants 
Calcification of implants was evaluated using quantitative calcium assay. None of 
the samples calcified in EL-Gel-FGF group (values ranged between 0 and 0.25 ± 0.1 
µg/mg dry weight), while 2 out of 6 samples in the 28d EL-Gel group calcified 
significantly (8.1 and 15.8 µg/mg dry weight) (Figure 5.8 A). Dahl’s Alizarin staining of 
scaffolds did not show calcium deposits in EL-Gel-FGF group (Figure 5.8 B) at both ime 
points but there were a few spots in the EL-Gel group which was consistent with the 
quantitative studies. The value for 28d EL-Gel group was statistically different from the 




Figure 5.7 Degradation of EL scaffolds in vivo. A) Gel image showing MMPs 2 and 9 in 
EL-Gel scaffolds 7day (Lane 1), EL-Gel scaffolds 28day (Lane 2), EL-Gel-F F scaffolds 
7day (Lane 3) and EL-Gel-FGF scaffolds 28day (Lane 4). B) VVG stain for elastic fibers. 
Arrows indicate degraded fibers on abluminal side (EL-Gel-FGF) at 28 days. 
Degradation was observed in both EL-Gel and EL-Gel-FGF samples at 28 days. Original 




Figure 5.8 Calcification of implanted elastin scaffolds at 7 and 28 days. (A) None of the 
samples calcified at 7 days but at 28 days some samples without bFGF calcified. (B) 







Tissue engineering of blood vessels has been focused on the search for the ideal 
material that will encourage regeneration to provide both a structural and functional 
replacement. The ideal vascular graft should be non-thrombogenic, non-antigenic, 
biodegradable and should have mechanical properties similar to the naiv  artery 
(collagen for strength and elastin for recoil). Most attempts to engineer small diameter 
blood vessels however, have failed clinically due to lack of one of the above 
characteristics. To eliminate immunorejection, a number of research rs have utilized the 
idea of in vivo tissue engineering of vascular grafts. Over 3 decades ago, Eiken [164], 
Schilling et al. [165, 166], and most well known, Sparks, [167, 168] first suggested the 
subcutaneous implantation of a mandril to allow a fibrocollagenous capsule to grow 
around it in 3-4 weeks. The mandril was removed and the tube that formed a ound it was 
used for vascular replacements. Though this method provided a completely autologous 
vessel, a follow up study by Hallin et al., [169] showed that the tubes occluded very 
quickly due to thrombus formation  mainly due to the exposure of collagen fib rs to 
blood. More recently, this idea of growing a blood vessel in the body was revived by 
Campbell et al.,[170, 171] when they implanted polymer tubing into the periton al and 
pleural cavities of animals to grow vessels similar to natural arteries. The collagenous 
capsule mainly contained myofibroblasts and was covered by a confluent layer of 
mesothelial cells. Before implantation as carotid interposition grafts in rabbits, the tubes 
were everted so that the mesothelium lined the lumen. This allowed the grafts to remain 
patent for at least 4 months. Although all these methods eliminated immunogenic 
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problems (and later, thrombogenicity), two main questions arise. First, since the 
formation of a capsule is the body’s way of sealing off a foreign body, these 
fibrocollagenous tubes that form in vivo are relatively avascular and thus may reduce 
exchange between cells and blood when implanted intravascularly. Second, these 
“biotubes” are rich only in collagen. Collagen provides tensile streng h to arteries 
however, in order to sustain continual pulsatile flow and prevent dilatation (aneurysm 
formation), elastin is a necessary component [216]. Unfortunately, elastogenesis in tissue 
engineered constructs has been very limited [172, 217].   
In the present studies we used porous elastin tubes carrying bFGF releasing gel 
for in vivo cellular repopulation. The bFGF releasing gel was contained within the lumen 
of the tubes by tying both edges of the tubular scaffold. This allowed cellular infiltration 
through only the abluminal side. The purpose of these studies was to provide intraluminal 
growth factor release to allow quicker abluminal cellular infiltration. On implanting these 
repopulated scaffolds into vasculature, elastin would provide the necessary lasticity to 
the graft.  
The release of bFGF improved cell infiltration significantly. B  28 days, EL-Gel-
FGF scaffolds were densely repopulated with host fibroblasts which synthesized new 
collagen within the elastic fiber network. Some of these fibroblasts showed a 
myofibroblast marker (smooth muscle α-actin) but were negative for smooth muscle 
heavy chain myosin staining (data not shown). These results are similar to those shown 
by others, who also showed a majority of myofibroblasts after implantation of 1 month 
[170, 171, 199]. These myofibroblastic cells have been shown to express strong sm oth 
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muscle cell markers under pulsatile flow either in vitro [5] or in vivo [171].  Thus, after 
implantation of such tubular scaffolds in the vasculature, myofibroblasts in the scaffolds 
may show SMC behavior. 
Cellular infiltration within scaffolds in the EL-Gel-FGF group however, was 
incomplete and did not reach the intimal side, which could be advantageous for vascular 
applications for several reasons. First, adventitial fibroblast infil ration would mimic 
native adventitia and collagen deposition would provide adequate mechanical strength to 
the scaffold. Second, elastin will be exposed to the blood flow after vascular implantation 
which will minimize thrombus related failure. Tieche et al., [193] have shown that elastic 
laminae possess anti-thrombotic and anti-inflammatory properties and how significantly 
lower leukocyte adhesion when in contact with blood. Carr et al.,[192] have also shown 
that elastin exhibits a four fold delay in clotting time when compared to synthetic 
biomaterials. Third, the space in the media that is not invaded by myofibroblasts during 
subdermal implantation could be infiltrated by smooth muscle cells laterally from the 
native artery after vascular implantation thus allowing a seamless interface with the 
native tissue.  
We also observed microvasculature within the EL-Gel-FGF scaffolds. This 
observation is very important as cells need nutrients during neo-tissue development and 
many in vitro tissue engineering approaches fail due to inadequate nutrient supply dee  
within the scaffolds. Inadequate neovascularization of prosthetic vascular grafts often 
leads to infection, one of the most common causes of graft failure [218]. The observed 
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microvasculature could be due to the release of bFGF, which is a well documented 
angiogenic growth factor [219, 220].  
One of the important aspects for vascular tissue engineering is appropriate 
mechanical strength of scaffolds prior to vascular implantation. We performed uniaxial 
tensile testing of rings of scaffolds after subdermal implantation o ensure that the 
scaffolds could still withstand physiological strains (arteries experience 1-4% strain and 
in extreme cases, 10% strain). [221].  The ultimate stress for the elastin scaffolds even 
before implantation is ~1/3rd that of fresh carotid arteries. This is due to the removal of 
collagen which provides tensile strength. After 7 days of subdermal i plantation 
mechanical properties were comparable to the unimplanted elastin scaffolds This may be 
because there was very little cellular infiltration and little degradation of the scaffold. 
After 28 days of implantation, scaffolds from both groups became stiffr and less elastic. 
Synthesis of new collagen by infiltrating cells may be the cause of the increased stiffness 
whereas matrix degrading enzymes responsible for elastin remodeling may have reduced 
its elasticity. Moreover, though we tried to remove the fibrous capsule surrounding the 
elastin implant before mechanical tests were performed, there may have been some 
fibrous tissue remaining, which may account for the increase in stiff e s in both EL-Gel 
and EL-Gel-FGF groups. EL-Gel scaffolds could be strained between 30 a d 50% after 
28 days whereas EL-Gel-FGF scaffolds could be strained between 50 ad 80% before 
failure. Synthetic polymer scaffolds possess much lower ultimate strain even before 
implantation. Electrospun scaffolds composed of PLGA-elastin-collagen had a maximum 
strain of 40% at failure [222]. For the tissue engineering of blood vessels, burst pressure 
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and compliance measurement are more important than static mechanical tests presented 
here. Although an extensive study was not performed to evaluate the burst pressure of the 
present scaffolds, water was pressurized through one EL-Gel-FGF scaffold after 28 days 
of implantation which burst at 300 mmHg. A wide range of burst pressur from 
240mmHg [223] to 650 mmHg [149] and in many cases in excess of 1000 mmHg [171, 
224] have been measured by different researchers. Native arteries hav  shown burst 
pressures between 2000 and 6000 mmHg depending on the animal and the vessel test d 
[225, 226]. Detailed studies of burst pressure of EL scaffolds will be undertaken in the 
future.  
An additional concern for vascular implants is pathologic calcification. We and 
others showed earlier that elastin based scaffolds are prone to calcification [227-229]. 
Cellular remnants are usually the nodes where calcification begins; however in some 
cases, even decellularization does not completely eliminate calcium deposition [230]. 
Attempts to alleviate elastin calcification have met with limited success even in adult rat 
models in which calcification is usually lesser than in juvenile animals[228, 231]. In the 
present studies, interestingly, controlled release of bFGF suppressed lastin calcification 
(the control scaffolds without bFGF showed some calcification p < 0.05). The role of 
bFGF in physiologic calcification is controversial. Some studies, mostly with bone, have 
shown that bFGF decreases mineralization by inducing hypophosphatemia [232]. The 
addition of bFGF to dentin pulp cultures suppressed the increases in ALPase activity, 
SPARC synthesis, and their mRNA levels [233]. However, other studies have shown that 
bFGF is associated with osteogenic properties especially when used in combination with 
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bone forming proteins such as BMPs [234, 235].  Our present studies, however, are the 
first to show suppression of elastin calcification by bFGF at 28 days in subdermal 
implantation model; however, whether this holds true for long-term studies and in the 
circulatory environment is unknown and needs further study in the future.    
We have extensively studied mechanisms of elastin calcification nd have shown 
that matrix degrading enzymes such as MMPs are involved in elastin c lcification [139, 
236]. In this study, an initial inflammatory response (macrophage infiltration) seen at 7 
days was reduced by 28 days. Macrophages were present in the surrounding capsule even 
at 28 days and MMPs were present in the scaffold (as seen by zymography). This led to 
some elastic fiber degradation on the outer edges of the scaffolds, but in EL-Gel-FGF 
scaffolds such MMP activity did not cause calcification. The mechanisms by which 
bFGF prevented elastin calcification in the rat subdermal implantatio  model would need 
further investigation.   
 
5.5 Conclusions 
Subdermal implantation of elastin tubes loaded with bFGF releasing garose gel 
provided a sustained release of growth factor which improved cell infiltration while 
preventing calcification of elastin. Although comprehensive mechanical testing of the 
scaffolds is required before implantation into the vascular system, this method provides a 
minimally invasive technique to prepare mechanically sound, autologous graft that can 





IN VIVO VASCULAR TISSUE ENGINEERING: INFLUENCE OF CYTOKINE 




Autologous saphenous vein or internal mammary artery has been the gold 
standard for vascular replacements; however, in the event of unavailability, synthetic 
grafts or allogeneic cadaveric arteries are used. In the cas of small diameter arteries, 
synthetic replacements fail due to thrombosis. Tissue engineering approaches have shown 
the potential to create biocompatible, strong and compliant grafts that have the capability 
to remain viable and patent [58].  
In vitro tissue engineering techniques have been extensively studied where porous 
scaffolds are seeded with cells in static cell culture, under mechanical stimulation such as 
rotary culture, pulsatile flow, and even vacuum seeding of all the vascular cells. Cells 
isolated from numerous sources have been used including stem cells diff rentiated into 
the required cell type. In particular, endothelial cell (EC) monolayer formation is what 
has been extensively investigated since the presence of a quiescent ndothelial monolayer 
is thought to be the best approach to reduce early failure of vascular grafts either by 
thrombosis or intimal hyperplasia. For in vitro EC seeding onto the graft lumen, various 
cell sources such as superficial vein ECs [77], EPCs from bone marrow [237], cord blood 
[238] and peripheral blood [239] have been used. The use of these cell sources however, 
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is hampered by the need to isolate a pure population of the cells and grow them in culture 
into enough numbers to seed the graft completely. Sometimes due to individual 
preconditions the isolated cells may not even grow in culture [240]. In situ recruitment of 
ECs after vascular graft implantation from the adjacent native tissue [241], circulating 
progenitors [195], and transmural migration of vessel wall endothelial progenitor cells 
EPCs [242], have been attempted. However, complete and rapid endothelialization has 
not been achieved. Although ECs have been given a lot of importance, recruitm nt of all 
three vascular cell types (fibroblasts, SMCs and ECs) is very important to create a 
functional and viable graft.  
We have focused our research on in vivo cell recruitment strategies where the 
body could be used as a bioreactor to prepare viable vascular grafts from pure elastin 
scaffolds. Earlier studies (described in Chapter 5) with bFGF loaded gels within elastin 
tubes, when implanted in subdermal pouches showed the recruitment of fibroblasts and 
some myofibroblasts in 28 days [243] however no smooth muscle or endothelial cells 
were recruited into the scaffold. In the current study we investigated the ability of local 
release of two different growth factors (stromal derived factor; SDF, which has been 
shown to attract endothelil cells, and basic fibroblast growth factor; bFGF, whcich is a 
well known angiogenic factor) to recruit the vascular cells into the elastin scaffold when 
implanted in adipose tissue in rabbits. We also implanted these elastin tubes with growth 
factors in subdermal tissue to compare the differences in cell recruitment. The main 
purpose of this study was to identify an optimal cytokine – implant location combination 
that would create a blood vessel that was histologically similar to the native artery with 
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endothelial cells in the intima, smooth muscle (-like) cells in the media (with collagen 
and elastin) and fibroblasts in the adventitia (with collagen). 
 
6.2 Materials and methods 
6.2.1 Tubular scaffold preparation 
Porcine carotid arteries (5-7mm diameter) were harvested at a local 
slaughterhouse, rinsed in cold phosphate buffered saline (PBS) and transported to the 
laboratory on ice. They were then cleaned of adherent tissue and fat and rinsed in cold 
PBS. Vessels were treated with cyanogen bromide (CNBr) [207] to remove cells, 
collagen and other ECM components, leaving behind pure elastin tubes. Briefly, f esh 
tubular carotid artery samples were treated with 50 mg/ml CNBr (Acros Organics; Morris 
Plains, NJ) in 70% formic acid (Acros Organics; Morris Plains, NJ )(8 ml/cm2) for 19 h at 
20° C with gentle stirring, followed by 1 h at 60° C and boiling for 5 min to inactivate 
CNBr. The scaffolds were then stored in 70% ethanol as a disinfectat. This method 
produced pure elastin scaffold. Prior to implantation, samples were washed extensively in 
sterile saline.  
6.2.2 Preparation of bFGF and SDF loaded elastin tubes 
Human recombinant basic fibroblast growth factor (bFGF, PeproTech Inc, Rocky 
Hill, NJ) was reconstituted in 5mM Tris buffered saline (TBS) (pH = 7.6) and diluted in 
the same buffer to a working concentration of 6.6 µg/ml. Human recombinant stromal 
derived factor 1-α (SDF, PeproTech Inc, Rocky Hill, NJ) was also reconstituted in the 
same buffer and diluted to a working concentration of  3.33 µg/ml. Agarose (MP 
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Biomedicals; Solon, OH) solution (2%) was made in TBS, microwaved for 2 minutes to 
dissolve the agarose and maintained at 40°C on a heating plate. This solution was mixed 
with the working solution of bFGF or SDF in a 1:1 ratio to give a final agarose solution 
of 1% containing 3.3 µg/ml bFGF or 1.67 µg/ml SDF. One side of the tubular elastin 
scaffold was tied with suture and 300 µl of either solution (for every 2 cm long scaffold) 
was pipetted into it. The agarose gel solidified immediately and then the other side of the 
scaffold was tied with a suture to keep the gel within the scaffold or the entire duration 
of implants. This entire procedure was done under sterile conditions. The caffolds (n = 6 
per group per time point) were prepared 1-2 hours before use and were stored in sterile 
conditions until implanted. 
6.2.3 Subdermal and adipose implantation of tubular elastin scaffolds 
bFGF and SDF loaded elastin tubes were implanted in subdermal pouches (SubQ-
FGF and SubQ-SDF respectively) and also in adipose pouches located in th  upper back 
(Adipose-FGF and Adipose-SDF respectively) (n = 6 per group) of New Zealand White 
rabbits weighing ~3.5kg, placed under general anesthesia. Briefly, 1 cm wide skin 
incisions were made on the back of the rabbits, and either four subcutaneous pouches or 
four adipose pouches were created in each rabbit by blunt dissection. One sample (~20 
mm long, containing 300µl gel) was placed into each pouch and the incision closed with 
surgical staples (i.e. three rabbits had two samples each of SubQ-FGF and SubQ-SDF 
and three separate rabbits had two samples each of Adipose-FGF and Adipose-SDF 
providing a total of six samples per group). Three of the six SubQ-FGF samples were 50 
mm long and were used for burst pressure analysis after explantation. Animals were 
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recovered and provided with food and water ad libitum. Upon recovery, analgesic 
(buprenorphine, 0.05 mg/kg, s.c.) was provided. After 28 days, animals were euthanized 
by intravenous administration of sodium pentobarbital with bilateral pneumothorax and 
the implants along with surrounding capsules were retrieved for analysis.  
6.2.4 Histology 
Explanted elastin tubes were rinsed with phosphate buffered saline (PBS), the gel 
was removed from the lumen and tubes were embedded in Tissue Tek OCT compound 
(Sakura Finetek, U.S.A. Inc., Torrance, CA), and frozen at -80°C. 6 µm thick sections 
were cut using a cryostat (Microm HM 505 N, Mikron Instruments, Inc.) and collected on 
glass slides. The samples were evaluated using hematoxylin and eosi  (H&E) staining for 
general morphology and Van Gieson stain for new collagen formation. Oil Red O 
staining was used to evaluate if fat cells were recruited by either Adipose-FGF or 
Adipose-SDF samples. Verhoff-Van Gieson stain (VVG) was used to evaluate the 
integrity of elastic fibers. For explant analysis, digital pictures were taken from each 
section at 200X magnification and 1000X for collagen fiber evaluation and analyzed 
using the Spot Advanced software (Diagnostic Instruments Inc., Sterling Heights, MI).  
6.2.5 Immunohistochemistry 
Cryosections (n = 3 per group) were immunostained using monoclonal anti-
vimentin antibody (1:200) for fibroblasts (Sigma, St. Louis, MO), anti-CD146 (1:100) for 
endothelial cells (Millipore), anti-α-smooth muscle actin (1:500) for myofibroblasts 
(Sigma, St. Louis, MO) and anti-caldesmon (1:500) for smooth muscle cells (Sigma, St. 
Louis, MO). Vectastain Elite ABC Kit for mouse IgG and DAB substrate were used to 
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visualize the specific staining (Vector Laboratories, Burlingame, CA). Negative controls 
were included with the omission of the primary antibodies. Sections were counterstained 
with hematoxylin. 
6.2.6 Burst pressure measurement 
Burst testing of the scaffolds was performed by the delivery of distilled water 
through a peristaltic pump. The maximum (burst) pressure of the scaffold was determin d 
using a pressure transducer connected to a data acquisition program on a laptop. Thirty-
millimeter long scaffolds were attached via tapered adapters directly onto the transducer 
on one side and the pressurized water on the other. The system was progressively 
pressurized until vessel failure.  
6.2.7 Calcium assay 
Quantitative analysis of calcium content in explanted scaffolds was performed 
according to a previously described procedure [215]. Briefly, a section of the capsule-free 
scaffold (n = 6 per group) was lyophilized, weighed and digested in 1ml of 6N HCl at 95 
°C for 10 h. Digested samples were evaporated under a continuous stream of nitrogen gas 
until dry, and the residual material was dissolved in 1ml of 0.01N HCl. Ca cium 
concentration was determined using an atomic absorption spectrophotometer 
(PerkinElmer, Norwalk, CT) and expressed as µg Ca/mg dry tissue. 
6.2.8 Hydroxyproline assay 
The collagen content in the samples was estimated using a hydroxyproline assay. 
20 µl aliquots of the reconstituted sample from the acid hydrolysed samples (described 
above for calcium assay) were assayed for hydroxyproline content as described earlier 
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[244]. Since elastin is known to also contain hydroxyproline (~1.2%) [245, 246] the 
values of hydroxyproline obtained for the explanted samples were corcted for this 
elastin-hydroxyproline content by subtracting the value obtained for unimplanted elastin 
scaffolds.  
6.2.9 Statistical analysis 
Results are expressed as means ± standard error of the mean (SEM). Statistical 
analyses of the data were performed using single-factor analysis of variance (ANOVA). 
Subsequently, differences between means were determined using the least significant 
difference (LSD) with an alpha value of 0.05. 
 
6.3 Results 
6. 3.1 Cellular infiltration and neo-matrix deposition 
In the subdermal implants (controls), cell infiltration was different for the two 
cytokines. In the bFGF group, cells remained close to the outer edge of elastin implant 
(~22.41 ± 6.78 % infiltration depth) whereas in the SDF group, there was more scattered 
and deeper cellular infiltration (53.85 ± 3.41 %) (Figure 6.1 and Table 6.1).  
Immunostaining indicated that the majority infiltrating cells in both groups were 
fibroblasts (Figure 6.2 A, B). In the SubQ-FGF group there were c lls that stained 
positive for smooth muscle α-actin (Figure 6.2 C) but none in the SDF group. Also, no 
other cell types were seen (caldesmon positive smooth muscle or EC) in either group. 
The amount of new collagen laid down by the cells was also quite similar (3.92 ± and 
4.69 ± µg/mg dry tissue for bFGF and SDF respectively) (Figure 6.3). 
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Figure 6.1 Histological features of subdermally implanted elastin scaffolds (A) H&E 
staining of SubQ-SDF (B) H&E staining of SubQ-FGF (C) Van Gieson staining of 
SubQ-SDF and (D) Van Gieson staining of SubQ-FGF. The yellow lines indicate the 
scaffold-capsule interface. C and D are magnified images (1000 X) of the region
indicated by a black square in A and B respectively. H&E stain (cell nuclei are dark blue 
and matrix is pink), Van Gieson stain (cell nuclei are dark blue, collagen is pink). Arrows 







Figure 6.2 Immunohistochemical characterization of infiltrating cells in subdermally 
implanted elastin scaffold. (A) SubQ-SDF immunostaining for fibroblasts, (B) SubQ-
FGF immunostaining for fibroblasts, (C) SubQ-FGF immunostaining for smooth muscle 






Table 6.1 Depth of cellular infiltration into elastin scaffolds implanted in adipose 
and subdermal tissue. There was significantly more repopulation in the Adipose-SDF 
samples as compared to the other groups (p < 0.01). 
 
 
Figure 6.3 Hydroxyproline analysis of explanted elastin scaffolds showing significantly 




In contrast, implantation of elastin tubes in the adipose tissue led to deeper and 
denser cell infiltration (Table 6.1 and Figure 6.4) with SDF group showing more 
infiltration as compared to the bFGF group. Collagen deposition on the other hand was 
slightly more in the bFGF group as indicated by hydroxyproline assay values of 9.78 ± 
2.11 ug/mg dry tissue for bFGF as compared to 7.59 ± 0.19 ug/mg dry tissue for SDF 
group. This was further confirmed by Van Gieson staining (Figure 6.4 C, D). The higher 
amount of collagen deposition in Adipose-FGF group despite lesser cell infiltration can 
be attributed to the types of cells that infiltrated the scaffold. A large proportion of the 
infiltrating cells in the Adipose-FGF group were fibroblasts (Figure 6.5 B). The SDF 
group had fewer vimentin positive cells (fibroblasts), which were mainly restricted to the 
capsule surrounding the elastin scaffold (Figure 6.5 A). Quite a few o  the infiltrating 
cells in Adipose-FGF were also positive for smooth muscle α-actin (Figure 6.5 D). 
Microvasculature containing caldesmon positive smooth muscle cells and endothelial 
cells were also seen in the collagen rich capsule only around the Adipose-FGF samples 
(Figure 6.6 B, 6.6 C). On the other hand, in the Adipose-SDF samples, no smooth muscle 
cells were recruited but a large number of ECs were seen within the scaffold interstices 







Figure 6.4 Histological features of adipose implanted elastin scaffolds (A) H&E staining 
of Adipose-SDF (B) H&E staining of Adipose-FGF (C) Van Gieson staining of Adipose-
SDF and (D) Van Gieson staining of Adipose-FGF. The yellow lines indicate the 
scaffold-capsule interface. C and D are magnified images (1000X) of the region indicated 
by a black square in A and B respectively. H&E stain (cell nuclei are dark blue and 
matrix is pink), Van Gieson stain (cell nuclei are dark blue, collagen is pink). Arrows 
indicate collagen within scaffold. Original magnifications, A, B 200 X and C, D 1000 X. 
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Figure 6.5 Immunohistochemical characterization of infiltrating cells in adipose 
implanted elastin scaffold. (A) Adipose-SDF immunostaining for fibroblasts, (B) 
Adipose-FGF immunostaining for fibroblasts, (C) Adipose-SDF immunostaining for 
smooth muscle α-actin, and (D) Adipose-FGF immunostaining for smooth muscle α-




Figure 6.6 Immunohistochemical characterization of infiltrating cells in adipose 
implanted elastin scaffold. (A) Adipose-SDF immunostaining for endothelial cells, (B) 
Adipose-FGF immunostaining for endothelial cells, and (C) Adipose-FGF 
immunostaining for smooth muscle cells (caldesmon). The red lines indicate the scaffold-
capsule interface. Arrows indicate endothelial cells. Original magnifications 400X. 
 
6.3.2 Burst pressure analysis 
The burst pressure of elastin scaffolds (pre-implant) could not be determined 
since they started to leak at ~100mmHg and thus did not burst. However, they could 
sustain this pressure for an infinite amount of time. Burst pressures of three SubQ-FGF 
samples (after 28 days of implantation) were determined using the same procedure. They 
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burst at 308, 282 and 305mm Hg respectively showing significant improvement in the 
properties due to ECM deposition.  
6.3.3 Absence of calcification in implants 
Calcification of implants was evaluated using quantitative calcium assay. None of 
the samples in any group (implant location or growth factor) calcified (values less than 
1µg/mg dry tissue).  
 
6.4 Discussion 
Autologous cell recruitment strategies have involved the isolation of cells 
(progenitors or mature cells) from the source (bone marrow, fat deposits or blood), and 
their in vitro culture under stimulatory conditions to obtain the required numbers for 
seeding onto the graft. This seeding procedure is then usually followed by an in vitro 
culture period wherein the tissue engineered artery is cultured to create a living vessel 
replacement. Although this technique is widely used and provides sufficient number of 
pure cell types, it has its drawbacks. Firstly, the time required to create a fully engineered 
graft is very long (anywhere between 8-12 weeks) [247]. In addition, the process of 
isolating the cells, seeding and culture engineering the graft are prone to contamination 
problems associated with regular cell culture systems and the possibility of change in 
cellular phenotype.  
In vivo tissue engineering techniques have also been explored as a means to create 
autologous vascular replacements. Most strategies have utilized the i ea of implanting 
inert materials in various locations to allow the formation of a tubular capsule that is used 
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as the replacement tissue [171, 199]. These tissue capsules are mainly composed of 
collagen, which provides adequate tensile strength to the grafts; however, in order to 
sustain continual pulsatile flow and prevent dilatation, elastin is a necessary component 
[216]. Unfortunately, elastin regeneration in tissue engineered constructs has been very 
limited [161, 172]. We have pursued a novel in vivo method to recruit vascular cells into 
tubular elastin scaffolds. On implanting these repopulated scaffolds as vascular grafts, we 
hypothesize that the elastin would provide the necessary elasticity to the graft. 
In earlier studies with bFGF loaded elastin tubes implanted in subdermal pouches 
in rats, we observed significant increase in cellular colonization due to the local release of 
growth factor [243].  The scaffold was repopulated in 28 days by fibroblasts and some 
smooth muscle α-actin positive myofibroblasts. There were no other vascular cell types 
observed. In the present studies we investigated the possibility of therelease of another 
factor (SDF-1α) from our agarose gel delivery system and also the implantation in 
adipose tissue to encourage smooth muscle and endothelial cell recruitm nt into the 
elastin scaffold. 
Like marrow, adipose tissue is derived from the embryonic mesoderm [248] and 
consists of a heterogeneous cell population including smooth muscle cells, fibroblasts, 
adipocytes, mast-cells and endothelial cells [249]. Adipose tissue al o contains a pool of 
stem and progenitor cells with unique regenerative capacity that is thought to go beyond 
traditional mesenchymal lineages [250]. Many groups working independently have 
shown that adult stem cells from adipose tissues can differentiate along multiple 
pathways in vitro, including the adipocyte, chondrocyte, endothelial, epithelial, 
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hepatocyte, neuronal, myogenic, and osteoblast lineages [251-255]. Subcutaneous 
adipose depots are accessible and abundant (in most animals and humans) providing a 
potential adult stem cell reservoir. Thus, adipose-derived cells exhibit potential 
advantages for tissue engineering applications. 
Stromal cell-derived factor-1 (SDF-1) is a chemotactic cytokine that enhances the 
homing of mobilized progenitor cells by promoting cell migration and proliferation [256]. 
SDF-1 has been shown to be produced by bone marrow stromal cells [257], activated 
platelets [258], and even adipose capillary endothelial cells [259] and is a potent 
chemoattractant to various cell types signaling via the CXCR4 receptor [260-262]. 
Platelet derived SDF-1 has also been shown to promote differentiatio  of human CD34+ 
cells into mature endothelial cells [263]. 
As adipose tissue contains pool of multipotent stem and vascular cel s, w  
evaluated the ability to recruit all the vascular cells into the elastin scaffold by our novel 
agarose gel release system to release SDF-1 (which has the ability to attract and 
differentiate endothelial progenitors) or bFGF (an angiogenic growth factor) in New 
Zealand White rabbits. We used the subdermal location as a control for this adipose 
implant study.  
Immunohistochemical analysis revealed clear differences in the types of cells 
recruited in the different groups. Fibroblasts were the only vascular e ls recruited in the 
subdermal tissue (SubQ-SDF and SubQ-FGF groups) however, a majority of these cells 
in the bFGF group were positive for SM-α actin  (as was seen in the earlier rat study) 
which was not the case in the SDF group. In the adipose tissue, SDF was able to recruit 
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SM-α actin positive fibroblasts and even endothelial cells but no smooth muscle cells. On 
the other hand, bFGF in the adipose tissue was also able to recruit SM-α actin positive 
fibroblasts and even caldesmon positive smooth muscle cells and a very small number of 
endothelial cells. The infiltrating cells synthesized collagen in an orderly manner on the 
adventitial side making the matrix similar to arterial tissue. Hydroxyproline analysis 
revealed significantly more collagen synthesis in the Adipose-FGF group than the other 
three factor-location combinations. Although there was more cell infitration in the 
Adipose-SDF group, the higher amount of collagen in Adipose-FGF can be attri uted to 
the fact that the majority of infiltrating cells were fibro lasts and a few of the other 
vascular cells. bFGF is known to be a potent angiogenic factor [219, 20]. 
Microvasculature composed of smooth muscle cells and ECs was seen in th  outermost 
layers of the Adipose-FGF group. ECs were not seen anywhere else within the scaffolds 
in this group. bFGF in the adipose tissue seems capable of attracting ll the vascular cells 
and bringing about repopulation of the elastin scaffolds in an organized, hierarchical 
manner as in vascular tissue with a vascularized, collagenous outerms  layer containing 
fibroblasts (adventitia), and smooth muscle cell and α-actin positive myofibroblasts 
(which have been shown to express strong smooth muscle cell markers under pulsatile 
flow either in vitro [5] or in vivo [171]) in the elastic medial layer. Thus, after 
implantation of such tubular scaffolds in the vasculature, myofibroblasts in the scaffolds 
may show SMC behavior. Since stromal cells secrete SDF, which is capable of attracting 
ECs, ECs should have been infiltrated elastin scaffold in the absence of SDF-releasing 
gels. However, we did not see any ECs attracted into the interst ces of the scaffold in the 
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Adipose-FGF group (which we saw in the Adipose-SDF group). Although the reason for 
this is not known, we hypothesize that it may be due to the action of bFGF on SDF. 
Nakayama et al. evaluated the effect of fibroblast growth factor 2 n bone marrow 
stromal cell expression of stromal cell-derived factor 1 (SDF-1) and showed that FGF-2 
reduced SDF-1 mRNA expression and secretion in stromal cells [264]. This may also be 
occurring in adipose derived stromal cells thus inhibiting the releas  of SDF and hence 
the attraction of ECs into the tissue. Thus, the creation of a dual factor release system 
may be necessary in which both SDF and bFGF are loaded in order to attract ll the three 
cell types into the scaffold since SDF-Adipose showed a large number of endothelial 
cells within the scaffold’s interstices but could not attract SMCs. 
One of the important aspects for vascular tissue engineering is appropriate 
mechanical strength of scaffolds prior to vascular implantation. Burst pressure 
measurement of tubular scaffolds by pressurizing water or saline through it until failure is 
a common procedure to evaluate mechanical properties such as strength as well as 
compliance. The burst pressure of elastin scaffolds (pre-implant) could not be determined 
since they started to leak at ~100mmHg and thus did not burst. However after 28 days 
subcutaneous implantation (SubQ-FGF group), the burst pressure of the repopulated 
scaffolds were ~300 mm Hg. A wide range of burst pressures from 240 mm Hg [223] to 
650 mm Hg [149] and in many cases in excess of 1000 mm Hg [171, 224] have been 
documented by different researchers for various natural and synthetic scaffold materials. 
Native arteries have burst pressures between 2000 and 6000 mm Hg depending on the 
animal and the vessel tested [226].  Although the burst values obtained with our 
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cellularized elastin scaffolds are not as high as those achieved with other materials in the 
literature, they are high enough to sustain normal arterial pressures and are definitely an 
improvement over the pre-implant elastin scaffolds. Also, all the grafts investigated in the 
literature that have high burst pressures ( > 1000 mmHg) have very high tensile strength 
but are not necessarily elastic and hence may cause compliance mismatch at the 
anastomosis when implanted into the vascular system, which is thought t be one of the 
main reasons for small diameter graft failure [265, 266]. The elastin scaffold however, 
may be able to overcome this problem due to its’ elastic nature. Moreover, before burst 
pressure testing of explanted scaffolds, we removed the outermost capsule, which may 
have negatively affected the burst pressure values. In practice, thes  capsules can be kept 
intact during vascular grafting thus they can combine with other perivascular tissue 
present in the area and that would further improve mechanical properties of elastin 
scaffolds. Burst pressures of elastin scaffolds implanted in adipose tis ue were not 
evaluated due to the small length (2 cm) of the scaffold. However, du  to higher cellular 
infiltration and significantly higher collagen deposition within Adipose-FGF samples, 
burst pressures of these samples may be greater than ~300 mm Hg obtained in subQ-FGF 
samples in this study.  
An additional concern for vascular implants is calcification. Elastin based 
implants are prone to calcification [227, 229]. Attempts to alleviate elastin calcification 
have met with limited success even in adult rat models in which calcifi ation is usually 
lesser than in juvenile animals [230, 231].  In the current studies almost no elastin 
calcification was seen in any group. This was due to combination of effects of ethanol 
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pretreatment of elastin tubes prior to implantation and growth factor release during 
implantation. Singla et al. also showed that the calcification rate of their collagen-elastin 
matrices pretreated with ethanol was significantly lower than t of the untreated control 
[194]. Our earlier studies without growth factor release but with ethanol pre-treatment 
gave calcium levels of ~15 µg Ca/mg dry tissue (lower than that seen without either 
growth factor or ethanol) [203] In the current study when growth factors were 
incorporated in these ethanol-pretreated elastin tubes calcification was lower than 1 
µg/mg of dry tissue in all groups. It is unclear at this time as to how growth factors 
prevent elastin calcification and further mechanistic study is needed.  
 
6.5 Conclusions 
Adult autologous stem cells represent an important source of cells for vascular 
tissue engineering. Their usefulness is directly related to the availability of the cells in 
patient populations with vascular diseases as well as their ability to differentiate 
efficiently into vascular cells. The presence of vascular and stem cells within adipose 
tissue provides a useful source of adult stem cells that can be utilized for in vivo 
repopulation of scaffolds to create autologous grafts. In this study subdermal and adipose 
tissue implantation of elastin tubes loaded with bFGF/SDF releasing agarose el provided 
a sustained release of growth factor which improved cell infiltration into the scaffold. 
Endothelial cells were recruited in large numbers by SDF in the adipose tissue whereas 
smooth muscle cells were found only in the Adipose-FGF group along with a few 
endothelial cells. The Adipose-FGF group looked most like a native artery (without the 
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luminal EC lining) with a vascularized fibroblastic adventitia, a medial layer with 
collagen (synthesized by infiltrating cells) and elastin (scaffold) with organized smooth 
muscle-like cells (myofibroblasts) and some endothelial cells. Athough the cellular 
infiltration into the scaffold was not complete in any group and finer aspects such as 
dosage of cytokines and duration of implant needs optimization, this study provides 
preliminary results in the use of specific cytokines and locations as a means for tissue 
specific autologous cell recruitment. The study also emphasizes the use of an agarose gel 
release system, which is easy to use, inexpensive and performs a dual function – provides 
structural support to the tubular scaffold to maintain its shape when implanted 
















DEVELOPMENT OF ELASTIN-HEPARIN MATRICES FOR VASCULAR 




Diseased blood vessels can be replaced by vascular grafts to restore gular blood 
flow and hence maintain homeostasis. Synthetic vascular grafts, made of Dacron or 
expanded PTFE, are widely used to replace occluded or aneurysmal arteries. When used 
in large-diameter applications, these synthetic vascular grafts show satisfactory patency 
rates; however, in small-diameter replacements (internal diameter < 6 mm), they usually 
occlude due to thrombus formation [41].  
Surface modification of polymers to produce blood-compatible materials which 
can prevent thrombus formation and intimal hyperplasia while encouraging endothelial 
cell growth has been of great interest. Heparin is a common molecule used for such 
modifications [267-269]. Heparin is a naturally-occurring anticoagulant produced by 
basophils and mast cells. It is known to reduce platelet aggregation nd inhibit 
coagulation by enhancing the action of anti-thrombin on coagulation factors (such as 
thrombin and factor Xa) [270]. When antithrombin (AT) combines with thrombin, an 
inactive thrombin-antithrombin complex is formed. Heparin can bind AT at a specific 
pentasaccharide sequence inducing a conformational change that results in a 1000 fold 
increase in the formation of a complex between AT and coagulation proteases [176]. The 
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first attempt to immobilize heparin onto biomaterials was carried out in 1963 [71]. These 
researchers used electrostatic binding of heparin to the biomaterial through its anionic 
groups. Due to the weak binding, the heparin was lost very quickly on establishment of 
flow.  Thus covalent binding of heparin to biomaterials was initiated which has been 
shown to be more effective in long-term retention of heparin [271-273]. 
Due to the low success rates with synthetic materials in small-caliber vascular grafts, 
attempts have also been made at using biologic materials for vascular prostheses. For this 
purpose, we have developed tubular elastin scaffolds from porcine carotid arteries [243]. 
Reconstituted elastin has been shown to be less thrombogenic compared to other 
materials (synthetic and natural) [192]; however, we observed a significant amount of 
platelet adhesion on our purified elastin scaffolds in an in vitro static adhesion assay as 
shown in Figure 7.1. 
 
 
Figure 7.1 Preliminary platelet adhesion studies showing attachment on EL scaffold 
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In order to alleviate this platelet adhesion, we immobilized heparin on the elastin 
scaffolds using EDC and NHS, to create EL-Hep scaffolds. Different molar ratios of 
NHS:EDC were evaluated to determine the optimal combination that would provide the 
maximum bound heparin while maintaining mechanical properties as well as in vitro 
biodegradability similar to original elastin scaffolds. Increasing concentrations of heparin 
were then immobilized to determine whether heparin immobilization improved the blood 
compatibility of the elastin scaffolds, by evaluating clot formation, thrombin inhibition 
and deposition of blood platelets in vitro. To our knowledge, this is the first study in 
which heparin was covalently linked to elastin scaffolds for vascular graft applications. 
 
7.2 Materials and Methods 
7.2.1 Elastin scaffold preparation 
Porcine descending aortas were harvested at a local slaughterhous , rinsed in cold 
phosphate buffered saline (PBS) and transported to the laboratory on ice. They were then 
cleaned of adherent tissue and fat and rinsed in cold PBS. Tissues wer  subsequently 
processed for the preparation of elastin scaffolds, by cyanogen bromide (CNBr) 
treatment, to remove cells, collagen and other ECM components except elastic fibers 
[207]. Briefly, fresh aorta samples were treated with 50 mg/ml CNBr (Acros Organics; 
Morris Plains, NJ) in 70% formic acid (Acros Organics; Morris Plains, NJ ) (8 ml/cm2) 
for 19 h at 20 °C with gentle stirring, followed by 1 h at 60 °C and boiling for 5 min to 
inactivate CNBr. The scaffolds were then stored in 70 % ethanol as a disinfectant. This 
method produced pure elastin scaffolds (shown in previous publication [203]). 
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7.2.2 Heparin immobilization 
Elastin scaffolds were equilibrated with MES-buffer (0.05 M, pH 5.6)for 30 min. 
Carboxylic acid groups of heparin were activated by adding NHS and EDC in various 
molar ratios. Heparin (Acros Organics; Morris Plains, NJ) waspre-activated for 10 min. 
Immobilization of heparin was investigated as a function of EDC (varying concentrations 
of heparin with constant EDC concentration) and NHS (molar ratio of NHS to EDC of 
0.1 to 1.0). 10 mg of elastin scaffold (circular disc of 5 mm diameter) was added to 2 mL 
of EDC/NHS activated heparin solution. After 4 h of reaction at 37 °C, the heparinized 
elastin scaffolds were washed with 0.1 M Na2HPO4 (2 h), 4 M NaCl (4 times for 24 h) 
and distilled water (4-5 times for 24 h) [267].  
7.2.3 Characterization of EL-Hep matrices 
7.2.3.1 Determination of immobilized heparin – Toluidine Blue assay 
The amount of immobilized heparin was determined colorimetrically using 
toluidine blue as described by Smith et al. [274]. The heparinized scaffolds (varying 
NHS:EDC molar ratios and varying EDC:Hep ratios, n = 3/ molar ratio) were 
homogenized in 2.5 mL 0.2% NaCl solution. Toluidine Blue solution (0.005%) was then 
added to each tube to bring it up to 5 mL and then mixed with a vortex mixer for 30 s. 
The same was done with varying amounts of a standard heparin solution to give a 
standard curve for 10 µg -70 µg heparin. Hexane (5 mL) was then added to each of the 
tubes and the tubes were then shaken vigorously for 1 min. After centrifugation (1000 
rpm, 3 min), the aqueous layer was diluted 1:10 with 100 % ethanol and the absorbance 
at 631 nm was measured within 30 min. 
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7.2.3.2 Localization of heparin – Alcian blue staining 
Alcian Blue staining was used for the localization of immobilized h parin in EL-
Hep scaffolds. Briefly, cryosections were fixed with 95 % ethanol for 1 min, incubated in 
acetic acid (3 % v/v, pH 2.5) for 3 min and then stained for 30 min using a solution of 
Alcian Blue (2 % w/v) in 3 % acetic acid solution.  
7.2.3.3 Mechanical testing 
Strips of elastin scaffolds and different NHS:EDC combinations of EL-Hep 
scaffolds (n = 4 each) were subjected to uniaxial tensile testing at a strain rate of 5 
mm/sec until failure on an MTS (Synergie 100) machine. Stress strain characteristics 
were plotted and the ultimate stress and engineering strain values were calculated. 
Young’s modulus was calculated between 10 and 20 % strain on the stress rain curve 
since this is the maximum strain usually experienced by arteries. 
7.2.3.4 In vitro enzyme degradation 
Pieces of lyophilized pure elastin scaffolds (~10 mg each. n = 3) were suspended 
in 1 mL of 1 U/mL ultrapure elastase solutions prepared in 100 mM Tris buffer, 1 mM 
CaCl2, 0.02 % NaN3, pH 7.8 and incubated at 37 °C for 9 h with shaking at 600 rpm. 
Samples were removed at 3 h and 9h, centrifuged 3 times for 3 min at 10,000 rpm, rinsed 
in Tris buffer, lyophilized, weighed and percentage of elastin degra ation calculated from 





7.2.4 In vitro thrombogenicity testing 
7.2.4.1 Platelet adhesion assay 
Platelet adhesion tests were performed under static conditions. Human whole 
blood was obtained in sodium citrate from Innovative Research Inc. and centrifuged at 
300 g for 10 min to obtain platelet rich plasma (PRP). The PRP was re-centrifuged at 700 
g for 15 min to obtain the platelet poor plasma (PPP) and a pellet which was re-
suspended in a suspension buffer composed of 145 mM NaCl, 5 mM KCl, 10 mM Hepes, 
0.5 mM Na2HPO4, and 6 mM dextrose, (pH 7.4). The platelet concentration was 
determined by using a Coulter particle counter and the density adjusted to 10 x 106 
platelets / mL. 100 µL of this suspension (with 1 mM CaCl2 and 1mM MgSO4) was 
added to wells carrying the EL and EL-Hep scaffolds of varying heparin concentrations 
(n = 3 / group; samples of 5 mm diameter). The platelet concentratio  nd volume of 
suspension was kept low in order to allow more sensitive determination of changes in 
platelet adhesion to the different surfaces. After an hour of incubation at 37 °C, the 
suspension was removed (and collected), samples washed 3x with 100 µL PBS (wash 
liquid) and the number of platelets in the suspension and wash liquid counted. The 
number of adherent platelets was calculated by a method described by Yang et al. [275] 
# of adhered platelets = no - nt 
where no is the number of platelets seeded and nt is the number in the suspension 
+ wash liquid 
Samples from each group were fixed for SEM in Karnovsky’s fixative (2.5 % 
glutaraldehyde and 2 % formaldehyde in 100 mM cacodylic acid buffer, pH 7.4), 
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dehydrated in a series of graded (50 – 100 %) ethanol followed by soaking in 
hexamethylene disilazane (HMDS) and letting it evaporate overnight in a chemical hood. 
The samples were then coated with platinum and scanned to evaluate the morphology of 
the attached platelets. 
7.2.4.2 Thrombin inactivation assay 
The anticoagulant activity of immobilized heparin was determined using a 
thrombin inhibition assay, based on a method described by Chandler [276]. The ability of 
immobilized heparin to mediate the inactivation of thrombin by ATIII was measured 
using a chromogenic substrate for thrombin (Benzoyl-Phe-Val-Arg-pNA). Briefly, 150 µl 
of substrate solution (containing the chromogenic substrate and human ATIII in ris 
buffer) was added to the samples and the assay was started by ad ing 50 µl of a human 
thrombin solution. The Tris buffer consisted of 50 mM Tris (pH 8.40) containi g 1 g/l 
PEO 6000, 1 g/l BSA (Sigma) and 150 mM NaCl. The reaction was followed for 20 min 
to obtain a time course evaluation of thrombin inactivation. At 5 minute itervals (n = 3 
per group per time point) after incubation at 37°C on an orbital shaker, the reaction was 
stopped by adding 50 µL of 40% acetic acid. 250 µL of the supernatant was transferred to 
a 96 well plate and the absorbance at 405 nm was measured.  
7.2.4.3 Plasma recalcification time study 
Platelet-poor plasma (PPP) obtained from centrifuging whole human blood was 
used to evaluate the clotting time of recalcified plasma (PRT). 100 µL of the PPP was 
introduced onto the samples and incubated at 37°C for 1 min. Then 100 µL of 0.025 M 
CaCl2
 solution was added to it. This solution was monitored for clotting by manually 
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dipping a stainless-steel wire hook coated with silicone into the solution to detect fibrin 
threads. The clotting time was recorded at the first sign of fibrin formation on the hook 
[139]. The clotting time reported is a mean value of three separate experiments carried 
out for each sample. 
7.2.5 Statistical analysis 
Results are expressed as means ± standard error of the mean (SEM). Statistical 
analyses of the data were performed using single-factor analysis of variance (ANOVA). 
Subsequently, differences between means were determined using the least significant 
difference (LSD) with an alpha value of 0.05. 
 
7.3 Results 
7.3.1 Characterization of EL-Hep scaffolds 
7.3.1.1 Localization of heparin 
Microscopic images of Alcian Blue stained sections of EL-Hep scaffolds (varying 
NHS:EDC combinations as well as varying heparin concentrations) showed 
homogeneous staining through the entire thickness of the specimen. In contrast, the 
native elastin scaffold as well as samples without NHS:EDC in the reaction showed no 
staining (Figure 7.2). This indicates that heparin is immobilized homogeneously 




Figure 7.2 Alcian blue staining (blue indicates polysaccharides).  (A  EL scaffold, (B) 
EL-Hep scaffold showing heparin bound to elastin fibres throughout the thickness of the 
scaffold, (C) EL-Hep scaffold without EDC/NHS in the reaction showing heparin was 
covalently bound to elastin. 
 
7.3.1.2 Effect of heparin immobilization on scaffold properties 
The use of EDC to covalently immobilize heparin increased the stiffness of the elastin 
scaffolds slightly irrespective of the amount of different NHS:EDC used (Young’s 
moduli in the range of 279 - 305kPa). Pure elastin scaffold had a modulus of 219 ± 35kPa 
with the stiffness increasing with increasing NHS:EDC molar ratio (Table 7.1).   
 
 
Table 7.1 Crosslinker concentration in EL-Hep scaffold preparation and mechanical 
properties of elastin and EL-Hep scaffolds. 
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At 3 h all the different NHS:EDC combinations degraded lesser than pure elastin 
scaffolds (7 - 15 % compared with 25 %) however at 9 h the EL-Hep 10-10 scaffolds 
degraded significantly more than all the others (~ 59 %) while pure elastin and EL-Hep 
5-30 and EL-Hep 9-15 degraded ~ 30 – 35 % (Figure 7.3). 
 
 
Figure 7.3 In vitro enzyme degradation of pure elastin and EL-Hep scaffolds with 
different NHS:EDC combinations. Values are expressed as percentage (%) d graded after 
exposure to enzyme. EL-Hep 10-10 degraded significantly more in 9h than the other 





7.3.1.3 Heparin immobilization (quantification) 
After a number of optimizations, the following conditions were chosen for the 
heparin immobilization reaction: buffer pH 5.6, 4 h reaction time, 10 min heparin pre-
activation, and 2mL reaction volume per sample (10 mg dry wt). Different NHS:EDC 
combinations (molar ratios 0.1 - 1) were evaluated with 0.2 % heparin in the reaction. 
The amount of heparin immobilized increased with increasing NHS:EDC molar ratio and 
was maximum when 10.4 mM NHS and EDC (molar ratio of 1) was used a  shown in 
Figure 7.4.  
 
Figure 7.4 Toluidine Blue assay for quantification of immobilized heparin in EL-Hep 
scaffolds with different NHS:EDC combinations. EL-Hep 10-10 had significantly more 
heparin immobilized than EL-Hep 5-30 (p <0.05) 
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With the same molar ratio but with higher concentration of EDC and NHS, the 
amount of heparin immobilized decreased for all three molar ratios (data not shown). 
Thus, using this optimal combination (referred to as EL-Hep 10-10), increasing 
concentrations of heparin (0.1 – 2 % w/v) were used in the reaction to create scaffolds 
with maximal heparin activity and hence increased blood compatibility. Scaffolds thus 
prepared showed correspondingly increasing immobilized heparin (1.25 – 1.9 µg/mg dry 
tissue) upto 0.5 % w/v (Figure 7.5) after which there was a plateau in the amount of 
heparin immobilized.  
 
Figure 7.5 Toluidine Blue assay for quantification of immobilized heparin in EL-Hep 
scaffolds with 10.4 mM NHS and EDC, and increasing amounts of heparin in the reaction 
mixture. The total heparin immobilized after 4 h plateaued after 0.5 % w/v in the 
reaction. 
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7.3.2 In vitro blood compatibility testing 
7.3.2.1 Platelet adhesion assay 
Figure 7.6 and 7.7 (higher magnification) show the SEM images of platelets adhered on 
pure EL, EL-Hep 0.1 %, EL-Hep 0.5 % and EL-Hep 2 %. SEM images of EL-Hep 0.2 % 
looked similar to 0.1 % and 1 % looked similar to 2% (0.1% and 1% data not shown). 
There was visible platelet attachment on EL, EL-Hep 0.1 %, EL-Hep 0.2 %, and EL-Hep 
0.5 % whereas EL-Hep 1 % and EL-Hep 2 % had hardly any platelets in spite of similar 
quantities of total immobilized heparin. In order to verify if this may be due to higher 
amount of surface bound heparin leading to increased activity in the 1 % and 2 % 
samples, we performed elemental analysis (XPS) on the EL-Hep 0.5 % and EL-Hep 2 % 
samples. The results confirmed that there was in fact 2.5 X more sulfur (indicative of 
heparin) on the surface of the EL-Hep 2 % scaffolds as compared to EL-Hep 0.5 % 
despite equal amounts of total heparin (spectra given in Appendix). The adhered platelets 
were not spread on any of the surfaces including pure EL scaffolds (comparison with 
ePTFE shown in Figure 7.8). When quantified, only the EL-Hep 2 % group showed 




Figure 7.6 SEM images of adhered platelets. (A) EL scaffold,  (B) EL-Hep 0.1 %,  (C) 
EL-Hep 0.5 % and (D) EL-Hep 2 %. Arrows point out some of the platelets. 
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Figure 7.7 Higfh magnification SEM images of adhered platelets. (A) EL scaffold, (B) 











Figure 7.8 Comparison of adhered platelets on ePTFE and EL scaffolds. (A) and (C) 
ePTFE,  (B) and (D) EL scaffold. White arrows point out some of the platelets, yellow 
arrows show spread out, activated platelets on ePTFE.  Platelets on ePTFE were mostly 





Figure 7.9 Quantification of platelets attached in static platelet adhesion assay.  EL-Hep 
2% scaffolds had significantly fewer platelets compared to all other groups (p < 0.05). 
 
7.3.2.2 Clotting time of recalcified plasma 
Figure 7.10 shows the PRT for the EL and EL-Hep surfaces compared to glass. 
PRT for glass was 253 ± 28 s. Clotting times for all scaffold surfaces were higher than 
glass. EL-Hep 0.1 % (495 ± 25 s) and EL-Hep 0.2 % (382 ± 38 s) were slightly lower 
than EL (617 ± 56 s) and EL-Hep 0.5 % (625 ± 104 s) was equal to EL. EL-Hep 1 % had 
a significantly enhanced PRT of 989 ± 115 s and EL-Hep 2 % samples did not cause clot 






Figure 7.10 PRT of glass, elastin scaffold and heparin immobilized elastin scaffolds. EL-
Hep 1 % had a significantly higher PRT than all other groups (p < 0.05). EL-Hep 2 % 
scaffolds did not clot during the 20 min test period. 
 
7.3.2.3 Thrombin inactivation 
Heparin acts like a catalyst in the thrombin-antithrombin complex formation 
reaction by binding ATIII and thus increasing its affinity for thrombin 1000 fold. 
Increasing the amount of heparin in the crosslinking reaction caused higher amounts of 
thrombin inactivation (Figure 7.11). Over the reaction time of 20 mins, there was a 
significantly higher thrombin inhibition by the 2 % heparin group as compared with pure 
elastin scaffolds. 
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Figure 7.11 Thrombin inactivation by heparinized elastin scaffolds in the presence of 
human AT, over a 20 min time period. At 20 minutes only the EL-Hep 2 % scaffolds 
show significantly more thrombin inhibition (p < 0.05) 
 
7.4 Discussion 
Exposure of blood to foreign materials, as in the case of all cardiov scular devices 
such as vascular grafts, stents, heart valves, etc., initiates interaction with various blood 
components which triggers the coagulation cascade eventually leading to the formation of 
a fibrin clot. Although necessary for normal hemostasis, blood clot formation is also 
responsible for several cardiovascular diseases and for the failure of s veral artificial 
devices. It is thus pertinent to prevent blood clot (thrombus) formation to maintain the 
integrity of the tissue or device. Although the exact order of initiation of the coagulation 
cascade on implantation of prosthetic devices is still not understood, three factors are 
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thought to be involved – adhesion of plasma proteins on the surface and activation of the 
contact activation system, formation of thrombin, or adhesion and activation of platelets 
[277, 278]. In this study, our aim was to evaluate the blood compatibility of elastin based 
scaffolds for use as potential small diameter vascular grafts by investigating all three of 
these factors by evaluating platelet adhesion, thrombin inactivation s well as clotting 
time. 
Elastin has been thought to be inherently non-thrombogenic [279], showing 
reduced platelet adhesion and activation and even lower clotting times han other 
biomaterials; however, we saw attachment of platelets to our elastin scaffolds in static 
platelet adhesion tests. Other researchers have also shown some amount of platelet 
adhesion onto isolated elastin [280] and even exposed microfibrils of elastic l minae 
[281, 282] although not as much as on collagen scaffolds. Thus our main goal was to 
reduce platelet adhesion onto the elastin scaffolds and to do this we immobilized heparin 
onto the elastin scaffolds. In addition to reducing platelet adhesion, we also wanted to 
evaluate the ability of the immobilized heparin to inactivate thrombin and reduce clotting 
of recalcified plasma. Heparin is a naturally-occurring anticoagulant known to control 
coagulation in various ways - by reducing platelet aggregation and enhancing the action 
of anti-thrombin on coagulation factors (such as thrombin and factor Xa) [270].  
Heparin was linked covalently to the surface of elastin scaffolds using EDC/NHS 
chemistry to create EL-Hep scaffolds by forming peptide bonds between carboxylic 
groups of heparin and the free amine groups on elastin. When creating these EL-Hep 
scaffolds, we wanted to retain the native elastin scaffold’s properties - especially the 
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mechanical and degradation characteristics. We thus created EL-Hep scaffolds using 
three different NHS:EDC combinations to find the optimal combination that would 
provide the most amount of bound heparin without changing the properties of the elastin 
scaffold significantly.  
With increasing NHS:EDC molar ratios, the amount of heparin immobilized 
increased with the maximum heparin immobilized in the 10-10 group (10.4 mM NHS and 
10.4 mM EDC). This may be due to increased NHS in the reaction which acts to stabilize 
the reactive intermediate formed by the action of EDC on carboxyl groups on heparin 
thus preventing its hydrolysis and in turn increasing its chances for reacting with amine 
groups on elastin. The maximum amount of heparin immobilized was 1.9 µg / mg dry 
elastin which is much lower than the quantities of GAGs immobilized on collagen 
scaffolds by a number of researchers using the same crosslinking chemistry [267, 283]. 
This may be attributed to the low primary amine groups in our scaffold. Elastin in its 
natural state is a highly crosslinked protein without any free amine groups. While 
processing the porcine carotid artery (removing collagen and cells) to create elastin 
scaffolds, we may have broken some crosslinks within elastin thus exposing a few free 
amines to allow the immobilization of heparin. This was also corroborated by the 
mechanical testing data. As expected, the EL-Hep scaffolds (with all the different 
NHS:EDC combinations) were slightly stiffer than the elastin caffold with the modulus 
increasing with increasing concentration of EDC in the reaction; however, this difference 
was not significant in any of the groups (highest modulus was 0.305 ± .009 MPa 
compared to 0.219 ± 0.026 MPa of pure elastin). The in vitro biodegradability studies 
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also showed little difference between all the groups with all the heparin crosslinked 
scaffolds degrading only slightly lesser than the pure elastin scaffold in 3 h. Even at 9 h, 
the EL-Hep 5-30 and EL-Hep 9-15 samples degraded just as much as pure elastin
scaffolds (30 – 35%) but the EL-Hep 10-10 samples degraded significantly more. This 
can be attributed to the fact that the EL-Hep 10-10 group has significantly more 
immobilized heparin (Figure 7.2). GAGs are known to readily bind and absorb water. 
Due to a higher amount of heparin in the 10-10 group, more water may have been 
absorbed leading to accelerated hydrolysis/degradation (at 9h compared with other 
groups) in the presence of elastase.   
Once the optimal NHS:EDC concentration (1:1 molar ratio, 10.4 mM each) was 
determined, EL-Hep scaffolds with increasing amounts of heparin in the crosslinking 
reaction (0.1 – 2 % w/v) were created to find the lowest amount of heparin required to 
reduce thrombogenicity of elastin scaffolds. Amount of total heparin immobilized (as 
shown by toluidine blue assay) increased with increasing heparin in the reaction, up to 
0.5 % w/v, after which the value remained the same.  
EL-Hep scaffolds with varying amounts of immobilized heparin were used for 
blood compatibility tests. Various molecules and factors are involved in the formation of 
a blood clot and we chose three separate methods to evaluate the bioactivity of the 
immobilized heparin. Although the amount of total heparin immobilized did not increase 
after 0.5 % w/v heparin in the reaction solution, we observed significant differences in 
the blood compatibility results with EL-Hep 2 % scaffolds. The heparin quantification 
assay evaluates the total heparin immobilized throughout the scaffold nd not just on the 
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surface. XPS analysis showed that there was 2.5 % more heparin on the surface of the 
EL-Hep 2 % scaffolds compared to the EL-Hep 0.5 % samples confirming that the 
significant improvement in blood compatibility with the 2% scaffolds was infact due to a 
higher amount of heparin on the surface compared with the other groups although the 
total amount immobilized may not be much greater.  
It has been suggested that platelet adhesion to biomaterial su f ces depends on 
surface topography, charge, surface tension and even wettability [284]. On contact with 
blood, plasma proteins adsorb onto the surface of the material and may change any or all 
of the above properties thus changing the platelet adhesion and activation. Fibrinogen is 
thought to be the most influential plasma protein for platelet adhesion ont  biomaterial 
surfaces [285] because it adsorbs and undergoes conformational changes to i t ract with 
unactivated platelets to promote their adhesion and even activation and secretion of 
chemical factors [286, 287]. There have been contrasting reports on platelet adhesion on 
biomaterials with immobilized heparin. Some researchers have shown reduced adhesion 
and activation [139, 288] while some have reported no change in platelet adhesion with 
heparin immobilization [289].  
In our static platelet adhesion tests, as seen by scanning electron microscopy 
(Figure 7.5), there were very few platelets on the 1 % and 2 % EL-Hep scaffolds. All 
other EL-Hep scaffolds had similar number of adherent platelets as hose on elastin 
scaffolds. When quantified, there were 30 % fewer platelets on 2 % EL-Hep scaffolds 
compared with all the other groups (data not shown). There was no platelet aggregation 
on any of the groups.  Platelet adhesion seems to depend on the type and conformation of 
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plasma protein that adsorbs to the material surface thus changing the surface 
characteristics affecting platelet adhesion and activation. Also, conformational changes of 
the adsorbed proteins may expose receptors for platelet adhesion and activation. It is 
therefore reasonable to assume that above a certain threshold, heparin immobilized onto 
elastin scaffolds may have changed the surface properties in such a way as to affect the 
amount or conformation of adsorbed proteins and thus reduced platelet adhesion. 
Platelets contain heparin binding sites [290] which may mediate binding of platelets to 
immobilized heparin at lower concentrations when other properties may not be affected 
as much. Other researchers have shown that a minimum amount of surface heparin is 
needed for significantly higher activity [291, 292]. Although the exact concentration of 
heparin on the surface cannot be quantified, the drastic differences in platelet adhesion 
can be attributed to more of the heparin being on the surface in the 2 % EL-Hep 
scaffolds.  
When anti-thrombin (AT) combines with thrombin, an inactive thrombin-
antithrombin complex is formed preventing clot formation. Heparin can bind AT at a 
specific pentasaccharide sequence inducing a conformational change that results in a 
more than 1000 fold increase in the formation of a complex between AT ad coagulation 
proteases [176]. In order to identify if heparin immobilized on elastin scaffolds could 
inhibit thrombin (the most important factor in the coagulation cascade) by binding 
antithrombin, a time course evaluation of thrombin inhibition in the presenc  of 
antithrombin was performed. As anticipated, increasing amounts of heparin caused 
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increasing inhibition of thrombin with a significantly increased inhibition with EL-Hep 2 
% samples (Figure 7.7).  
It has been shown that this AT binding sequence on heparin influences, almo t 
immediately on contact with plasma, the inhibition of factor FXII (FXII) [293, 294]. This 
prevents the activation of any other enzymes further in the contact activation system. 
Although the amount of FXII inhibition was not quantified in this study, the clotting 
process was monitored by adding recalcified plasma to elastin and EL-Hep scaffolds of 
the same area and monitoring the formation of fibrin fibres over a 20 min period since the 
contact activation process is known to be completed within 12 mins [295]. Glass is 
known to be a strong activator of the contact system and hence was used a control to 
compare the clotting times to it. Accordingly, it did show the fastest clotting of 
recalcified plasma completing the clotting process in 4-5 minutes while elastin scaffolds 
formed clots in 10-11 mins. EL-Hep 0.1 % and EL-Hep 0.2 % scaffolds showed reduced 
clotting times and EL-Hep 0.5 % did not show an increase in clotting ime when 
compared with elastin scaffolds. This correlates with the platelet adhesion results and 
may be due to inaccessibility of AT binding sites on heparin at these low concentrations 
either due to lower concentration of sites or due to the conformation of adsorbed plasma 
proteins. With increasing heparin concentrations, (EL-Hep 1 % and 2 %), clotting times 
increased significantly with EL-Hep 2 % scaffolds not clotting i the test period of 20 





Heparin was immobilized onto elastin scaffolds using EDC and NHS. Using 
increasing amounts of EDC: Heparin ratios, increasing amounts of heparin were 
immobilized up to 0.5 % w/v. Although the amount of total bound heparin plateaued after 
0.5%, surface bound heparin was 2.5 X higher in 2% EL-Hep samples compared to 0.5 % 
EL-Hep leading to significantly improved blood compatibility. Platelet adhesion was 
much lower, plasma clotting time was increased and thrombin inactivation was also 
significantly higher. Improved blood compatibility may improve overall biocompatibility 
of these elastin based scaffolds by reducing inflammatory reactions which are also 
initiated by the interaction of plasma proteins and blood cells with the material surface. 

















ENDOTHELIAL CELLS SEEDED ON ELASTIN-HEPARIN MATRICES 
EXPRESS NORMAL EC MARKERS AND RESIST DETACHMENT ON 
EXPOSURE TO SHEAR STRESS 
 
8.1 Introduction 
Small-diameter vascular grafts rapidly fail as a result of platelet deposition and 
thrombus formation eventually leading to occlusion [296, 297]. Normal blood vessels are 
lined by a quiescent endothelial monolayer on the luminal side that main ains a delicate 
balance of anti-thrombotic and fibrinolytic properties. The success of autologous 
saphenous veins as small diameter vascular replacements is thought to be mainly due to 
the presence of this endothelial layer [298, 299]. Thus endothelialization of the luminal 
surface seems to be the most logical step toward achieving a non-dhesive, non-
thrombogenic, and anti-proliferative blood contacting surface [300]. However, two major 
problems remain. First, the cells do not attach to the graft surface very well and hence 
detach easily on application of flow. Also, the underlying matrix greatly affects the 
function of the seeded cells giving rise to an activated phenotype which in fact may 
aggravate thrombosis. 
A quiescent endothelium is characterized by the expression of several cell surface 
markers as well as secreted factors. Typically, thrombomodulin (TM) expression is high, 
while tissue factor (TF) expression, prostacyclin (PGI2) secretion, nitric oxide (NO) 
secretion is low to negligible. Furthermore, von Willebrand factor (vWF) is present 
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within the quiescent endothelial cell (EC) but not secreted, and the number of cell 
adhesion molecules expressed on the EC surface is also low [301, 302]. Activation of 
ECs causes a reversal of this profile. All materials that are clinically used today as 
vascular replacements are inherently thrombogenic and need to be m dified to prevent 
failure especially in small caliber vessels. A number of researchers have investigated the 
ability of ECs to attach to various synthetic graft materials [303-305] and have shown 
improved cell adhesion to traditional materials by coating with extracellular matrix 
components such as fibronectin [306, 307], vitronectin [308], and collagen [309]. 
In our lab, we have created heparin coated pure elastin scaffolds (EL-Hep) as 
potential tissue engineered grafts (Chapter 7). Heparan sulfate which is found on the 
surface of endothelial cells and within the basement membrane is known anticoagulant 
[310, 311]. Thus the modification of the graft surface with heparin before EC seeding 
may provide the advantage of providing an anti-thrombogenic surface whereECs may 
not be present or may detach on exposure to flow thus improving overall anti-thrombotic 
properties. However, studies have shown that EC adhesion and proliferatin is poor on 
heparan sulfate [312]. Good EC adhesion, proliferation, their resistance to detachment on 
exposure to shear and the expression of the correct molecules are important factors for 
functionalized materials to succeed as small diameter vascular grafts.  
Therefore, in this study, we investigated the attachment and viability of rat 
vascular ECs cultured on EL-Hep scaffolds for 1 and 7 days. We also tested the retention 
of the cells on exposure to orbital shear stress (~12 dynes/cm2) co paring it to cells on 
TCPS. In order to determine the functional properties of the ECs seeded on these EL-Hep 
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scaffolds, we evaluated the expression of three cell surface mol cules – PECAM-1, 
thrombomodulin (TM) and ICAM-1. Immunohistochemical analysis was performed to 
compare it with normal rat aortic endothelial cell expressions and quantitation was 
preformed by cellular ELISA to compare the values to those of expression on TCPS. 
 
8.2 Materials and methods 
8.2.1 Elastin scaffold preparation 
Porcine descending aortas were harvested at a local slaughterhous , rinsed in cold 
phosphate buffered saline (PBS) and transported to the laboratory on ice. They were then 
cleaned of adherent tissue and fat and rinsed in cold PBS. Tissues wer  subsequently 
processed for the preparation of elastin scaffolds, by cyanogen bromide (CNBr) 
treatment, to remove cells, collagen and other ECM components except elastic fibers 
[207]. Briefly, fresh aorta samples were treated with 50 mg/ml CNBr (Acros Organics; 
Morris Plains, NJ) in 70% formic acid (Acros Organics; Morris Plains, NJ ) (8 ml/cm2) 
for 19 h at 20°C with gentle stirring, followed by 1 h at 60°C and boiling for 5 min to 
inactivate CNBr. The scaffolds were then stored in 70% ethanol as a di infectant. This 
method produced pure elastin scaffolds (shown in previous publication [203]).  
8.2.2 Heparin immobilization 
Elastin scaffolds were equilibrated with MES-buffer (0.05 M, pH 5.6)for 30 min. 
Carboxylic acid groups of heparin (Hep-COOH) were activated by adding NHS and EDC 
in 1:1 molar ratio (10.4mM each) and 2% w/v heparin. Heparin was pre-activated for 10 
min. For every 10mg of dry elastin scaffold, 2mL EDC/NHS activated h parin solution 
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was added. After 4h of reaction at 37°C, the heparinized elastin scaffolds were washed 
with 0.1 M Na2HPO4 (2 h), 4 M NaCl (4 times for 24 h) and distilled water (4-5 times for 
24 h) [267] 
8.2.3 Endothelial cell culture 
Rat aortic endothelial cells (RAEC) were obtained from VEC Technologies, Inc 
(Rensselaer, NY) and cultured in MCDB-131 complete medium (VEC Technologies, 
Inc). Cells in passage 4–8 were used in this study. Scaffolds (6 mm diameter for 
functional studies and 22 mm diameter for shear studies) were pre-incubated in medium 
for 1 h and placed on non treated culture dishes. A highly concentrated cell suspension 
(~5 x 106/mL) was used to cover the complete surface of the scaffold to allow maximal 
cell adhesion for 1 h after which samples were transferred to well plates (96 well plate for 
functional studies and 12 well plates for shear studies). Cells wre also seeded in wells 
(TCPS control) of respective plates. Well plates with cells and cell-seeded scaffolds were 
placed in a humidified incubator at 37 °C, with 5% CO2. Medium was changed every 
other day. 
8.2.4 Shear stress application 
After 1 and 7 days, 12 well plates with seeded EL-Hep scaffolds attached to the 
bottom of the wells with non-cytotoxic cyanoacrylate (tested for cytotoxicity – data not 
shown) and control plates with cells on TCPS were either kept as static (n = 6 each) 
controls or exposed to shear stress (n = 6 each) using an orbital shaker as described by 
several researchers [313-315]. A rotational frequency greater than 200 rpm has been 
reported to correspond to arterial magnitudes (11.5 dynes/cm2) of shear stress [316, 317]. 
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Briefly, shear stress was applied to the plates using an orbital shaker (VWR Signature 
Model DS-500; VWR International, West Chester, Pa) placed inside the incubator. The 
approximate maximum shear stress at the bottom of the well can be calculated as  
Τmax = a √ ηρ (2πf)
3 
Where a is the radius of gyration of the shaker (cm), ρ is the density of the 
medium (g/mL), η is the viscosity of the medium at 37°C (poise), and f is the frequency 
of rotation (rotations per second). Using this equation, under the conditions of our 
experiments, we calculated a maximal shear stress of 12.7 dynes/cm2 at a frequency of 
250 rpm. 
Laminar shear (20 dynes/cm2) was applied using a custom designed flow chamber 
only to EL-Hep samples after 1 day of static seeding to evaluate cell loss and 
morphological differences.  
The samples were then either evaluated qualitatively by LIVE/DEAD assay (live 
cells appear green and dead cells red, n=3) as described by the manufacturer (Molecular 
Probes, Eugene, OR) or quantitatively (only day 1) using crystal violet (n=3). For the 
crystal violet assay, cells or scaffolds were rinsed with warm PBS before fixing with 
methanol/acetone (1:1) at -20°C for 10 min. They were then again washed wit  PBS and 
stained for 30 min with 0.005 % crystal violet (Sigma-Aldrich) in deionized water. Wells 
were then extensively washed with deionized water and allowed to air-dry. The crystal 
violet that absorbed onto the nucleus was solubilized with 1% Triton X-100 (Sigma-
Aldrich) for 3 days and then transferred into new 96-well plates and the absorption was 
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measured at 590 nm. Cell numbers were calculated from crystal violet absorbance values 
using a standard curve plotted with known numbers of endothelial cells. 
8.2.5 Functional (molecular) studies 
8.2.5.1 Immunohistochemistry 
EL-Hep samples (7d static and after shear; n = 3 per group) were either emb dded 
in Tissue Tek OCT compound (Sakura Finetek, U.S.A. Inc., Torrance, CA), and frozen at 
-80 °C or fixed in 10 % neutral buffered formalin at room temperature for 24 h, processed 
with an automatic tissue processor (Tissue TEK VIP, Miles Inc., Mishawaka, IN) nd 
embedded in paraffin. After either procedure, 6 µm thick sections were cut and collected 
on glass slides. 
Sections (n = 3 per group) were immunostained using monoclonal mouse anti-rat 
CD31 (1:10; frozen section) (GeneTex Inc., SanAntonio, TX), monoclonal mouse anti-rat 
CD54 (1:200; frozen section) (AbD Serotec, Raleigh, NC) and mouse anti-
thrombomodulin (1:100; paraffin section) (gift from Covance Inc., CA). Vectastain Elite 
ABC Kit for mouse IgG and DAB substrate (Vector Laboratories, Burlingame, CA) were 
used to visualize the specific staining. Negative controls were included with the omission 
of the primary antibodies. Sections were counterstained with hematoxylin.  
8.2.5.2 Quantification of ICAM and TM  expression (cellular ELISA) 
The expression of the surface-bound adhesion molecule ICAM-1 and TM was 
quantified using a method described by Lehle et al. [318]. EC function was verified by 
the determination of spontaneous and TNF-α induced (treatment for 20 h) cell surface 
expression of ICAM-1 on RVECs seeded on TCPS (control) and EL-Hep scaffolds. To 
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activate the cells, 5µL of TNF-α reconstituted and diluted in PBS (10 µg; Calbiochem, 
Gibbstown, NJ) was added to the wells (n = 3 per group) and treated for 20 h as the 
expression of ICAM-1 is thought to peak 20h after activation with TNF- α. 
The adherent cells were then washed once with warm PBS, fixed with a cold 
mixture of 1:1 methanol/acetone for 10 min, then washed twice with PBS containing 0.2 
% bovine serum albumin (BSA; Sigma-Aldrich, St. Louis, MO), and incubated for 1 h at 
37 °C with 50 µL of the primary antibody (mouse anti-rat ICAM or mouse anti-TM) 
diluted 1:200 or 1:100 respectively with PBS containing 0.02 % BSA. Samples wer  then 
washed twice, incubated with a biotinylated goat anti-mouse IgG (50 µL/well, 1:200, 
Vector Laboratories, Burlingame, CA) for 30 min at 37 °C, followed by repeated 
washing and further incubation for 30 min with alkaline phosphatase streptavidin (50 
µL/well, 1:1000, Vector Labs). The substrate p-nitrophenylphosphate (1 mg/mL, Sigma-
Aldrich) in 0.1M diethanolamine (Sigma-Aldrich) pH 10.3 was then added, and after 15 
min the absorption was measured at 405 nm with a spectrophotometer. 
To control for loss of cells during fixation and washing procedures, crytal violet 
staining was used (as described above). ICAM-1 expression was normalized to cell 
numbers and calculated as a percentage of the expression by cells on TCPS stimulated by 
TNF. For the determination of TM expression, only the basal values (without TNF 





8.2.6 Statistical analysis 
Results are expressed as means ± standard error of the mean (SEM). Statistical 
analyses of the data were performed using single-factor analysis of variance (ANOVA). 
Subsequently, differences between means were determined using the least significant 
difference (LSD) with an alpha value of 0.05. 
 
8.3 Results 
8.3.1 Effect of shear stress on EC retention 
Cells were seeded on TCPS (control) and EL-Hep scaffolds in 12 well plates and 
cultured for either 1 day or 7 days (n = 12 / group / time point). The shear group (n = 6 / 
group / time point) was exposed to 4 h of orbital shear (250 rpm setting) after the 1d or 
7d static culture period after which 1d samples were evaluated either by L/D assay shown  
or quantification of cell retention by crystal violet (n = 3 / group / time point). The 7d 
samples were only evaluated by L/D assay. Some 1 day seeded EL-Hep samples were 




Figure 8.1 Live Dead assay images. (A) 1d static culture on TCPS, (B) 1d static on 
TCPS followed by 4h orbital shear, (C) 1d static culture on EL-Hep scaffold, (D) 1d 
static on EL-Hep followed by 4h orbital shear. Green = live and red = dead cells. 
Direction of flow is clockwise. Maximum shear was 12.7 dynes/cm2 
 
ECs exposed to static conditions were randomly aligned and uniformly polygonal 
both on TCPS as well as EL-Hep (Figure 8.1 A and C respectively). Cells were lost from 
EL-Hep scaffolds on establishment of flow (both orbital, Figure 8.1 D and laminar, 
Figure 8.2 B) as seen by empty spots without cells as well as de d (red) cells. Cell loss 
was dramatic on TCPS after 1d static culture (Figure 8.1 B) where ardly any cells 
survived the shear; however, after 7d static culture cells were able to withstand the shear 
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even on TCPS (Figure 8.3 B). ECs on EL-Hep exposed to laminar shear str ss after 1d 
static culture as well as orbital shear after 7 day static culture, aligned in the direction of 
flow (Figure 8.2 B and 3D). 
 
 
Figure 8.2 Live Dead assay images. (A) 1d static culture on EL-Hep scaffold, (B) 1d 
static on EL-Hep followed by 4h laminar shear (20 dynes/cm2). Green = live and red = 






Figure 8.3 Live Dead assay images. (A) 7d static culture on TCPS, (B) 7d static on 
TCPS followed by 4h orbital shear, (C) 7d static culture on EL-Hep scaffold, (D) 7d 
static on EL-Hep followed by 4h orbital shear showing alignment of cells in the direction 
of flow (clockwise). Green = live and red = dead cells. Maximum shear was 12.7 
dynes/cm2 
 
Quantification of cells using crystal violet (Figure 8.4) showed that after 1d 
culture there were ~2.81 x 105 cells/cm2 on TCPS (control) static samples, ~ 2.39 x 105 
cells/cm2 on EL-Hep static and ~ 1.8 x 105 cells/cm2 (75 % of static) on EL-Hep samples 
exposed to shear. There were such few cells on TCPS samples exosed to shear that they 
could not be quantified exactly. Exposure of 1d seeded EL-Hep scaffolds exposed to 
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laminar flow (20 dynes/cm2) gave similar results with 75 – 80 % cells remaining on the 
scaffold surface after 4 h of physiological levels of shear stress (data not shown).   
 
 
Figure 8.4 Quantification of cells on TCPS after 1 day static culture, EL-Hep after 1 day 
static culture and EL-Hep after 1 day static culture followed by 4h orbital sher.  Hardly 
any cells were present on TCPS after 1 day static culture followed by 4h orbital shear 
whereas 75 % of cells remained on EL-Hep after exposure to orbital shear. 
 
8.3.2 Expression of cell surface molecules 
8.3.2.1 Effect of underlying matrix on surface molecule expression 
To evaluate whether endothelial cell markers were conserved or whether the cells 
were activated when seeded on the EL-Hep scaffolds, staining for three cell surface 
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molecules was performed after 7 days of seeding. Rat aorta was used as a positive control 
for all IHC evaluation of the molecules. Preservation of the monolayer integrity was 
assessed by labeling intercellular molecules localized at cell-cell junctions 




Figure 8.5 Immunohistochemical staining for PECAM-1. (A) 7d static culture on EL-
Hep scaffold, (B) 7d static on EL-Hep followed by 4h orbital shear, (C) Rat aorta. Insets 
show negative controls. Original magnifications 1000X. 
  
The intense staining of thrombomodulin on RVECs seeded on EL-Hep scaffolds 
(Figure 8.6) indicated that a large number of the cells maintained this antithrombogenic 
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protein on their surface. When quantified, TM expression on cells seeded on EL-Hep 




Figure 8.6 Immunohistochemical staining for thrombomodulin. (A) 7d static culture on 
EL-Hep scaffold, (B) 7d static on EL-Hep followed by 4h orbital shear, (C) Rat aorta. 
Insets show negative controls. Original magnifications 1000X. 
 
ICAM-1 expression on the EL-Hep scaffolds was lower than that seen on rat aorta 
(Figure 8.7 A, C) however when stimulated by TNF-α, the cells responded and ICAM-1 
expression was visibly increased (Figure 8.7 D). In order to quantify th s ICAM 
expression, basal and stimulated expression levels of cells seeded on TCPS and EL-Hep 
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were compared by cellular ELISA (Figure 8.8). When compared to cells s eded on 
TCPS, the basal expression of ICAM-1 of cells on EL-Hep was slightly higher (45.3 ± 
7.4 % vs. 28.2 ± 1.8 % of activated expression level) but this difference was not 
significant. Also, when simulated by the inflammatory cytokine TNF-α, the cells on EL-
Hep responded showing a significantly increased ICAM-1 expression (70.3 ± 11.7 %).  
 
 
Figure 8.7 Immunohistochemical staining for ICAM-1. (A) 7d static culture on EL-Hep 
scaffold, (B) 7d static on EL-Hep followed by 4h orbital shear, (C) Rat aorta, (D) 7d 
static culture on EL-Hep activated by TNFα. Insets show negative control. Original 




Figure 8.8 Expression of ICAM-1 on RVECs cultured on TCPS and EL-Hep scaffolds 
activated by TNF-α for 20h. White bars set in front represent basal (unactivated) levels. 
Dashed line represents basal level of cells on TCPS. Values were calculated as a 
percentage of TNF activated cells on TCPS (considered as 100% shown by dash-dot 
line). Basal levels were significantly lower than activated ICAM-1 levels (p < 0.01). 
 
8.3.2.2 Effect of shear stress on surface molecule expression 
Although not quantified, the expression of both PECAM-1 (CD31) (Figure 8.5 B) 
and thrombomodulin (Figure 8.6 B) remained high and ICAM-1 (Figure 8.7 B) seemed 
slightly higher than that that of static culture when RVECs seeded on EL-Hep scaffolds 





Blood compatibility of vascular prostheses is very important for their success. The 
most common cause of failure of small diameter vascular prosthese  is occlusion due to 
thrombosis. Thrombosis involves the activation of three interconnected regulatory 
systems, the coagulation cascade, the complement cascade and the cellular components 
of the blood such as leukocytes and platelets which when activated, lead to the formation 
of a clot within the blood vessel thereby obstructing blood flow. Endothelial cell (EC) 
seeding of the blood contacting surface has been proposed as a method to reduce this 
thrombosis progression and hence prevent graft failure [77, 319]. However, there are two 
main problems associated with this technique. First, the seeded cells do not adhere well 
enough to the biomaterial so that on establishment of flow they detach le ving behind 
vacant, exposed, pro-thrombotic spots of the underlying material [320, 321]. The other 
major problem is that ECs get activated just by mere culture on graft materials [304, 
322].   
The role that graft surface properties play in EC adhesion and growth, and the 
effects of surface properties on seeded EC behavior have been studied by several 
researchers [323-325]. In order to avoid thrombosis related failure, we have created novel 
elastin-heparin scaffolds that have very good in vitro blood compatibility with almost no 
platelet adhesion, highly increased plasma clotting time and high t rombin inactivation 
(data submitted for publication). In the present study, we wanted to test the ability of ECs 
to adhere to these natural, extracellular matrix based scaffolds and provide a normal, 
quiescent lining of ECs hence preventing failure of these small diameter grafts by both 
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thrombosis as well as hyperplasia. Normal, un-activated, confluent endo helium provides 
a natural anti-thrombogenic surface by balancing the cell surface expression and 
secretion of various molecules. Although the interplay of several different molecules 
determines the health of the endothelium, we decided to evaluate the expression of three 
molecules – PECAM-1, thrombomodulin and ICAM-1 on ECs seeded on the elastin-
heparin scaffolds. In addition to functional studies, we also quantified h  retention of 
cells after exposure to high levels (~ 12 dynes/cm2) of shear stress.  
We have shown in earlier studies that elastin scaffolds support EC growth [203] 
however the ability of the elastin-heparin scaffolds to form tight bonds with cells that 
enable them to resist detachment on establishment of fluid flow had not been tested. A 
number of researchers have shown the loss of in vitro seeded cells on the establishment 
of flow. Rosenman et al. [87] showed that in a canine vascular graft model there was a 
rapid loss of seeded cells (70.2 % of those seeded) in the first 30 minutes of establishing 
flow. Even with the coating of extracellular matrix elements such as fibronectin on the 
surface of synthetic polymer grafts to improve cell adhesion and retention on exposure to 
flow, most studies have shown only ~ 60% cells remaining on the graft surface [326, 
327].  
In this study, the seeding density selected for shear studies was uch that the cells 
were confluent 24 h after seeding. This was done to allow the application of shear as soon
as possible after seeding. The 24 h attachment period used in this study is much longer 
that that available clinically and future studies will involve shear xposure after 2 h 
seeding to evaluate the feasibility of single stage EC seeding on EL-Hep scaffolds.  
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After static seeding for 1 day, similar number of cells attached to TCPS as well as 
EL-Hep scaffolds however on exposure to 4 h shear, majority of the cells came off the 
TCPS and were dead (Figure 8.1 B) whereas 75 % (compared with stat c EL-Hep) of the 
cells on the biomaterial scaffold remained attached (Figure 8.1 D and Figure 8.4). The 
relative amount of cells retained (75%) is similar to that seen with other synthetic 
polymers [176, 320]. After 7 days of static culture however, there was hardly any cell 
loss on either TCPS or EL-Hep (Figure 8.3) (quantification not performed) on exposure 
to shear. There was also alignment of cells in the direction of flow (tangential to well 
wall) only on the EL-Hep (Figure 8.3 D) but not on TCPS even after just 4h of flow 
similar to that seen with laminar flow (Figure 8.2 B).  
EC attachment to synthetic polymer grafts has been shown to be minimal and 
adhesion has been improved by coating the graft surfaces with natural, basement 
membrane components such as FN [324, 328], collagen [329, 330] laminin [95, 331] etc. 
which carry specific sites recognized by integrins on the cells that help bind the cells to 
the matrix.  Our natural material scaffold provided the right base for EC attachment and 
did not need any coating to improve adhesion. Other researchers using natural materials 
to create tissue engineered grafts have appreciated the fact that since the architecture of 
the underlying matrix decides the status and adhesion of ECs, a natur l ECM protein 
scaffold may promote endothelial cell attachment without pretreatment with adhesive 
proteins [332]. The effect of heparin immobilization on EC growth and proliferation is 
quite contradictory. Some investigators have shown an inhibitory effect of heparin on EC 
adhesion [333] however most have shown tendency of heparin to promote EC adhesion 
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and growth [334, 335]. Although cells grow well and adhere on EL-Hep there is some 
amount of cell loss (25%) on exposure to high shear as seen with all materials (natural 
and synthetic) and these spots of exposed scaffold can be initiation points for thrombus 
formation. The heparin immobilization on the elastin scaffolds should act to prevent 
thrombus formation in the event of EC detachment hence maintaining the anti-
thrombogenic properties of the graft. 
Not only must ECs attach and grow well on the graft surface but they must remain 
functional by exhibiting normal EC molecules. The behavior of ECs is known to be 
influenced by the underlying matrix [336] and hence this behavior must be evaluated to 
prove the efficiency of this method of thrombus prevention. In the present study the 
expression of three EC molecules – PECAM-1, ICAM-1 and thrombomodulin was tested 
on cells after static cultured on the EL-Hep scaffolds for 7 days to allow the maturation 
and exhibition of true phenotype and compared to expression on normal rat aorta 
(control). For quantification of expression, cells were similarly cultured on TCPS. The 
phenotype of the ECs was checked by PECAM-1 expression, anticoagulant property by 
TM expression and activation by basal ICAM-1 expression. The response of seeded cells 
to stimulation by the cytokine TNF-α was also evaluated by quantifying increase in 
ICAM-1 expression.  
PECAM-1 occurs on the EC membrane and regulates EC adhesion to other ECs 
and to leucocytes. A reduction in PECAM expression has been associated with EC 
damage [337]. Our studies showed a high amount of PECAM expression (Figure 8.5) 
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indicating the presence of a normal endothelium on the material surface. Even on 
exposure to high shear stress PECAM-1 expression remained high.  
To evaluate the expression of TM and ICAM-1, in addition to IHC comparing 
their expression on normal aorta, we performed an in situ functional characterization 
technique (cellular ELISA) comparing the expression to cells seeded on TCPS.  ICAM-1 
is constitutively expressed at low levels on the surface of several c lls (including ECs) 
[338] and is upregulated on activation by inflammatory cytokines such as interleukins, 
TNFa, interferons [339, 340]. Qualitatively the expression of both TM and ICAM-1 on 
statically cultured EL-Hep scaffolds was similar to that seen on normal aorta. On 
exposure to shear, TM expression remained high (Figure 8.6 B) whereas ICAM-1 
expression seemed slightly elevated on the seeded EL-Hep scaffolds (Figure 8.7 B). 
Quantification of ICAM-1 expression (Figure 8.8) was performed for four 
situations: RVECs on TCPS (control) and EL-Hep in resting conditions, and RVECs on 
TCPS and EL-Hep under TNF-α stimulation. The presence of graft material (EL-Hep) 
does not seem to affect ICAM-1 expression much – it was slightly higher than that on 
TCPS (45.3 ± 7.4 % vs. 28.2 ± 1.8 %). This demonstrates that the EL-Hep scaffolds do 
not activate, in vitro, the proteins involved in the adhesion between leucocytes and 
endothelium. These values are similar to the expression on several other polymers where 
up to 25 % higher expression was observed [318, 341, 342]. On the other hand, other 
researchers have shown no significant change in the expression of ICAM-1 after 24 h 
culture on PET grafts [343, 344]. Upon cytokine stimulation ICAM-1 expression 
increased significantly (70.3 ± 11.7 % of expression of stimulated cells on TCPS) 
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indicating that the higher basal levels seen on EL-Hep were not an activated phenotype. 
TM expression was also seen to be stable at 7 days (90.2 ± 6.3 % of that on TCPS) 
suggesting the conservation of the anticoagulant properties of ECs.  
 
8.5 Conclusions 
Our results show that the novel elastin-heparin scaffolds created in our lab 
promote a quiescent endothelial lining on the luminal surface which is capable of 
responding to cytokine stimulation. We believe that the availability of binding sites on 
the matrix surface and the familiar natural architecture promotes strong adhesion of the 
cells such that they are able to resist detachment on application of physiological range of 















CONCLUSIONS AND RECOMMENDATIONS 
 
8.1 Conclusions 
Tissue engineering techniques provide novel approaches to the fabrication of ideal 
blood vessel replacements – that are biocompatible, porous to allow nutrient exchange, 
non-thrombogenic and mechanically similar to host tissue. Several materials, synthetic 
and natural as well as different cell sources have been investigat d. Based on the work 
presented here to create an ideal tissue engineered small diameter blood vessel, the 
following conclusions can be drawn: 
• Cyanogen bromide treatment of porcine carotid arteries completely removes 
cells and collagen, leaving behind tubular pure elastin scaffolds which are 
porous, highly elastic, biocompatible and biodegradable. 
• In vitro repopulation of the scaffolds with vascular cells in static and dynamic 
(pulsatile flow bioreactor) culture was not achieved 
• A novel in vivo cell recruitment technique with the use of a growth factor 
delivering agarose gel was investigated in a subdermal pouch model. This 
technique was extended to compare effect of two different growth factors 
(bFGF and SDF-1α) and two different implant locations (subdermal and 
adipose). The sustained release of bFGF in adipose tissue recruited several 
smooth muscle α-actin cells (myofibroblasts), smooth muscle cells and some 
endothelial cells. 
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• Thrombogenicity of the elastin scaffolds was significantly reduc by 
covalent binding of heparin. EL-Hep 2 % showed very few adhered platelets, 
elevated thrombin inactivation and highly elongated plasma clotting time ( > 
20 mins). 
• Endothelial cells cultured on EL-Hep scaffolds were viable and able to r sist 
detachment on exposure to laminar flow ( 20 dynes/cm2) and orbital flow ( 12 
dynes/cm2). These cells formed a confluent monolayer that was quiescent – 




The studies listed below are recommended for future work in the use of elastin 
based scaffolds as small diameter tissue engineered grafts. 
• The in vivo cell recruitment capability of EL-Hep scaffolds needs to be tested. 
In addition to being an anticoagulant, heparin is known to have binding 
domains for angiogenic growth factors such as bFGF and VEGF. This could 
improve cell recruitment in the in vivo models. 
• The delivery of more than one growth factor in vivo needs to be explored. In 
our studies, endothelial cells were recruited in large numbers by SDF in the 
adipose tissue whereas smooth muscle cells were found only in the Adipose-
FGF group whereas myofibroblasts were recruited in both groups. The delivery 
of both factors may help recruit large numbers of all three vascular cells. 
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• The use of adipose derived endothelial cells can be explored as a means of 
endothelialization of the cellularized graft just before vascular grfting. The 
cells can be isolated and grown in culture while the in vivo cell recruitment is 
underway. On explanting the cellularized tube, these cells can be seed d onto 
the luminal surface before vascular grafting.   
• Endothelial cells seeded on the scaffolds need to be tested for retention after 
only 1 -2 hours of static seeding to evaluate the adhesion capacity for single 
stage seeding (clinically relevant application) 
• The long term functionality of the graft needs to be tested in a suit ble animal 
model (eg. dog). Although the in vitro blood compatibility was very good, the 






































XPS spectra for sulfur in EL-Hep scaffolds 
 























ISO10993: Biological evaluation of medical devices - Part 6: Tests for local effects 
after implantation  
 
This part specifies test methods for the assessment of the local effects after implantation 
of biomaterials intended for use in medical devices. Evaluation should be undertaken by 
comparing the tissue reaction to that of a similar specimen/material of which the clinical 
acceptability and biocompatibility characteristics have been established. 
 
1. Test methods, general aspects 
• For short-term testing, animals such as rodents or rabbits are commonly used. For 
long-term testing, animals such as rodents, rabbits, dogs, sheep, goats, pigs, and 
other animals with a relatively long life expectancy are suitable. 
• For biodegradable materials a pilot study in rodents should be undertaken to 
determine the expected rate of degradation before embarking on studies on larger 
animals. For degradable/resorbable materials the test period should be related to 
the estimated degradation time of the test product. 
• The specimens of test and control materials should be implanted under the same 
conditions in animals of the same species and of the same age, sex, and strain in 
corresponding anatomical sites. The number and size of implants inserted in an 
animal depends on the size of the species and the anatomical location. 
• Whenever possible, the reference control and the test specimens should be 
implanted into the same animal. 
• The test period should be determined by the likely clinical exposure time or be 
continued until or beyond a steady state has been reached with respect to the 
biological response. 
• For non-degradable and non-resorbable materials the short-term respons s are 
normally assessed from 1 week up to 4 weeks and the long-term responses in tests 
exceeding 12 weeks. The local biological response to implanted materials 
depends both on the properties of the materials and on the response to the 
associated trauma of surgery. The tissue configuration in the vicinity of an 
implant changes with the time elapsed after surgery. During the first two weeks 
after implantation the reaction due to the surgical procedure itself may be difficult 
to distinguish from the tissue reaction evoked by the implant. In muscle and 
connective tissue, depending on the species, and the severity of the surgical 
trauma, a steady state is seen in the cell population after 9 weeks to 12 weeks. 
Implantation in bone tissue may need longer observation periods before a steady 
state is reached. In general, it is expected that experiments that go up to or beyond 







The biological response should be evaluated by documenting the macroscopic and 
histopathological responses as a function of time. The responses to the test sample should 
be compared to the responses obtained at the control sample or sham operated sites. 
For each of the endpoints samples should be obtained from at least 3 different animals. 
 
2.2 Macroscopic assessment 
Each implant site should be examined for alterations of the normal structure. Recordings 
of the nature and extent of any tissue reaction observed, such as hematoma, edema, 
encapsulation, and/or additional gross findings should be made. The presence, form, and 
location of implant including possible remnants of degradable materials should also be 
recorded. Macro photography should be used for documentation. 
In addition to the inspection of the implant site, whenever an animal has s own signs of 
ill health or reactions to the implant, a gross necropsy as appropriate should be 
conducted. 
 
2.3 Implant retrieval and tissue sample collection 
After the animal has been humanely killed, the implant together with sufficient 
unaffected surrounding tissue should be excised to enable evaluation of the local 
histopathological response. If the candidate material is not evident at the site examined 
(degradable/resorbable materials), the explantation site should be extended to include 
several millimeters of normal tissue on all sides of the expected implant site. For non-
degradable implants, draining lymph nodes should be collected as indicated by the gross 
pathology. For degradable implants, draining lymph nodes should be collected, wh n 
feasible, as evaluation of draining lymph nodes is of importance to demonstrate migration 
of degradable materials. 
 
2.4 Microscopic assessment 
The scoring system used for the histological evaluation should take into account the 
extent of the area affected, either quantitatively (e.g. in micro eters) or semi-
quantitatively. The implant orientation in relation to the implant dimensions, number of 
sections, and cutting geometry should be recorded. 
The biological response parameters, which should be assessed and recorded, include: 
• the extent of fibrosis/fibrous capsule (layer in micrometers) and inflammation; 
• the degeneration as determined by changes in tissue morphology; 
• the number and distribution as a function of distance from the material/tissue 
interface of the inflammatory cell types, namely polymorphonuclear l ucocytes 
(neutrophils), lymphocytes, plasma cells, eosinophils, macrophages, and 
multinucleated cells; the presence, extent, and type of necrosis; 
• other tissue alterations such as vascularization, fatty infiltration, granuloma 
formation, and bone formation; 
• the material parameters such as fragmentation and/or debris presence, form and 
location of remnants of degraded material; 
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• the quality and quantity of tissue ingrowth, for porous and degradable implant 
materials. 
 
Adverse histological responses shall be documented by photomicrograph and t e test 
sample should be evaluated as compared to the negative control sample based on a 
scoring system: 
• non-irritant (0.0 up to 2.9) 
• slight irritant (3.0 up to 8.9) 
• moderate irritant (9.0 up to 15.0) 
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